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Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less. 
MARIE CURIE 
 
 
 
 
Imagination is more important than knowledge. 
ALBERT EINSTEIN 
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ABSTRACT 
 
My PhD project addressed the paternal and maternal contribution associated 
with correct early embryonic development, focusing on microRNAs (miRNAs, 
short non-coding RNAs regulating gene expression at post-transcriptional 
level) involved in controlling reproductive function in cattle. To this end, next 
generation sequencing (NGS) methods and bioinformatic analysis pipelines 
were set up and validated using low quantities of starting materials, e.g. 
blastocysts and oocytes. The role of miRNAs carried by spermatozoa during 
early embryogenesis was investigated by assessing in vitro produced 
blastocysts from semen of bulls with high and low blastocyst rates. Moreover, 
follicular fluid and oocyte miRNAs were analyzed in order to unravel molecular 
mechanisms involved in poor fertility cows. In particular, a model based on 
low and high antral follicle count ovaries was used to study the influence of 
ovarian function on oocyte developmental competence. The results indicated 
that: 1) sperm miRNAs may impact embryo developmental competence 
affecting the expression of gene networks involved in several cellular 
processes including cell adhesion, communication and metabolism of the 
blastocyst; 2) the different oocyte quality is associated with a different miRNA 
blueprint in both follicular fluids and oocytes through the mis-regulation of 
biological processes critical for oocyte competence. In conclusion, these 
studies contributed to improve our knowledge on the function of miRNAs in 
the sperm, oocytes and pre-implantation embryos. Several miRNAs were 
identified as potential biomarkers of blastocyst and oocyte competences, 
which will be valuable to optimize Reproductive Biotechnologies. 
 
 	  	  	  
	   2	  
	  
Chapter 1 
General Introduction 
For several decades, selection for production traits has been the main goal for 
cattle breeding. However, many functional traits, such us milk production, 
have negative correlation with genetic merit for health and fitness [1]. Indeed, 
milk production of the modern dairy cows has increased, but the fertility of 
these cows has steadily declined [2]. The reasons for this are difficult to 
understand because fertility is a complex trait affected by the environment, 
genetics and management. It is estimated that the calving rate in high 
producing cows is less than 40% and foetal loss is closer to 60%. Moreover, 
70-80% of these losses occur during the pre-implantation period of embryonic 
growth, between days 8 and 16 [3, 4]. 
 
The PhD project was focused on the study of early stages of reproduction to 
unravel the molecular mechanisms associated with poor cow and bull fertility.  
 
1.1. Advances in cattle reproductive biotechnologies: state of the art 
The problem of bovine reproduction is closely linked to the livestock industry 
as breeding techniques have usually been motivated by curiosity and 
consolidated by breeder’s needs and interests. Indeed, artificial insemination 
(AI) was initially developed as a hygiene measure to prevent disease 
transmission but is now widely used for genomic selection. The advent of 
embryo genotyping, in combination with Assisted Reproduction Techniques 
(ARTs) [5, 6], allows the reproduction of the desired genotype from selected 
parents. The close similarities between humans and livestock species, such 
as cattle, sheep and horses, have allowed the improvement of knowledge in 
ARTs, to be translated to humans. ARTs are dependent on two factors: the 
easy availability of both the gametes and pre-implantation embryos and the 
ethical requirements [7]. In the last 25 years new ARTs, which were 
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developed for cattle, have been transferred and adapted for other species, 
such as human, buffalo and horses. The most important of these are: (a) 
ovum pick up (OPU), which followed the establishment of reproducible 
techniques for in vitro maturation [8], fertilization [9,10] and culture of sheep 
[11] and cattle embryos [12], in OPU oocytes are collected from living donors 
of known genetic value; (b) intracytoplasmic sperm injection (ICSI), which is 
useful in cases of sperm-related male infertility but its efficiency in cattle is still 
not comparable to that in humans so it is usually only used for research 
purposes [13]; (c) nuclear transfer and somatic cell nuclear transfer (SCNT) 
widely used in cattle for cloning animals of great commercial interest [14]. In 
livestock species, the main objective for these reproductive biotechnologies is 
to give rise to in vitro produced (IVP) embryos, which are then transferred to 
recipients. According to Embryo Transfer Society statistics (Fig. 1), the 
number of embryo transfers (ET) has increased more than 10 times [15] in 
recent years and is now approaching the number of embryos produced in 
vivo. In conclusion, ARTs in cattle are becoming a consolidated reproductive 
biotechnology and, in particular, OPU is increasingly preferred for ET over 
conventional superovulation.  
 
 
 
Figure 1. Summary of the International Embryo Transfer Society statistical data 
collected by the data retrieval committee. In vitro production of embryos is steadily 
increasing with the majority of them now being produced by ovum pick up (OPU) 
[16]. 
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1.2. Overview of physiology of reproduction and pathways of 
differentiation of the gametes 
The gonads are the primary reproductive organs responsable for producing 
both gametes and steroid hormones which control reproductive function. 
Normal gametogenesis in the gonads is a prerequisite for mammalian 
reproduction. This involves complex molecular mechanisms for cellular 
functions as well as the interaction of different gonadal cell types. Germ cells 
develop into oogonia (primitive eggs) or spermatogonia (stem cell precursors 
of sperm). Germ cells develop also in the supporting somatic cells, which are 
either the Sertoli cells and Leydig cells in the male or the granulosa cells and 
the theca cells in the female. A remarkable aspect of gametogenesis in the 
testis or ovary is that germ cells exhibit strictly regulated spatiotemporal gene 
expression for functional development of sperm or oocytes [17, 18]. Moreover, 
a large proportion of mRNAs are partially stored and translationally inactive in 
mammalian haploid germ cells [19, 20].  
Spermatogenesis is initiated in the male testis with the beginning of puberty, where 
male primary germ cells undergo mitotic division and produce spermatogonia, from 
which the primary spermatocytes are derived. Primary spermatocytes undergo 
successive meiotic division producing four spermatids, and a metamorphic change 
(spermiogenesis) occurrs in the spermatids to produce spermatozoa. The molecular 
mechanisms, which regulate primary germ cells development, differentiation and 
exit from the mitotic cell cycle, are associated with a timed expression of 
meiotic genes. A number of mRNAs located in the nucleous are transcribed 
and stored for some days in spermatocytes without detectable protein 
expression [21]. The expression of meiotic genes which is required for 
initiation of meiotic processes during spermatogenesis and the expression of 
a multitude of testicular genes are known to be under control of post-
transcriptional regulatory mechanisms [22-24].  
Female reproduction is characterized by a dynamically regulated sequential 
recruitment, selection and growth of the follicles, atresia, ovulation, and 
luteolysis, which occur in the ovary and are dependent on precise expression 
and interaction of several intraovarian gene products in both an autocrine and 
paracrine manner. These mechanisms of follicular growth can be classified 
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into three phases: i) the gonadotropin-independent phase that involves 
follicular growth through primordial, primary, and secondary stages; ii) the 
gonadotropin-responsive phase that involves transition of preantral follicles to 
early antral stage, and iii) the gonadotropin-dependent phase that involves 
continual growth beyond the early antral stage and includes follicle 
recruitment, selection, and ovulation [25]. The differentiation of the primordial 
follicles into the diverse follicle developmental stages are initiated by 
primordial germ cells. These cells enter meiosis at birth and develop into mature 
oocytes capable of fertilization. They are nurtured, retained and subsequently 
developed in the ovary through a complex follicular developmental process on a 
cyclic basis [26, 27]. The growth and development of mammalian oocytes is 
critically dependent on a bidirectional communication between the oocyte and 
its companion somatic cells [28]. The viability of primordial and primary 
follicles is determined mainly by survival factors derived from the oocyte, 
whereas the relative expression level of tumor suppressors, apoptotic 
proteins, and survival factors in granulosa cells determines whether an 
ovarian follicle will grow or undergo atresia in the late pre-antral stage [29].  
 
The development of the sexual organs and gametes, i.e. oocyte and spermatozoa, is 
characterized by a substantial reorganization of their transcriptome. Understanding 
the regulation of gene expression at the level of ribonucleic acids (RNAs) in 
gametes and early embryos has improved as the technology available has 
advanced. In particular, the discovery of the microRNAs (miRNAs) in 1993 by 
Ambros and colleagues [30] demonstrated that small non-coding RNAs have 
regulatory roles and impact on cellular phenotype and function. Several 
studies have accumulated evidence on the expression of miRNAs and their 
biogenesis pathway genes in germ cells and gonadal somatic cells [31-35], 
which suggest the potential involvement of miRNAs in translational control 
during reproductive function. The improvement of our knowledge of, in 
particular miRNAs, is revealing numerous pathways and mechanisms which 
may impact on fertility. 
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1.3. Small RNAs: classes and biogenesis in mammalian  
Small non-coding RNAs are post-transcriptional regulators of gene 
expression, which range in size from 18 to 32 nucleotides (nt). They are 
generally divided into three functional classes: microRNAs (miRNAs), 
endogenous small interfering RNAs (endo-siRNAs) and Piwi-interacting RNAs 
(piRNAs) [37-41]. These classes differ in their biogenesis, i.e. their maturation 
from the primary transcription product to the active form (Fig. 1).  
MiRNAs can be divided into two sub-classes: canonical and non-canonical 
groups. Canonical miRNAs are initially transcribed as long RNAs containing 
self-complementary hairpins, also called pri-miRNAs (Fig. 1A). During 
maturation the 60-75 nucleotide hairpin structures are bound by the RNA-
binding protein Dgcr8 (Di George syndrome critical region 8), which directs 
the RNase III enzyme Drosha to cleave the base of the hairpin [42-47]. 
Following cleavage mediated by Drosha-Dgcr8 complex, also called the 
microprocessor, the released hairpin (pre-miRNAs) is transported to the 
cytoplasm, where Dicer, another RNase III enzyme, then cleaves it into a 
single short 18-25 nt dsRNA [48-51]. Non-canonical miRNAs bypass 
processing of the microprocessor or Dicer [37, 52] using other endonucleases 
or directing transcription of a short hairpin. For example, mirtrons, which are 
miRNAs matured from introns, come from mRNA splicing [53-55]. After 
splicing from host mRNAs, the lariat is de-branched and refolds into a short 
stem–loop structure that resembles as a pre-miRNA. Some mirtrons have 
also extra sequences at the 5ʹ - or 3ʹ - end and are trimmed by exonucleases 
[56]. In other case, endogenous short hairpin RNAs are generated directly 
through transcription [37, 52] and, in particular, although these endogenous 
short hairpin RNAs were initially thought to be transcribed by RNA 
Polymerase III, it has been recently shown that some of them, for example 
mir‑320, are transcribed by RNA Polymerase II [57]. Another important 
example is that of miR-145, which is produced in a dicer-indipendent manner. 
This miRNA requires the catalytic activity of AGO2 [58-60]. Pri-miR-145 
cleavage is first mediated by Drosha, which gives rise to a 18 bp hairpin. This 
hairpin is too short to be bound and processed by Dicer, thus, AGO2 slices 
pri-miR-145 in the middle of the 3ʹ  strand. Then ribonuclease PARN trims 
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down the 3ʹ - end and produces the mature miRNA [61]. The existence of 
alternative pathways reflects the evolutionary flexibility of miRNA biogenesis. 
However, it is notable that the vast majority of functional miRNAs follow the 
canonical pathways for their biogenesis, and that only about 1% of conserved 
miRNAs, for example, miR-320 and miR-451, are produced independently of 
Dicer or Drosha in vertebrates. Most other non-canonical miRNAs are low in 
abundance and poorly conserved. Thus, the functional relevance of non-
canonical miRNAs should be interpreted with caution. Indeed, many miRNAs 
are conserved among different species while some are species-specific [62-
66]. 
In contrast, siRNAs, which are also 18-25 nt in length and derive from long 
dsRNAs (Fig. 1B) in the form of either sense or antisense RNA pairs or as 
long hairpins, are directly processed by Dicer to produce multiple functional 
siRNAs from the same primary transcript [67-72]. In summary, canonical, non-
canonical miRNAs and endo-siRNAs involve generally Dicer processing and 
in the mature form are 18-25 nucleotides in length.  
The piRNAs have a different biogenesis: they are processed by a different 
mechanism, which is not mediated by Dicer [73, 74]. Indeed, how piRNAs are 
produced and their modes of action are not fully understood [75]. The piRNAs 
are 25-32 nt in length and are expressed abundantly in the mammalian 
gametes [76-78]. These kind of small RNAs interact with a distinct family of 
Argonaute proteins, which are the Piwi proteins and include Miwi, Miwi2 and 
Mili, which in mouse are also known as Piwil1, Piwil4 and Piwil2, respectively. 
Although the mechanism of piRNA biogenesis has not been fully resolved, 
they are generated from long single-stranded RNA precursors that are often 
encoded by complex and repetitive intergenic sequences. One proposed 
model for their biogenesis is the ‘ping-pong mechanism’ (Fig. 1C) [79-96]. In 
this model, the Argonaute protein Mili cleaves the primary piRNA to define the 
5'-end of piRNAs, which is subsequently bound by Miwi2. Miwi2 cleaves the 
other strand of the precursor, thereby generating a 5'-end of the piRNA that 
can bind to Mili, thus forming a positive amplification loop. Many of the details 
of this model remain to be uncovered. Furthermore, the ping-pong model is 
likely to explain the biogenesis of only a subset of mammalian piRNAs, those 
that are derived from repetitive sequences, such as transposons, and those 
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that are associated with Miwi2 and Mili. These piRNAs are involved in the 
early stages of spermatogenesis. The mechanism of biogenesis of piRNAs 
derived from complex intergenic sequences, associated with Miwi2 and Mili, 
which function in the later stages of spermatogenesis, is not known.  
 
 
Figure 1. Mechanisms of biogenesis of the different small RNA classes [82]. 
 
1.4. Mechanism of action of small RNAs 
1.4.1. MiRNAs and endo-siRNAs act in the cytoplasm 
Mature miRNAs and endo-siRNAs interact with Argonaute proteins (AGO 1–4 
and AGO2 in mammals; also known as EIF2C1-4) forming the RNA-induced 
silencing complex, RISC (Fig. 1D) [83]. RISC interacts with target mRNA 
using the complementarity between the miRNA or endo-siRNA sequence and 
the 3'-UTR of the mRNA target. If complete complementarity exists, cleavage 
of the target mRNA can occur through AGO2, which has an endonucleolitic 
activity. If there is incomplete complementarity, the primary mechanism of 
post-transcriptional gene regulation (PTGR) occurs blocking translation 
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through AGO 1-4, which have translational repression and de-adenylation 
activities [84-86]. However, PTGR can act via mRNA degradation even if the 
complementarity is not complete between the small RNA and 3'-UTR of the 
target mRNA [87]. 
The cellular location, where miRNAs and endo-siRNAs act, could be the 
Processing bodies (P-bodies). P-bodies are discrete cytoplasmic foci that 
contain proteins involved in mRNA degradation. They are involved in several 
post-transcriptional processes: mRNA decay, translational repression, non-
sense-mediated mRNA decay and RNAi-mediated repression. All four Ago 
proteins [88-90], GW182 [88] and two RNA helicases RCK/p54 [91] and 
MOV10 [92] have been found in P-bodies, suggesting that miRNA 
suppression is localized to the P-body. However, it has also been suggested 
that P-body formation is a consequence rather than the cause of miRNA-
mediated gene silencing, because when siRNA or miRNA silencing pathways 
are blocked, P-bodies are not formed [93]. 
1.4.2. PiRNA function is in the nuclear and/or perinuclear region 
PiRNAs can act only after their association with PIWI proteins. These small 
RNAs and PIWI proteins are located in the nucleus or perinuclear region [80, 
94, 95], where they repress genetic elements, mainly transposons [61]. 
PiRNAs link the N-terminal PAZ (Piwi/Argonaute/Zwille) and MID (middle) 
domains of the Piwi protiens, which together recognize and bind the 3'- end of 
piRNAs [97]. The C-terminal domain of PIWI proteins has RNase H activity, 
which is capable of recognizing the 5'- end of piRNAs and facilitates the 
cleavage of the target sequence [95, 98]. In gametes, the PIWI-piRNA 
complex acts on transposons before or after their transcription. When they act 
at transcription level, the mechanism of action can be through chromatin 
silencing of transposable elements via histone modification or altering the 
DNA epigenetic status [99, 100]. While post-trascription repression is 
achieved by cleaving trasposons through the PIWI-piRNA complexes, thereby 
producing secondary piRNA through the ‘ping-pong model’ described above 
[80] (see 1.1.). This mechanism of action is supported by the observation that 
transposons are expressed at a higher level in the presence of PIWI protein 
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mutations [101]. In Drosophila, piRNAs are involved in telomere function, 
including telomere protection complex assembly, thereby maintaining 
chromosome integrity [102]. Expression of PIWI proteins in human somatic 
stem cells [103] and neoplastic cells [104-107] suggests that piRNA may also 
be involved in regulating stem cell function and carcinogenesis. However, the 
range of mechanisms and pathways regulated by the Piwi-piRNA complex 
remains unclear. 
1.5. Small RNAs in reproductive function 
MiRNAs are involved in both female and male reproduction. They are 
regulated by a paracrine or autocrine signalling, and are produced by a wide 
array of cells including oocytes, embryos, endometrial and granulosa cells 
[108, 109]. Moreover, they are found in biofluids, such as plasma and serum 
or follicular ovarian fluid as freely circulating stable molecules [110] or enclosed 
in exosomes [111, 112]. The extracellular miRNAs may be taken up by specific 
cells of endometrium, placenta or ovarian follicles, where they bind to their 
target mRNAs, repressing their translation and modulating cellular events and 
functions  [110, 199, 200].  
1.5.1. Small RNAs and ovarian function 
1.5.1.1. Folliculogenesis 
Follicle development is a highly orchestrated cyclic process that depends on 
gonadotropin action. Folliculogenesis starts with the activation of resting 
follicles and gradually leads to the growth and development of a pre-ovulatory 
follicle. The follicle development is accompanied by the sequential 
differentiation of oocytes and their surrounding somatic cells, which form the 
granulosa and theca layers [113]. 
In cattle, recruitment of follicles (primordial and primary follicles, <2 mm in 
diameter), selection and growth of leading follicles (small and mid-antral 
follicles, 2-8 mm in diameter), ovulation of the pre-ovulatory dominant follicle 
(large antral follicle, >8 mm in diameter) and degeneration of an-ovulatory 
subordinate follicles (Follicular atresia) takes place in a wave-like progression, 
with typically 2 or 3 follicular waves per oestrous cycle [114, 115] (Figure 2).  
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Figure 2. Folliculogenesis in cattle [116]. 
 
In several species folliculogenesis has been shown to be post-transcriptional 
regulated by small RNAs [117-119] and a particular interest is focused on the 
role of miRNAs. Cellular differentiation processes, which occur during follicular 
development, seem to be regulated by the expression and interaction of many 
miRNAs in a spatio-temporal manner in different follicle compartments: granulosa 
cells [120, 121], theca cells [122], follicular fluid and oocyte [123].  
Folliculogenesis may be coordinated by individual miRNAs, which regulate 
ovarian steroid hormones, by targeting hormone receptors as well as affecting 
hormone biosynthesis and release. There are several findings on Estradiol 
(E2), which is important in inducing ovarian follicle development and its 
production is correlated to aromatase. In particular, miR-378 is positively 
linked to aromatase expression and E2 synthesis in granulosa cells [124]. 
Moreover, miR-133b stimulates ovarian oestradiol synthesis by targeting 
Foxl2, which mediates the transcriptional repression of StAR and CYP19A1 to 
promote E2 biosynthesis [125]. Also miR-383 promotes E2 byosintesis in 
ovarian granulosa cells. It inhibits RNA binding motif single-stranded 
interacting protein 1 (RBMS1) altering its mRNA stability and leading to the 
inactivation of c-Myc, which induces steroidogenesis in these cells [126]. 
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Finally, miR-423-5p and miR-378 regulate E2 synthesis by targeting 
CYP19A1 mRNA and repressing CYP19A1 protein content and enzyme 
activity in newborn piglets [127]. 
In addition to the expression of individual miRNAs, there are subsets of 
miRNAs, such as miR-183 cluster and miR-132 cluster, which are organized 
in genomic groups and are differentially expressed during different phases of 
folliculogenesis by specific cells of follicle. This indicates they have a 
functional role during follicular development in granulosa cells [1118]. 
However, only a small set of miRNAs among a large number of expressed 
miRNAs is found to be specific for follicle stages, while majority of the 
miRNAs (>80%) are expressed at all stages [1118]. This indicates that 
commonly expressed miRNAs may play a role in maintaining normal 
physiological ovarian function during all the follicular phases of the oestrus 
cycle. Information on the stage specific miRNAs may help to decipher the 
molecular mechanism of follicular development, ovulation and atresia. 
Finally, follicular fluid miRNAs have been recently identified in cattle. In 
particular, their profiles can be different between developing and mature 
oocytes. Moreover, differences can be associated also with several miRNAs, 
which are present as freely and exosome-vehiculated forms [110]. Those 
miRNAs present at the different stages may be associated with the growth 
status of oocyte and may act as regulators of oocyte developmental 
competence by facilitating cell-to-cell communication in the follicular 
environment [110]. 
1.5.1.2. Oocyte development and maturation: the role of small RNAs 
Mammals are born with a finite oocyte number that originates from the 
primordial germ cells during embryonic development [128] (table 1). In 
particular, in mammals the developmental process begins during oogenesis 
when both maternal RNAs and proteins accumulate as the oocyte grows and 
matures [129]. Oogenesis is reliant on a dynamic gene regulatory network 
that includes oocyte-specific transcriptional regulators [130]. A hallmark of the 
oocyte is its high level of transcription, which is driven on maternal mRNAs, 
and proteins that are crucial for the early development of the newly fertilised 
zygote [131]. The early stages of embryogenesis are, therefore, regulated by 
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maternally inherited components stored within the oocyte. As development proceeds 
the process of early embryogenesis then becomes dependent on the expression of 
genetic information from the embryo [129]. 
 
Table 1. Maximum number of female germ cells reached in foetal ovaries at the time 
of birth or late gestation in different species [201].  
Species 
Maximum number of germ 
cells (Day of pregnacy) 
Number of germ cells 
close after birth (Day after 
birth) 
Bovine 2,700,000 (110) 68,000(13 day after birth) 
Pig 1,100,000 (50) 500,000 (at birth) 
Buffalo 23,540 (210) 20,000 (at birth) 
Rat 75,000 (18) 27,000 (2 days after birth) 
Human 6,800,000 (150) 2,000,000 (at birth) 
 
Bovine oocyte maturation involves the resumption and completion of the first 
meiotic division from germinal vesicle (GV) stage to metaphase II (MII) with 
corresponding cytoplasmic maturation. Storage of mRNA during oocyte 
maturation and its timely availability during early embryo development are 
essential for oocyte quality and developmental competence. There is 
differential expression of transcripts in in vitro matured and immature bovine 
oocytes, which underlines the tight temporal control of protein synthesis 
required for oocyte maturation in preparation for subsequent fertilisation and 
early embryo development [132]. As with mRNA, miRNA expression in mouse 
shows a dynamic change during oogenesis, where a large proportion of 
maternal genes directly or indirectly under control of miRNAs [133].  
MiRNA, siRNA and piRNA are expressed in oocytes of many species at 
different stages of development [76, 124, 134-138]. However, only siRNAs 
seem to have a critical role in oocyte maturation. This has been inferred by 
comparing the knockout phenotypes of Dicer and Dgcr8 mutant mice. Dicer 
knockout in the oocyte resulted in meiotic arrest with severe spindle and 
chromosomal segregation defects and loss of both miRNAs and endo-
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siRNAs, as they are usually processed by Dicer [139-141]. In contrast, Dgcr8 
knockout has not observable phenotype, and mRNA levels remain unchanged 
even though the oocytes are characterized by the loss of miRNAs [140]. 
These findings suggest that endo-siRNAs, and not miRNAs, underlie the 
meiotic defect of Dicer knockout oocytes. Reporter assays using Dgcr8 knock 
out mice oocytes have shown siRNA activity in mature oocytes, but little to no 
miRNA function [142]. Finally, miRNA function is suppressed in fully-grown 
oocytes although miRNA biogenesis is unaffected and miRNA targets are 
present (Figure 3). The mechanism of suppression is unknown. P-bodies 
seem to be correlated with miRNA destabilization. This hypothesis is 
supported by the loss of P-bodies in maturing oocytes followed by their 
resumption at the blastocyst stage [143-146]. PiRNAs are also expressed in 
mouse oocytes [137], but deletion of the Piwi proteins does not produce an 
observable oocyte phenotype [93, 146, 147]. Therefore, it is unclear whether 
they play a role in oogenesis. 
1.5.1.3. Implications for female fertility 
Increasing evidences on the role of miRNAs during female reproduction have 
allowed the association of these molecules to several diseases [149-150], 
which generally affect oocyte developmental competence. However, the 
underlying mechanism of developmental competence has not been yet 
identified and a crucial part of this process is certainly the latter phase of 
oocyte growth, in which developmental potential is gained. This is known in 
mice [151], humans [152] and cattle [153]. While the building process is now 
better understood, we are still far from a clear blueprint of what composes a 
competent oocyte.  
Polycystic ovarian syndrome (PCOS) 
Polycystic ovarian syndrome (PCOS) is an anovulatory disorder, which is 
characterized by the development of ovarian cysts and affects women of all 
reproductive age [154]. The underlying mechanisms resulting in PCOS are 
not understood, however, the expression of several miRNAs are characteristic 
of PCOS patients [155]. Using microarray and quantitative PCR, five (let-7i-
3p, miR-5706, miR-4463, miR-3665, miR-638) miRNAs were found to be 
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overexpressed in blood of women with PCOS compared to healthy controls, 
while four (miR-124-3p, miR-128, miR- 29a-3p, let-7c) were underexpressed 
[156]. When deep sequencing was used to profile exosomes from the 
follicular fluid of women with PCOS, miR-132 and miR-320 were found to be 
less abundant in the follicular fluid compared to controls [157]. These authors 
also demonstrate that miR-132 and miR-320 stimulated production of 
estradiol (E2) in a human granulosa-like tumor cell line, while inhibition of 
these miRNAs supressed E2 production. 
In addition to variations in serum and follicular miRNA populations associated 
with PCOS, differences are also observed miRNA in the developing embryos 
in these women, which could have an impact on oocyte developmental 
competence. Blastocysts derived from oocytes obtained from PCOS patients 
have an under-regulated subset of miRNAs, like let-7a, miR-19a, miR-19b, 
miR-24, miR-92, and miR-93 [158], which can compromise embryo 
development and, thus, fertility.  
Premature ovarian failure (POF)  
Premature ovarian failure (POF) is a disorder with multifactorial origin, which 
affects ovarian function in women under 40 years of age. The condition is 
characterized by early ovarian senescence and diminished antral follicle count 
(AFC) [159]. Several studies have identified alterations in miRNA levels of 
women with POF. Interestingly, these studies focused on circulating miRNAs 
in plasma and serum. MiR-22 plasma levels were reduced in women with 
POF compared with control women. Under-regulation of miR-22 was also 
correlated with a lower AFC [160]. Moreover, the miRNAs circulating in 
plasma, which are associated with POF, have important roles in regulating 
many signalling pathways. MiR-23a, which was abundant in the plasma of 
POF patients inhibits XIAP and caspase-3 expression, resulting in apoptosis 
in human granulosa cells [161]. These results indicate that circulating miRNAs 
can be potentially used as non-invasive biomarkers of POF. 
Interestingly, Single-nucleotide polymorphisms (SNPs) are found in genomic 
DNA coding for miRNAs, which have been associated with disease 
susceptibility. A study of miRNA polymorphisms identified an association 
between combined genotypes in the genome coding for miR-146aC>G, miR-
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196a2T>C, and miR-499A>G and POF in women. Therefore transcriptional 
changes in miR-146a and miR-196a2 induced by miRNA SNPs may be 
involved in POF development [162]. 
 
The study of miRNAs in the follicular fluid and oocyte could improve the 
missing knowledge on the role of miRNAs in the acquisition of oocyte 
developmental competence.  
 
1.5.2. Male reproduction and small RNAs 
Spermatogenesis is a process where spermatogonia differentiate into motile 
spermatozoa within the seminiferous epithelium of the testis. During the 
course of differentiation numerous mRNAs are regulated post-transcriptionally 
[104]. A repertoire of small RNAs is present in differentiating male gametes 
throughout spermatogenesis [163-166]. Among these, the miRNAs are 
abundant in male gametes at times of active gene transcription in meiotic 
stages, specifically pachytene, as well as in early spermatids prior to nuclear 
silencing. They are proposed to play roles in post-transcriptional silencing of 
genes during process of spermatogenesis (Figure 3) [167, 168]. The 
functional role of both miRNAs and endo-siRNA is demonstrated but the 
deletion of Dicer results in a loss of mature sperm [163, 169]. This could be 
attributed to the loss of either miRNAs or endo-siRNAs. However, the deletion 
of Ago2, a protein that is essential for cleavage of mRNA targets by endo-
siRNAs, has not obvious testis phenotype, suggesting that the regulation of 
spermatogenesis is miRNA based [163]. Furthermore, RNA-binding protein 
Dead end 1 (DND1), which is implicated in preventing miRNA access to cell 
cycle-related target mRNAs, has been shown to be essential for male gamete 
development during embryogenesis [170, 171]. The roles of individual 
miRNAs during spermatogenesis have also been investigated, for example, 
miR-122a regulates the expression of TNP2, which is a testis-specific gene 
involved in chromatin remodelling during spermatogenesis [164].  
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Figure 3. MicroRNA associated with different stages of spermatogenesis [125, 164, 
172-174]. 
 
PiRNAs are found at relatively high levels in spermatocytes. Their expression 
begins at the pachytene stage of meiosis and persists until after the spermatid 
stage, when they gradually disappear during spermatid differentiation [79, 
175]. In mouse, piRNAs have been separated into two classes based on the 
timing of their expression, their repetitive versus non-repetitive nature, and the 
Piwi proteins with which they are associated [76-78, 175,176]. The first class 
is highly repetitive and is expressed before meiotic pachytene. This class of 
piRNAs interacts with Mili and Miwi2 protiens [79, 177]. The second class of 
piRNAs is non-repetitive, becomes abundant during the pachytene stage and 
is also associated with Mili and Miwi proteins [79, 175, 177]. Deletion of Mili 
and Miwi2 results in early arrest of meiosis in meiosis I (at the primary 
spermatocyte stage), whereas deletion of Miwi results in arrest following 
meiosis II (the round spermatid stage) [94, 99, 146]. The functional role of 
both repetitive and non-repetitive piRNAs has to be clarified.  
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1.5.2.1. MiRNAs and motile spermatozoa: a repertoire for early 
embryonic development 
While a large number of miRNAs are found in mature spermatozoa in testes 
[178], most of the RNAs with computationally predicted 3′UTR targets are 
absent [179]. This suggests that the role of the miRNAs present in the 
spermatozoa is in the oocyte at or following fertilization. They can act as 
signals for early embryonic histone replacement [180] or affect epigenetic 
modifications, or may regulate gene expression during early embryonic 
development, either via epigenetic modifications or at the level of post-
transcriptional control. The role of miRNAs in histone modifications is 
supported by finding that more than 10% of all small RNAs are located to 
histone-enriched transcription start sites (TSS) and promoter regions [163].  
How miRNAs carried by spermatozoa impact embryogenesis can also be 
investigated at the level of individual miRNAs. For example, one of the most 
abundant miRNA carried by spermatozoa is human miR-34c [179, 181], which 
has also been identified in sperm of horses and mice [65, 66]. MiR-34c has 
been shown to be essential for the first cleavage division in mouse zygotes 
[34]. The mechanism of action and functional role in spermatogenesis and 
fertility of miR-34c remain to be fully clarified [63, 64, 66, 183]. In mouse 
testes, miR-34c expression is p53 independent [165], whereas miR-34c 
targets p53 in cancer cells [184]. This suggests an influence on growth [185, 
186]. Furthermore, miR-34c has been found in bovine spermatozoa, oocyte 
and early embryos, suggesting a paternal contribution of this miRNA [187].  
Spermatozoa also contain several intact miRNA precursors (pri-miRNAs, 100 
–150 nucleotides). Since the zygote has the capacity to process immature 
miRNAs [182], the potential role of the pri-miRNAs requires consideration, 
e.g. pri-miRNA-181c is the most abundant immature miRNA in human 
spermatozoa. 
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1.5.2.2. MiRNAs as biomarkers of male fertility 
Infertility is estimated to affect 15% of the couples worldwide and male 
infertility is expected to be responsible for 50% of this [188]. Generally, male 
infertility is accompanied by qualitative and quantitative abnormalities in 
spermatozoa [189, 190]. When the problem in fertility is associated to alteration in 
morphology of spermatozoa, such us normozoospermia, asthenozoospermia and 
oligoasthenozoospermia, it is possible to identify different miRNA profiles between 
fertile and infertile men [191]. Regulation of function can be exerted by low levels of 
specific miRNAs, such as miR-34c, which is very abundant in spermatozoa and is 
under-regulated in oligoasthenozoospermia compared to normozoospermia. 
Moreover, alterations in miRNA profiles can be demonstrated by a subset of 
miRNAs. A panel of five miRNAs, miR-34b*, miR-34b, miR-34c, miR-429, and 
miR-122, has been proposed as potential biomarkers for the diagnosis and 
assessment of male subfertility. The power to discriminate between affected 
and normal men was assessed using these five miRNAs with the support 
vector machine classification (SVM) analysis, which is method performing 
classification tasks by constructing hyperplanes in a multidimensional space. 
In this case, the panel of miRNAs was capable of discriminating between 
individual with subfertility from normal subjects with reliability of 98.7 %, 
specificity of 98.8 %, and sensitivity of 98.4 % [192]. 
Bovine spermatozoa are also rich in miRNAs, which have different expression 
levels in bulls with pronounced differences in Non-Return Rates (NRR), 
implicating these miRNAs in differences in fertility. Seven miRNAs were 
identified as differentially expressed in spermatozoa from high and moderate 
fertility bulls, which suggests that miRNAs may play important roles in 
mammalian gametogenesis and early development [64]. Information derived 
from miRNAs in spermatozoa could be considered as biomarker for male 
fertility [193]. 
 
MiRNAs in spermatozoa may influence gene expression in the embryo post 
fertilization and impact on development. Thus, it is important to focus on how 
the differences in the miRNA blueprint are associated to high and low fertility 
and the way this may affect developmental potential of early embryo.  
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1.5.3. New insights in gametes small RNAs: from fertilization to early 
embryogenesis 
A considerable number of small RNAs are present in oocytes, many of which can be 
associated to dynamic expression profiles during oogenesis and folliculogenesis. 
Indeed, expression of miRNAs generally increases during oocyte maturation 
and embryo development. Conversely, there are miRNAs, which are 
abundant in the immature oocyte and diminish throughout maturation, while 
others remain relatively stable [136]. The expression profiles of small RNAs, 
particularly miRNAs, throughout gamete maturation and early embryogenesis 
strongly implicate them in the timely regulation of embryonic gene expression. 
There is an inverse correlation between piRNAs and miRNAs, suggesting a 
different role of these small RNAs in the reproductive function (Figure 4). 
MiRNAs in spermatozoa could influence gene expression in the embryo post 
fertilization. Paternal contributions to the zygote and its developmental 
competence are increasingly recognized as important element of successful 
fertilization. Sperm are known to deliver proteins, RNAs and small RNAs, 
which are critical for embryo development [194]. Moreover, some RNAs and 
small RNAs present in spermatozoa and early embryos are absent from non-
fertilized mature oocytes (MII oocytes), suggesting a unique role for these 
RNAs in post-fertilization mechanisms [195]. 
 
 
Figure 4. Piwi-interacting RNAs (piRNAs) and microRNAs (miRNAs) are essential in 
the developing male germline, whereas endogenous small interfering RNAs (endo-
siRNAs) play their most crucial role in oocyte maturation. There is a transition from 
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endo-siRNAs or piRNAs to miRNAs during pre-implantation development. PGCs 
indicates primordial germ cells [82]. 
 
The small RNAs may be responsible for the transmission of information 
across generations. Small non-coding RNAs that, are produced in gametes 
and which may be transmitted to progeny, may be influenced by, for example, 
environment or diet [116, 196]. Exposure of adult males and females to poor 
environments may result in adverse effects in their progeny. Such effects 
have been linked to epigenetic variations in spermatozoa and oocytes [197, 
198]. This indicates that small RNAs, which are present in both spermatozoa 
and oocytes at the time of fertilization, have a critical role, not only on 
reproductive function, but also on the phenotype of the offspring [116, 196].  
To unravel the mechanisms underlying the transmission of epigenetic 
information detailed studies of small RNAs will need to be carried out in 
developing and mature gametes of individuals exposed to different 
environments, as well as early embryos and somatic tissues in the next 
generation. 
 
In conclusion, our knowledge of miRNAs with respect to reproduction and 
fertility is increasing rapidly. Further studies of miRNAs will contribute to 
understanding the molecular mechanisms important in regulating sperm and 
oocyte maturation and may identify potential biomarkers of quality for 
gametes and pre-implantation embryos. 
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AIMS OF THE THESIS 
The following aims were addressed using a deep sequencing protocol which 
was set up during the PhD program. The protocol, which is based on high-
throughput approach, facilitated the study of both the known and putative 
novel bovine sequences in a sample. These data were used to look at the 
whole gene networks regulated by miRNAs and provide insights into cellular 
metabolism and complex biological systems involved in gamete and embryo 
development. The main objectives of the PhD were: 
 
1) to use the small RNA sequencing methods and bioinformatic analysis 
pipelines exploring in vitro produced blastocysts. This increased knowledge of 
the bovine miRNAs repertoire and improved our understanding of the role of 
miRNAs in pre-implantation embryos. 
 
2) to study the influence of miRNAs derived from spermatozoa on embryo 
developmental potential. In particular, to study in vitro produced embryos 
fertilized with sperm associated to high and low blastocyst rates. 
 
3) to examine molecular mechanisms of poor cow fertility using oocytes from 
ovaries with high and low function.  
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CHAPTER 2 
Profiling of microRNAs in bovine blastocysts 
using deep sequencing 
 
2.1. Introduction 
Knowledge of the key factors regulating pluripotency and differentiation during 
pre-implantation embryo development is essential to optimize in vitro embryo 
production (IVP) protocols and evaluate the developmental competence of the 
IVP embryos. Producing good quality blastocysts is essential for Artificial 
Reproductive Rechniques (ARTs) in humans [1] and economically important 
animals including ruminants [2, 3]. The number of bovine embryos produced 
in vitro and transferred into cow recipients has increased more than 10 fold in 
the last dozen years [4], which indicates that IVP is considered a reliable and 
cost-effective technique, and is increasingly being used in cattle breeding to 
accelerate the rate of genetic gain. 
MicroRNAs (miRNA) are short non-coding RNAs of 20-25 nucleotides, that have 
been shown to be important in control of, amongst others, reproductive functions, 
such as oocyte maturation [5, 6], implantation [7] and early embryonic 
development [8, 9]. They are regulated by a paracrine or autocrine signaling 
and are produced by cells, e.g. of the embryo, endometrium, and granulosa 
cells and oocytes [10, 11]. MiRNAs are found in biofluids such as plasma or 
follicular ovarian fluid as circulating stable forms [12] or in exosomes [13, 14]. 
Extracellular miRNAs may be taken up by specific cells in tissues like 
endometria, placenta or ovarian follicles, where they bind to their target 
mRNAs, repressing their translation and modulating cellular events and and 
functions [12, 72, 73]. MiRNAs of presumed placental origin have been 
detected in the plasma of pregnant females in several mammal species [15, 
16]. However, miRNAs are present in all biofluids and this characteristic has 
prompted their study as potential non-invasive biomarkers for physiological 
and pathological processes [16, 17]. In some pathologies associated with 
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reproduction, such as polycystic ovary syndrome or male factor infertility, 
miRNA profiles are altered [7, 18]. Several study have focused on the analysis 
of miRNAs in bovine blastocyst but their role during the early stage of embryo 
development is not well understood [19-21]. Recently, the presence of 
miRNAs secreted into culture media by embryos during IVP has been 
associated with embryo quality or developmental competence [22, 23]. 
Biomarkers that have been developed to assess embryo developmental 
competence are generally based on proteins and/or variations in the 
expression of mRNA [24, 25]. 
Advances in technology for deep sequencing has made possible to analyze 
all the miRNAs present in the sample. However, the very low quantities of 
RNA present in 100-150 cells, which compose a blastocyst, make miRNA 
profiling of early embryos technically challenging. This work describes the use 
of 3 procedures, which aim to optimize a low input deep sequencing approach 
for the analysis of all miRNAs present in bovine blastocysts and investigates the 
molecular mechanisms, which characterize the early stage of embryo 
development that are regulated by miRNAs. 
 
2.2. Materials and methods 
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich 
(Milan, Italy).  
 
2.2.1. Oocyte collection and in vitro maturation 
Bovine ovaries were collected post slaughter and transported to the laboratory 
in PBS at physiological temperature (about 37°C). Cumulus oocyte 
complexes (COCs) were isolated from mid-antral follicles (2-6 mm) within 2 hr 
of collection, washed 4 times in modified PBS (supplemented with 36 µg/L 
pyruvate, gentamycin (50ug/mL), and 0.5 mg BSA/mL, sigma, fraction V, A-
9647) and once in maturation medium (TCM199 + 10 µg/mL epidermal growth 
factor (EGF) + 10 % (v/v) fetal calf serum (FCS)). COCs were matured in 
group of 50 per well for 24 hours (h) at 38.8° C with an atmosphere of 5% 
CO2 in air with maximum humidity.  
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2.2.2. In vitro fertilization (IVF) and culture (IVC) 
Following 24 h maturation, COCs were washed 4 times in PBS and once in 
the fertilization medium (TALP: 10 µg/mL heparin salt – 184 units/mg, 
Calbiochem, San Diego, CA) before being transferred individually into 
fertilization plates in 250 µl of fertilization medium. Mature COCs were 
fertilised using cryopreserved semen of the same bull, which was rountinely 
used for IVF. 
Motile spermatozoa were obtained by centrifugation of thawed spermatozoa 
through a Percoll (Pharmacia, Upsalla, Sweden) discontinuous density 
gradient (3.0 mL of 45% Percoll layered over 2.5 mL of 90%) for 10 min at 
700 g, at room temperature. Viable spermatozoa were collected at the bottom 
of the 90% Percoll fraction. The pellet was suspended in TALP and then 
centrifuged at 100 g for 5 min at room temperature, following which the 
supernatant was removed. The concentration of Spermatozoa was estimated 
using a haemocytometer, and were then diluted in the appropriate volume of 
TALP to give a concentration of 2 X 106 spermatozoa/mL; 250 µL of this 
suspension was added to each fertilization drop to obtain a final concentration 
of 1 X 106 spermatozoa/mL. Fertilization dishes were then incubated for 24 h 
in an atmosphere of 5% CO2 at 38.8°C in air with maximum humidity. At 18-
20 h post fertilization, cumulus cells were removed from presumptive zygotes 
by moderate mixing using a vortex mixer in 1-2 mL PBS for 3 min. The 
presumptive zygotes were then washed twice in modified PBS and once in 
culture media (synthetic oviduct fluid supplemented with 10% FCS) before 
being transferred into 25 µl drops of culture media under mineral oil (Sigma, 
Italy) and cultured at maximum humidity in an atmosphere of 5% CO2 and 5% 
O2 at 38.8°C [71]. The resulting blastocysts were collected at the day 7 of in 
vitro embryo development (day 0 = day of fertilization) and snap frozen in 
pools of  5, in liquid nitrogen, and stored at -80°C.  
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2.2.3 RNA extraction procedures 
Total RNA extraction was carried out using three different protocols using 
pools of 30 embryos for each sample independently of the RNA extraction 
procedure. RNA quality and quantity of each sample was assessed using 
RNA Pico Chip and 2100 Agilent Bioanalyzer.  
 
2.2.3.1. Procedure 1 : Classical Trizol – M1 
Briefly, pools of 30 embryos were lysed in 1 mL Trizol reagent (Life 
Technologies, CA, USA). Two hundred microliters of chloroform was added to 
the sample and mixed for 15 seconds using a vortex mixer, and then 
incubated at room temperature for 5 minutes. The samples were then 
centrifuged at 12000 g for 10 minutes in order to separate the aqueous phase 
from organic phase. The aqueous phase was carefully remove and 1 volume 
of isopropanol added and mixed by inversion, then centrifuged at 12000 g for 
15 minutes. The supernatant was discarded without disturbing the RNA pellet. 
The pellet was washed using 1 volume of 75 % ethanol and was centrifuged 
at 7500 g for 5 min. The ethanol was discarded and the pellet was dried for 5-
10 minutes at room temperature. The RNA was dissolved using RNAse free-
water and stored at -80°C. 
 
2.2.3.2. Procedure 2: Classical Trizol plus RNA clean and concentrator-5 
– M2 
The procedure was as described above until the final step of precipitation 
from the aqueous phase isolation. At this point, the aqueous phase was 
concentrated to 5 µl using the “RNA Clean and Concentrator” spin column 
procedure as described by the supplier (Zymo research corp, USA). The RNA 
was eluted using RNAse free water and stored at -80°C. 
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2.2.3.3. Procedure 3: Allprep DNA/RNA/miRNA and RNA clean and 
concentrator-5  – M3 
Embryos were mixed in 1 mL of lysis buffer as supplied with the AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen, USA) and lysed by repeated 
pipetting with P1000 Gilson pipette for about one minute. RNA extraction was 
carried out according to the manufacturers’ recommended procedure (Qiagen, 
UK). RNA was eluted into 50 µl of RNAse free water and was concentrated 
into 5 µl following the recommended RNA clean and concentrator procedure 
(Zymo research corp, USA). RNA samples were stored at -80°C. 
 
2.2.4. Library preparation and deep sequencing 
A small RNA library was prepared from 5 µl of the total RNA from each 
sample using the Truseq Small RNA kit (Illumina Inc., USA, Figure 1) with 
some modifications, as follows: to minimize primer dimer formation, total RNA 
was mixed with half of the TruSeq Small RNA sample reagents, followed by 
15 cycles of PCR to amplify the library. Five µl of each unique indexed library 
were pooled in 6-plex and resolved on a Pippin gel cassette 3% Agarose Dye 
free (BluPippin, Sage Science, MA, USA). Library RNA fragments in the 140-
160 base pairs size range (the length of miRNA inserts plus the 3′ and 5′ 
adaptors) size ranges were recovered in 40 µL of Pippin elution buffer and 
then purified by Qiagen MinElute PCR Purification kit (Qiagen, CA, USA). The 
indexed libraries were quantified in triplicate on a ABI9700 qPCR instrument 
using the KAPA Library Quantification Kit, according to the manufacture’s 
protocol (Kapa Biosystems, Woburn, MA, USA). Then, ten µL of the pooled 
libraries at a final concentration of 2 nM were used for sequencing on a 
Illumina HiSeq2000 using a 50bp Single-Read sequencing protocol. Finally, 
eight libraries (3 for M1, 2 for M2 and 3 for M3) were sequenced into a lane of 
Illumina Hiseq2000 flow cell. 
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Figure 1. The principal phases of library preparation procedure with Truseq Truseq 
Small RNA kit (Illumina Inc., USA) are: adapter ligation, reverse transcription, PCR 
amplification, and pooled gel purification to generate a library. The protocol takes 
advantage of the natural structure common to the most known miRNAs, which have 
a 5ʹ-phosphate and a 3ʹ-hydroxyl group as a result of the cellular pathway used to 
create them. Because of this, the Illumina adapters in the kit are directly, and 
specifically, ligated to miRNAs. 
 
2.2.5. Bioinformatic pipeline: setting up the methods for the analysis of 
sequencing data 
Raw sequences (e.g. raw reads) were obtained from Illumina Hiseq25000 as 
FASTQ files after preliminary sequence quality control procedures using 
FastQC v0.11.2. Then, raw reads were trimmed using ‘Trimmomatic software’ 
to remove adapter sequences of library [26]. The Quality Control threshold 
was set as a minimum base quality of 15 over a 4 bases sliding window and 
only sequences with length above 15 nucleotide were retained. Trimmed 
miRNA sequences (i.e. filtered or clean reads passing the threshold), which 
pass the threshold, were annotated using miRDeep2 software [27] This 
software was used for detection of novel and know miRNAs using bovine and 
homologous human sequences. In particular, the FASTA files of all matured 
bovine miRNAs, precursor bovine miRNAs and miRNAs of human were 
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downloaded from miRBase database (release 21: June 2014) 
(http://mirbase.org/ftp.shtml).  
Known bovine and human miRNAs (mature and precursors) were used as a 
reference in the discovery process. Sequence reads were mapped to bovine 
reference genome and aligned sequence reads were blasted against both 
mature and precursor miRNAs of bovine and human. All known bovine and 
human miRNAs were used to quantify the frequency of miRNA sequences in 
each sample and produce a list of miRNA IDs and the relative abundance of 
mapped reads expressed as counts.  
Novel miRNAs and their respective read counts were inferred using the same 
software (Figure 2). MiRDeep2 predicts the probability of un-annotated 
sequence being novel miRNA based on the genomic context, which 
surrounds the sequence and the capability of the sequence to fold into hairpin 
structure with low free energy [27]. Secondary structure of miRNA precursor 
was predicted using RNAfold [28] and minimum free energy algorithm [29].  
 
 
 
Figure 2. Graphic illustration of a representative predicted novel miRNA by 
miRDeep2. The primary miRNA hairpin with both mature and star miRNAs 
highlighted with red and blue colors, respectively (A). MiRDeep2 scores and 
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provisional ID are shown (B). The consensus matured miRNA sequence and other 
isomiRs and their corresponding read counts are indicated. Mismatched nucleotides 
of isomiRs with the miRNAs hairpin are written in capital letter (C) [28]. 
 
2.2.6. MiRNA target prediction and functional analysis 
Gene target prediction for the miRNAs was carried out using DIANA miRPath 
v2.0 with homologous human miRNA and gene union options. DIANA 
miRPath can use predicted miRNA targets (in CDS or 3’-UTR regions) 
provided by the DIANA-microT-CDS algorithm or experimentally validated 
miRNA interactions derived from DIANA-TarBase v6.0 [69]. A Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis 
was obtained using DIANA miRPath in order to identify significantly targetted 
canonical pathways (P<0.0001) and predict the target genes putatively 
regulated by miRNAs. The list of target genes was used for Gene ontology 
(GO) analysis to infer gene function and molecular mechanisms enriched by 
the predicted miRNA target genes. To this end, the list of target genes were 
imported to DAVID Bioinformatics systems (http://david.abcc.ncifcrf.gov/) to visualize 
the non-redundant biological terms for large clusters of genes in a functionally 
grouped clusters [30]. 
 
2.3. Results 
2.3.1. Sample quality and quantity 
At the day 7 after fertilization, blastocysts were examined under the 
stereomicrosocpe and only those embroys, which were classified as grade 1 
quality according to IETS standards, were collected for small RNAseq 
analysis. RNA was extracted from 8 pools of 30 blastocysts using the three 
different procedures (3 for M1, 2 for M2 and 3 for M3, Table 1). RNA integrity 
number (RIN) was between 8.9 and 9.7 for all the samples. However, the 
quantity of the total RNA, assayed using Agilent Bioanalyzer 2100 varied from 
3.5 to 18.0 ng, indicating that this difference was not dependent on the 
procedures of RNA extraction (table 1).  
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Table 1. RNA quantity and quality in nanograms (ng) and RNA integrity (RIN), 
respectively, for each sample (sample ID) and procedure (procedure ID). 
 
Procedure ID Sample ID
Total RNA 
quantity (ng) RIN
M1A 10.5 9.4
M1B 3.9 9.7
M1C 18.0 8.9
M2A 8.3 9.7
M2B 11.6 9.7
M3A 3.5 9.6
M3B 10.5 9.7
M3C 7.8 9.7
Procedure 1
Procedure 2
Procedure 3
 
2.3.2. Overview of sequencing data 
Sequencing produced 26M, 5M and 15M of reads for M1, M2 and M3, 
respectively. A mean of 81.2% (M1), 81.9% (M2) and 86.6% (M3) of reads 
were maintained after filtering of low quality reads. Between 5 and 12% of 
filtered reads could be mapped to known mature miRNAs in the human and 
bovine miRBase (table 2).  
Comparing the three procedures, a similar number of miRNAs was identified 
in M1 and M3, for which the number of filtered reads was higher than M2. The 
procedure was characterized by a proportionately fewer miRNAs and in 
addition the number of novel miRNAs that were not present in miRBase 
differed among the procedures of RNA extraction: 62% (M1), 37% (M2) and 
40% (M3) (table 3). 
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Table 2.  Sequencing data reported by procedure and sample showing the number 
(n) of: raw reads (raw sequences or data obtained from the sequencer), trimmed 
reads (filtered sequences or data obtained by removing adapters and low quality 
sequence), percentage (%) of trimmed reads, mapped reads (n) and percentage (%) 
obtained from MiRDeep2. 
 
2436344
4573463
13061986
1936178
19376332
1594601
10.0
M3B 22348265 2476582 12.8
105116 6.6
4.0
M2B 5762574 146986 3.2
Procedure 3
M3A 14760122 1305092
M3C
Known MiRNA 
mapped reads(n)
Mapped read s(n)
Procedure 2
M2A 3188883 98444
19740535
25483222
4933294
4345780
1194270 24.2
M1C 6576100 228544 5.3
%Known  miRNA mapped 
reads
Procedure 1
M1A 37420115 1359181 5.3
M1B
Procedure ID Sample ID Filtered reads (n)
 
 
 
 
 
Table 3. The annotation and discovery of miRNAs obtained by MiRDeep2 analysis 
are reported as total miRNAs, novel miRNAs, known miRNAs and percentage (%) of 
novel miRNA. 
 
Procedure ID Sample ID Total miRNAs Novel miRNA Known miRNA % novel miRNA
M1A 797 420 377 52.7
M1B 745 328 417 44.0
M1C 494 181 313 36.6
M2A 386 144 242 37.3
M2B 432 155 277 35.9
M3A 729 307 422 42.1
M3B 780 325 455 41.7
M3C 348 117 231 33.6
Procedure 1
Procedure 2
Procedure 3
 
 
There were miRNAs which differed among the technical replicates of the 
procedures: only 432 miRNAs overlapped for the samples of M1, 316 
overlapped between M2 samples and 333 between M3 samples (Graph 1A, 
1B and 1C). Only 249 miRNAs were in common among all the RNA extraction 
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procedures (Graph 1D). This difference may be explained by the very low 
abundance of some of the miRNAs. Of the known miRNAs, 562 (M1), 1045 
(M2) and 699 (M3) miRNAs had between 0 to 10 counts; 443 (M1), 201 (M2) 
and 316 (M3) had between 100 and 1000 counts and 222 (M1), 82 (M2) and 
205 (M3) had more less than 1000 counts; only 135 (M1), 35 (M2) and 143 
(M3) had over 1000 (data not shown).  
 
 
!!
! !
(a) (b) 
(d) (c) 
 
 
 
 
Graph 1. Venn diagrams per sample for each RNA extraction procedure, indicating 
the number of overlapping miRNAs among and within samples and proceedures M1, 
M2, M3 (1A, 1B, 1C respectively). The number of overlapping miRNAs between the 
procedures is also indicated, identifying those, which were common between 
samples (1D). 
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The most abundant length of all sequences classified as miRNA was 22 bp, 
which corresponds to the mature miRNAs length for all samples of each 
extraction procedures (Graph 2). Considering only the mature miRNA 
sequences, the enriched lengths were 22, 23 and 25 bp (Graph 3).  
 
 
 
 
 
 
! 
 
Graph 2. Mapped reads are reported as unique mature miRNAs and  length of 
distribution (length is expressed as nucleotide = nt). 
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Graph 3. Mapped reads are reported as sum of all mature miRNA sequences and  
length of distribution (length is expressed as nucleotide = nt). 
 
 
 
In summary: a total of 1363 unique miRNAs were identified, following 
discovery and annotation using miRdeep software. These miRNAs differed 
quantitatively and qualitatively among the extraction procedures: M1 identified 
679 miRNA (ranging from 494 to 797) of which a mean of 420 were novel, M3 
identified 619 (±33) miRNAs of which a mean of 250 were novel and M2 
allowed to identify 409 (±236) of which 150 were novel (table 3).  
Of the most abundant miRNAs, bta-miR-148a, bta-miR-92a, bta-miR-192, bta-
miR-378 and bta-miR-10b were highly represented in all the procedures of 
RNA extraction (table 4). 
 
 
 
 
 
 
 
 
 
	   49	  
Table 4. The top 20 most abundant miRNAs reported as miRNA ID and avarage 
read counts for samples of each procedure. 
 
Procedure 1 Procedure 2 Procedure 3
miRNA ID Avarage read counts miRNA ID Avarage read counts miRNA ID Avarage read counts
bta-miR-10b 191422 bta-miR-10b 24128 bta-miR-10b 299902
bta-miR-378 84726 bta-miR-92a 13797 bta-miR-378 163837
bta-miR-371 37424 bta-miR-378 11791 bta-miR-192 78539
bta-miR-22-3p 56652 bta-miR-148a 6893 bta-miR-22-3p 63588
bta-miR-92a 58504 bta-miR-371 5721 bta-miR-148a 68241
bta-miR-26a 39459 bta-miR-192 4235 bta-miR-92a 71244
bta-miR-192 47495 bta-miR-423-5p 3870 bta-miR-30e-5p 49358
bta-miR-148a 49916 bta-miR-22-3p 5564 bta-miR-371 46660
bta-miR-30e-5p 38521 bta-miR-21-5p 4281 bta-miR-26a 45982
bta-miR-6119-5p 25061 bta-miR-30e-5p 3884 bta-miR-6119-5p 32787
Novel:hsa-miR-4706 17008 bta-miR-26a 3683 bta-miR-21-5p 39731
bta-miR-423-5p 19791 bta-miR-6119-5p 2321 bta-miR-30d 33302
bta-miR-191 18576 bta-miR-30d 2357 bta-miR-191 18569
bta-miR-21-5p 21224 bta-miR-191 1748 bta-miR-6526 16201
bta-miR-30d 19946 bta-miR-25 1585 bta-miR-423-5p 19765
bta-miR-186 12851 bta-miR-1468 1234 bta-miR-27b 16496
bta-miR-6526 9988 bta-miR-2478 973 bta-miR-186 13654
bta-miR-151-5p 9670 bta-miR-1246 1361 Novel:hsa-miR-4706 10275
bta-miR-16b 9737 bta-miR-27b 1311 bta-miR-25 13997  
2.3.3. Target prediction and functional analysis 
The 20 most highly expressed miRNAs were compared between procedures 
(table 4). A total of 14 miRNAs were common to all 3 procedures The most 
abundant miRNAs were bta-miR-148a, bta-miR-92a, bta-miR-192, bta-miR-
378 and bta-miR-10b (Table 4). Bta-miR-6119-5p was exclusively annotated 
in miRbase for cattle. Thus, functional analysis was carried out using the 13 
miRNAs which had human homologues (hsa-miR-10b-5p, hsa-miR-378a-3p, 
hsa-miR-192-5p, hsa-miR-22-3p, hsa-miR-148a-3p, hsa-miR-92a-3p, hsa-
miR-30e-5p, hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, hsa-miR-
30d-5p, hsa-miR-191-5p and hsa-miR-423-5p). KEGG pathway analysis 
identified many canonical signaling pathways which were enriched with genes 
targeted by these miRNAs (P<0.0001, table S1 – supplemental material). The 
more significant pathways were related to cancer (e.g. Pathways in cancer 
(hsa05200), Prostate cancer (hsa05215), Colorectal cancer (hsa05210), 
Bladder cancer (hsa05219) Transcriptional misregulation in cancer (hsa05202), 
Chronic myeloid leukemia (hsa05220), Endometrial cancer (hsa05213), Pancreatic 
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cancer (hsa05212)) and diseases (e.g. Prion diseases (hsa05020), HTLV-I infection 
(hsa05166), Hepatitis B (hsa05161), Fanconi anemia pathway (hsa03460)). Other 
significant canonical pathways were related to control cell growth and death (e.g. Cell 
cycle (hsa04110), p53 signaling pathway (hsa04115)) and signal transduction (e.g. 
Wnt signaling pathway (hsa04310), TGF-beta signaling pathway (hsa04350), ErbB 
signaling pathway (hsa04012)). 
Considering the most significant KEGG pathways, a total of 179 genes were 
targeted by abundantly expressed miRNAs in blastocysts. Of these genes, 5 
genes (STAT3, TGFBR1, VEGFA, HLA-G, HBEGF and TGFBR1) were 
identified as blastocyst specific in the NCBI gene database. DAVID cluster 
functional analysis grouped the genes into 124 GO clusters. The first 10 
clusters (P< 0.0001) code for proteins involved in biological processes, 
molecular function and cellular components (Table S2 – supplementary 
material). The top ten gene clusters included: (1) regulation of phosphorus 
metabolic process; (2) cell cycle; (3) components of intracellular organelles 
and nucleoplasm; (4) immune system development; (5) regulation of 
transferase activity; (6) regulation of kinase activity; (7) protein 
phosphorylation mechanisms (8) phosphatase activity; (9) regulation of 
cellular component movement; (10) regulation of macromolecule biosynthetic 
process. 
 
2.4. Discussion 
The blastocyst consists of about 100-150 cells and preparing sufficient total 
RNA to carry out the profiling of miRNAs using a deep sequencing protocol is 
difficult. Studies to date that have profiled miRNAs in low input samples, such 
as blastocysts or gametes, have used targetted approaches to detect the 
espression of known miRNAs like miRNAs expression in mouse blastocysts 
performed with an in-house designed microarray with 743 mature miRNAs on 
[31] and the analysis of 366 mature miRNAs assessing pools of 10 bovine 
blastocysts with a Taqman assay [32]. Other studies have used commercial 
miRNA chips. For example, a study of bovine gametes, immature and mature 
oocytes (MII) used a mammalian miRNA chip with 3272 miRNAs including 94 
bovine miRNAs [21]. The selected miRNAs on such chips are represented by 
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known and predicted miRNAs from diverse species, like human, mouse or 
cattle. The protocols described invariably use an amplification step before the 
analysis, which may distort apparent relative expression levels. This study 
analyzed all the miRNAs present in the bovine blastocyst and was carried out 
using three procedures for total RNA extraction and a high-throughput 
sequencing approach, adapted for low input samples, in order to reduce bias. 
Specifically amplification steps for the miRNAs before library preparation were 
avoided. The quantity of RNA obtained varied considerable among samples 
even for the same procedure. These variations in input of RNA quantity 
impacted the number of reads per sample, which was independent on the 
procedure. Libraries were prepared successfully from all the samples with a 
minimum of 10 ng as total input RNA input (data not shown).  
In total, across all three approaches, 1363 miRNAs were identified in bovine 
blastocysts among which 41.5% were novel bovine miRNAs. The annotation 
and discovery processes carried out using miRDeep was able to attribute 218 
of the novel bovine sequences to a human homologous miRNA. However, 
60% of novel bovine miRNA sequences did not have a matching human 
miRNA. This suggests that these miRNAs expressed in bovine blastocysts 
may have a restricted pattern of expression, or are expressed at very low 
levels and therefore have not been described in other studies. The number of 
novel bovine miRNAs reported here is in line with the proprtion of unknown 
bovine small RNAs identified in other studies, for example, 50-60% novel 
miRNAs were recently described in studies of bovine spermatozoa [33] and 
granulosa cells of preovulatory dominant and subordinate follicles [34] using a 
small RNAseq. Tipically, studies of human tissues like human embryonic stem 
cells [35] have a lower proportion of unknowmn miRNAs. 
The most abundant mature miRNAs identified in the present study were 
characterized with respect to their target genes and the pathways in which 
these genes were represented. This analysis showed an enrichment of target 
genes, which are mostly oncogenic factors and, thus, were associated with 
biogenesis of several cancers. Many studies have correlated the gene 
expression patterns in tumor cells with expression in gametes, embryos or 
during foetal development [36-38], suggesting that early embryonic 
development and tumor transformation have similar metabolic programs. 
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Indeed, miR-21, which was one of the most abundant miRNAs identified in the 
blastocysts is widefully described as have oncogenic activity and is up-
regulated in several cancers, including breast, colon, pancreas, lung and liver 
cancers, and leukemia [39-43]. MiRNA-21 blocks diffentation and apoptosis 
by regulating several genes involved in cell cycle, including PTEN, PDCD4, 
MYC, BCL-2, E2F2, TP53, VEGFA, TGFβ and TPM1. Some of these genes, 
particularly E2F, BCL2, MYC, VEGFA and TP53 have been shown to be 
involved in oncogenic pathways [44-46]. TP53, which has a direct inhibition of 
expression of the tumor suppressor gene LATS2 [47], is also targeted by miR-
30d, which was expressed in blastocysts in the present analysis. The target 
genes of miR-21 are also targeted by several of the other abundant miRNAs 
such as miR-26a, miR-92a, miR-378a and miR-192. In particular, miR-192 
has been shown to inhibite apoptosis of cancer cells by targeting BCL2 and 
BAX [48]. MiR-10b is involved in cancer biogenesis and has been found to be 
associated with breast cancer, in particular, through the negative regulation of 
BRCA1, which is a tumor suppressor gene [49]. MiRNA-26a has also been 
implicated in metastasis through epithelial-to-mesenchymal transition of 
cancer stem cells, where it acts in cooperation with miR-21 [50]. In the 
present study, miR-10b was predicted to target NR4A3, which is also known 
as NOR1 and is involved in trascriptional regulation [51]. MiR-191, another 
found to be abundant in blastocystsis, was overexpressed in acute myloid 
leukemia [41] and solid cancers like that of breast and lung [42]. It may also 
be involved in metastasis through regulation of the transforming growth factor 
beta (TGFβ) signaling pathway inducing the expression of genes, which 
promote cell migration [53]. MiR-92a is part of the miR-17~92a cluster, which 
includes miR-17, miR-18a, miR-19a and miR-92a-1, and which has oncogenic 
activity through the regulation of TGFBR2, SMAD2, and BMP family genes 
[54]. However, other miRNAs, which belong to this genomic cluster, were not 
found to be abundant in bovine blastocysts. Nevertheless, predicted target 
genes, including SMAD4 and TGF-beta-RII, which are important for cell 
proliferation, were among the targets of abundant miRNAs, specifically miR-
21, miR-26a, miR-371a and miR-423. These miRNAs have been suggested 
as pontential biomarkers of liver cancer in the circulation [55] although their 
mechanism of action is not fully undestood. Some miRNAs seem to have a 
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carcinogenic effect when  they are expressed at low levels, like miR-22 which 
can have an opposing effects depending on the type of cancer. Indeed, this 
miRNA was found to be down-regulated in solid cancer, such as liver [56] or 
prostate [57], and hence it may have an anti-tumor action. In other cancers, 
however, such as chronic lymphocytic leukemia (CLL), which is characterized 
by accumulation of clonal B cells arrested in G0/G1 stages, it was up-
regulated and induced phosphatase and tensin homolog down-regulation and 
the activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway [58]. This 
miRNA also targets genes involved in the cell cycle, like E2F and CDK6, 
which are targeted also by miR-21. The down-regulation of miR-148a is 
associated with cancer metastasis [59]. In the present study this miRNA was 
predicted to target HSP90B1 and CYCS, which have an apoptotic action [60] 
and are also regulated by cell cycle genes, such as BCL-2, MYC, which are 
involved by the way in the MAPK and TGFβ/SMAD signaling pathways. 
Finally, miR-30e down-regulation induces the development of cancer through 
the activation of TGF-β and NF-κB signaling pathways [61].  
In summary, there is simple evidence that the most abundant miRNAs, which 
are shown in the present study to be important for bovine blastocyst 
development, are also associated with the regulation of oncogenic pathways 
and have been described for several cancers. However, it is not clear what 
makes the difference between tumour cells, which are generally characterized 
by loss of cell cycle regulation, and embryonic cells, which are rapidly dividing 
and pluripotent, but are delicately regulated to avoid uncontrolled cell 
proliferation. Some studies focused on early embryos cell proliferation have 
recently evidenced that contact inhibition may make the difference between 
embryonic and tumor cells [62]. However, the mechanisms underlying contact 
inhibition are still unclear. 
Some of the most abundant miRNAs expressed in bovine blastocysts 
identified in this study have been described in other reproductive functions: 
bta-miR-10b has been shown to be important in ovarian function and has 
been implicated in early stage embryo development because it is highly 
abundant in oocytes during maturation although its role in early stage 
embryos is not known [63, 64]. Bta-miR-378 and bta-miR-26a were 
associated to ovarian follicle growth [34, 64] and have been identified in 
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embryonic tissues [70]. In particular, miR-378 is expressed in porcine cumulus 
cells and lack of its expression is associated with impaired oocyte maturation 
[65]. It reduces progesteron receptor expression and that of other genes such 
as ADAMTS1, CTSL1, and PPARG, which are important for follicular 
maturation and remodeling [66]. This miRNA is also involved in regulation of 
genes involved in neuronal developmental in human embryonic stem cells 
[67]. Bta-miR-21 is highly expressed during the early stages of embryo 
development, including blastocyst, and may be involved in maternal-embryo 
communication [21]. As described above, this miRNA cooperates with other 
abundant miRNAs in bovine blastocyst. Homologous human miR-191 and 
miR-192 are associated with oocytes quality and, in particular, are more 
highly expressed in blastocysts from oocytes recoved from young women 
compared with those from older ones [68]. Our analysis is consistent with this, 
in so far that miR-191 has a higher expression in blastocyst of good quality. 
However, miRNA-192  has recently been reported to be present in culture 
media of degenerated bovine embryos [22].  
MiRNAs are likley to play a active part in regulating blastocyst development, 
where they control and coordinate the  expression of a range of genes. 
Various miRNAs, which have a higher level of expression, are associated with 
good quality embryos as all the blastocysts analyzed in this study were 
classified according to IETS standards as good grade of quality. 
Understanding the roles of these miRNAs and manipulating their expression 
may help to investigate molecular mechanisms underlying correct embryo 
development.  
In conclusion, this study focused on the miRNAs present in the bovine 
blastocyst and identified several novel miRNAs. The study also identified 
genes and pathways that are potentially regulated by miRNAs in early embryo 
development. Many of these genes are involved in the cell cycle and have 
also been implicated in tumor cells. Indeed, pathway analysis inferred the 
enrichment of genes targetted by the miRNAs and being involved in cancer 
related pathways. Similarities have been in the miRNA regulation of genes 
targeted by the abundant miRNAs in bovine blastocyst with changes in gene 
regulation associated with cancer transformation. Further studies will be 
necessary to understand the true function of miRNAs in the developing cells, 
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especially to define genes, which are actually regulated, and the implications 
for the pathways in which they play a role. Moreover, the analysis of miRNA 
expression in parallel with transcritiome studies will better elucidate their 
function. Because miRNAs are released by the embryo and can be detected 
in culture media, the miRNAs identified in this study are potential biomarkers 
of blastocyst quality and developmental compentece, which may be used to 
improve the success rate for reproductive biotechnologies.  
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CHAPTER 3 
Differences in microRNAs after in vitro fertilization using 
sperm with high and low blastocyst rates 
 
3.1. Introduction 
Early embryogenesis is affected by oocyte and sperm quality, which is 
correlated with specific biomolecules, including proteins and RNAs, which are 
delivered to the zygote at fertilization [1-4]. Among these biomolecules, the 
repertoire of RNAs is important in directing the embryo during the first steps of 
division until the embryo genome is activated [5]. In cattle this occurs later 
than other mammalian species, at the 8-16 cell-stage embryo [6]. The 
parentally derived RNAs influence zygote developmental potential to the 
blastocyst stage. Generally 30-40% of the fertilized oocytes [7] reach this 
stage, therefore understanding the factors that regulate early development is 
an important step for improving reproductive efficiency.  
It is well known that the maternal contribution has a large impact on early 
embryo development. Maternally derived mRNAs present in the oocyte 
decrease rapidly following fertilisation [8]. The lack of some maternal mRNAs 
has been indeed associated with a low oocyte competence and quality [9]. 
However, the role of the sperm contribution during embryogenesis is unclear. 
For a long time, sperm have been considered to carry only the paternal 
genetic component, but now, accumulating evidence suggests that various 
sperm biomolecules actively participate in early development [10-13]. Indeed, 
during fertilization, the sperm transmits not only nuclear DNA but also other 
biomolecules, such as oocyte activation factors (OAF), which are critical for 
fertilization [14], centrosomes critical for cell division [14] and a population of 
messenger RNA (mRNA) that are critical for early development [10, 15]. 
Moreover, studies investigating epigenetic modifications in the developing 
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spermatozoa have provided new insights into paternal contribution during 
embryogenesis. Sperm epigenetic programming can have a significant 
influence on both the developing spermatozoa and embryo. In humans, 
alterations of the epigenetic programming have been related to fertilization 
potential and the early development of the embryo [16]. Epigenetic 
programming includes microRNAs (miRNA), which are regulators of gene 
expression at the mRNA level. Recently, the study of miRNAs in the oocyte 
and early embryo showed that a small set of miRNAs can influence the 
developing embryo, and mis-programming may result in early embryonic 
death [17, 18]. Oocyte miRNAs may be important during oocyte-to-zygote 
transition [19]. Spermatozoa are enriched in miRNAs, which have been 
investigated in mature bovine spermatozoa by comparing high and low fertility 
bulls [20]. However, few miRNAs were associated with differences in bull 
fertility and there is currently no information on their impact on pre-
implantation embryo. Understanding the influence of sperm miRNAs during 
early embryogenesis will broaden our knowledge on the paternal contribution 
of mature spermatozoa. Morevoer, miRNAs are also used as biomarkers for 
diseases, and are therefore potentially new biomarkers for gamete and 
embryo quality. 
This study investigated the paternal influence on the early stages of bovine 
embryo development through miRNA profiling. The experiments were carried 
out in two parts. First, I investigated whether a correlation could be establish 
between field fertility data and in vitro embryo production (IVP), considering 
two aspects: (i) the existency of genetic factors that determine semen quality 
and (ii) the effect of season on sperm quality (part 1). The results of the first 
part indicated that differences in blastocyst rates obtained after IVP depended 
on the individual bull and not on the field estimates of fertility or the season. 
Thus, in the second part of this study, miRNA profiling was carried out 
comparing high and low blastocyst rate bulls identified in part I (part II). 
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Part I. Effect of sire fertility and season on in vitro embryo 
development using Estimated Relative Conception Rate in 
high index dairy bulls  
 
3.2. Materials and Methods 
3.2.1. Bull samples and experimental design 
 
Semen from 10 holstein-fresian bulls was collected and cryopreserved by an 
Artificial Insemination (AI) center located in Northern Italy (Inseme Spa, Lodi, 
Italy) and was commercially available for AI. In particular, the bulls of this 
study were located in the tails of the Gaussian distribution of Estimated 
Relative Conception Rate (ERCR) in Italy: 5 high (H) and 5 low (L) fertility 
bulls (Table 1). ERCR is a measure of conception rate used worldwide as field 
fertility index. It is based on non-return rate at 56 days corrected for herd-
year-month of insemination, energy-corrected milk production adjusted to 
3.5% fat and 3.2% protein content, days open at first mating and parity and is 
expressed as the conception rate of a sire relative to that of other sires. ERCR 
is mainly determined from many services in a large number of herds and is 
indeed routinely used as fertility index in Italy by the Italian Breeders 
Association (AIA). The estimation of conception rate in ERCR is corrected for 
the main factors affecting fertility, therefore the biological factors controlling 
differences in index value for individual bulls are not well defined.  
Reliability for all considered bulls was higher than 85% (Reliability = 100 × [1 
– (1 – (Number of inseminations/ (Number of inseminations + 200))½) × 2.3]). 
Semen was collected from all bulls during the summer and winter (indicated 
as S and W, see table 1) in order to look at the heat effects on 
spermatogenesis, which spans approximately 61 days in cattle [21]. In 
Northern Italy, the warmest and coolest months are July/August and 
January/February, respectively.  
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Table 1. The table reports the Estimated Relative Conception Rate (ERCR) for the 
10 bulls used in the study, the sampling season (W = winter or cool month; S = 
summer or warm month) and Reliability for the high and low fertility bulls. 
 
!W!(Winter) S!(Summer)
A 2.4 4202 99 March September
B 2.0 3209 98 February September
C 4.1 2371 98 February September
D 2.0 4074 99 February September
E 2.8 16767 99 February September
F 62.9 1427 96 March September
G 61.7 1892 97 March September
H 62.4 346 85 March September
I 61.8 2929 98 February September
J 61.8 360 86 February late;August
ERCR!(value)! Reliability!(%)ID!Bull!
SAMPLING!MONTH!OF!SEMENArtificial!
inseminations!(n)
 
 
 
 
 
 
 
IVF outcomes are influenced by several variables, including the origin and 
handling of oocytes, the number of inseminations carried out at the same 
time, the ambient temperature, etc. Each replicate (i.e. “set up” or day of 
ovary collection, number of oocyte retrieved and in vitro fertilization) was 
designed to ensure that a high fertility versus a low fertility bull sampled in the 
S and W months was compared (Figure 1). 
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Figure 1. Matrix of comparison of bulls during each replicate (e.g. experiment day or 
“set up”). Each replicate allowed the comparison of a high ERCR bull versus a low 
ERCR bull using semen collected in the warm (s) and cool (w) month of the year. 
Each bull was repeated at least three times. 
 
High Low
SET UP 1 A, W and S F, W and S
SET UP 2 B, W and S G, W and S
SET UP 3 C, W and S H, W and S
SET UP 4 D, W and S I, W and S
SET UP 5 E, W and S J, W and S
SET UP 6 A, W and S G, W and S
SET UP 7 B, W and S H, W and S
SET UP 8 C, W and S I, W and S
SET UP 9 D, W and S J, W and S
SET UP 10 E, W and S F, W and S
SET UP 11 A, W and S H, W and S
SET UP 12 B, W and S I, W and S
SET UP 13 C, W and S J, W and S
SET UP 14 D, W and S F, W and S
SET UP 15 E, W and S G, W and S
Fertility Status (ERCR)Experimental 
replicate
 
 
3.2.2. In vitro embryo production 
IVP was carried out using the procedures described in chapter 2 (par. 2.2.1. 
and 2.2.2.). The resulting blastocysts were collected at the day 7 of in vitro 
embryo development and snap frozen in pools of 5-10, in liquid nitrogen and 
stored at -80°C. 
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3.2.3 Data collection and statistical analysis 
Assessment of in vitro embryo development was carried out by recording 
embryo cleavage (48 hour post insemination, hpi) and blastocyst rates at days 
6, 7, 8 and 9 following fertilization. The mean percentage and standard error 
(SEM) were calculated using at least three replicates for the same bull and 
the same season of semen collection.  
Statistical analysis was carried out using R software using a generalized 
linear mixed model (logit algorithm for a binomial distribution of data) to test 
significant differences between H and L groups in the S and W months of 
semen collection. The model was fitted using the function “glmer” of the R 
package “lme4”. This model incorporates both fixed-effects and random 
effects in a linear predictor, using maximum likelihood [51]. 
One-way ANOVA was carried out in order to compare each bull within the two 
seasons using the cleavage and Day 7 embryo development rates which are 
the parameters routinely used to assess in vitro embryo development [7]. 
 
3.3. Results 
A total of 5987 COC were fertilized in vitro, 20% of which (n=1170) developed 
to the blastocyst stage by Day 7 post fertilization. The H group bulls differed 
only for blastocyst rate for S and for both the cleavage and blastocyst rates for 
W (P<0.05). Bulls A and E had a lower value than the other bulls in S and W 
and did not differ for the cleavage rate between seasons (Table 2). The 
cleavage rate of the H group bulls was normally distributed, ranging from 
65.3% to 81.1% for S and from 63.0% to 79.1% for W. The blastocyst rate for 
the same bulls ranged from 13.5% to 27.0% for S and from 13.1% to 29.6% 
for W (Table 2).  
The cleavage rate for the L group bulls ranged from 35.9% to 78.8% for S and 
from 22.8% to 75.6% for W. Blastocyst rates of L bulls were 5.2 % to 35.9% 
for S and 1.5% to 25.5 % for W. In this case, differences were seen in 
cleavage and blastocyst rates among bulls of the L group between the 
seasons in which the semen was collected (P<0.05). Bull F, in particular, had 
a very low rate of in vitro embryo development (i.e. cleavage and blastocyst 
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rates) compared with the other low fertility bulls both in S and W. This bull 
produced only 3 blastocysts from 202 COCs when S semen was used and 8 
blastocysts from 153 COCs for W versus a mean of 16.9% for S and 20.1% 
for W for the group as a whole.  
H group did not differ for the cleavage and blastocyst rates when using semen 
collected in S and W (P>0.05, Table3). Similar results were obtained for the L 
group, which did not differ for both the same parameters when comparing the 
seasons (P>0.05, Table 3). Interestingly, cleavage rate was higher in the H 
group than the L group (Figure 1) for W (P<0.001). Blastocysts rates at 6, 7, 8 
and 9 days post insemination were similar for H and L groups and for both S 
and W (Table 3). 
 
Table 2. Cleavage and D7 blastocyst rates following in vitro fertilization of oocytes 
with sperm by bull within high and low ERCR groups. Cleavage and blastocyst rates 
were calculated as mean value ± Standard Error of Mean (SEM). The rate is 
represented as a % of cleaved oocytes.  
 
N
cleavage                                  
n (%)
D7 blastocyst rate      
n (%) N
cleavage                                  
n (%)
D7 blastocyst rate     
n (%)
A 283 194 (68.6±4.8) 42 (14.8±3.2a) 284 179 (63.1±4.9a) 49 (17.3±3.3a)
B 190 154 (81.1±2.5) 63 (33.2±4.6b) 196 155 (79.1±1.6b) 58 (29.6±5.2b)
C 318 238 (74.8±3.2) 86 (27.1±3.7ab) 313 221 (70.6±3.8ab) 53 (16.9±2.1a)
D 349 257 (73.6±4.3)  70 (20.1±3.9ab) 338 259 (76.6±2.9b) 79 (23.4±1.8ab)
E 297 194 (65.3±3.6) 40 (13.5±3.3a) 366 243 (66.4±3.9ab) 48 (13.1±3.1a)
F 153 55 (35.9±8.3c) 8 (5.2±2.2b) 202 46 (22.8±3.4b) 3 (1.5±0.9b)
G 379 238 (62.8±2.8b) 51 (13.5±2.8b) 397 233 (58.7±5.8a) 67 (16.9±4.1b)
H 295 224 (75.9±3.4a) 106 (35.9±3.7ac) 291 220 (75.6±1.2a) 66 (22.7±4.1ab)
I 251 192 (76.5±1.5a) 67 (26.7±2.5a) 243 170 (69.9±4.1a) 62 (25.5±3.5ab)
J 481 379 (78.8±3.2a) 86 (17.9±4.9ab) 361 244 (67.6±7.4a) 66 (18.3±6.1b)
High ERCR
Warm month (S) Cool month (W)
Low ERCR
Fertility status Bull ID
 
A,b,cValues with different superscripts differ significantly (P<0.0001). 
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Table 3. Cleavage and blastocyst rates (from day 6 to day 9 of in vitro embryo 
development, day = D) following in vitro fertilization of oocytes with sperm from high 
and low ERCR bulls. Cleavage and blastocyst rates were calculated as mean value ± 
Standard Error of Mean (SEM). The rate is represented as a % of cleaved oocytes.  
 
D6 D7 D8 D9High*ERCR*bulls* 71.2±3.1a 9.9±1.6 19.8±2.9 23.3±2.4 23.6±2.7Low*ERCR*bulls 58.9±9.4b 9.1±3.1 16.9±4.2 19.9±4.7 20.2±4.7
High*ERCR*bulls* 72.7±2.71 8.8±1.5 21.7±3.7 26.2±3.8 26.8±3.9Low*ERCR*bulls 65.9±8.1 8.9±0.8 20.1±0.5 23.8±0.5 24.3±0.6
Blastocyst*rateCleavage*rateFertillity*statusSeason*temperature*of*semen*collection
Cool
Warm 	  
a,bValues with different superscripts differ significantly (P<0.0001). 
 
3.4. Discussion 
Field fertility is normally assessed using 56-90 day non-return rates (NNR) 
[22-27], or Estimated Relative Conception Rate estimated (ERCR), the latter 
is corrected using factors influencing bull fertility [28-31]. This study examined 
the relationship between the estimated field fertility, measured as ERCR of 
the sire, and in vitro embryo production (IVP), and also tested the effect of 
heat stress.    
The cleavage rate following IVF has been usually associated with NRR 
[22,23, 31-33] but a weak correlation has been found between blastocyst rate 
and NRR [24, 35-37]. In the present study, large differences between bulls 
were observed for in vitro embryo development, following IVF success, 
however, this was not dependent on ERCR. There were bulls, which were 
outliers with respect to the cleavage and blastocyst rates in both high and low 
fertility groups, i.e. high ERCR bulls with a low cleavage and blastocyst rates 
and low ERCR bulls with a high cleavage and blastocyst rates. These values 
influenced the means of both the H and L group, but, nevertheless, 
differences between the H and L groups were observed for cleavage rates for 
semen collected in the cool month. However, no differences between high 
and low fertility bulls were seen for in vitro blastocyst rate at 6 to 9 days of in 
vitro embryo development. These results are similar to those obtained for 
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NRR [22-24, 31-37]. This suggested that using a fertility index based such as 
ERCR, which estimates overall fertility and includes traits such as the milk 
production, may be not appropriate for predicting in vitro fertilization efficiency 
and early embryo development. Low fertility bulls may be associated with 
lower pregnancy rate for several reasons, e.g. through early embryonic loss, 
which is not routinely detected by breeders. Embryonic loss mostly occurs 
during the pre-implantation period of embryonic growth, between days 8 and 
16 and is considered to be the main factor influencing the reproductive 
success in cattle [39, 40]. However, the reasons of embryo mortality are not 
fully understood, and may be associated with errors in molecular 
programming, which can affect viability of developing embryos [41, 42]. The 
association between bull field fertility, which was assessed in a way similar to 
ERCR, and IVF success was recently associated DNA fragmentation in 
spermatozoa [43]: low fertility bulls have a relatively high number of DNA-
nicks. In these cases fertility can be addressed by increasing sperm 
concentration during IVF. In the present study, sperm was diluted as normally 
practiced for IVF. Using a large number of in vitro matured oocytes, 
differences were observed between H and L groups for cleavage rate 
following IVF. Bull fertility, estimated as ERCR, is poorley correlated with IVF 
success. Fertility may be affected by other factors, which were not considered 
in the present study and should be further investigated.  
Male fertility is affected by ambient temperature [44, 45], therefore the IVF 
rate of semen from the same bulls collected following the warmest and 
coolest months in Italy was compared to test for an effect of temperature 
stress on in vitro embryo development. Most species show seasonal 
variations in fertility, including ovulation frequency, spermatogenic activity, 
gamete quality, and also sexual behaviour [46]. Although highly selected 
breeds of cattle do not show significant reproduction seasonality [47, 48], they 
can be affected by heat stress, which may impact negatively on 
spermatogenesis [49, 50]. Summer temperatures may reach ~40°C and fall to 
0°C in winter in the Mediterranean area. The results presented here, however, 
indicate that in vitro fertilization and developmental competence of embryos is 
not affected by season of semen collection, and cleavage and blastocyst rates 
were similar for both high and low ERCR bulls in S and W. 
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In conclusion, the results indicate that semen of low fertility bulls, measured 
as ERCR, is as capable of fertilizing oocytes in vitro and to produce pre-
implantation blastocysts with the same quality and quantity as high fertility 
bulls. Indeed, the in vitro produced blastocysts were morphologically of good 
quality for both high and low fertility bulls (data not reported). Therefore, an 
alternative approach was explored to assess high vs low fertility.  
 
Part II. Profiling of blastocyst microRNAs from high and low 
blastocyst rate bulls using deep sequencing 
 
3.5. Material and Methods 
As the correlation between field fertility and in vitro embryo development was 
not found, the experimental design was changed and bulls were classified 
based on number of blastocysts produced in vitro using semen collected 
during the same period, in order to exclude the effect of season, to give the 
“Blastocyst rate”.  
 
3.5.1. RNA extraction 
Total RNA extraction was carried out using pool of 30 blastocysts for each 
sample using Allprep DNA/RNA/miRNA and RNA clean and concentrator-5 
procedures (described in chapter 2 par. 2.2.3.3. – procedure 3). Then, the 
RNA quality and quantity of each sample was assessed using RNA Pico Chip 
and a 2100 Agilent Bioanalyzer.  
 
3.5.2. Small RNA sequencing 
Library preparation and deep sequencing were carried out using the 
procedure set up in Chapter 2 (par 2.2.4.).  
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3.5.3. Bioinformatic and functional analysis 
Filtering of raw sequences, annotation and discovery of miRNAs were carried 
out according to the pipeline described in Chapter 2 (par 2.2.5.). 
Gene expression analysis was perfomed using the R package ‘EdgeR’ 
(http://bioconductor.org/packages/release/bioc/html/edgeR.html) in order to identify 
differentially expressed miRNAs. MiRNAs with log2 fold change differences ≥ 1, 
P-value ≤ 0.05 and False Discovery Rate (FDR) ≤ 0.1 were considered as 
significantly differentially expressed. The interaction between differentially 
expressed miRNAs and their target mRNAs was predicted using miRWalk 
2.0; a widely used web-based database to predict animal miRNA-target 
mRNA interactions [52]. A total of 6 prediction programs were combined into a 
pipeline for the analysis as follows: miRanda-rel2010 [53], PicTar2 [54], PITA 
[55], RNA22v2 [56], RNAhybrid2.1 [57] and Targetscan6.2 [58]. The lists of 
predicted target genes of individual miRNAs were imported to DAVID Bioinformatics 
systems; a freely available bioinformatic tool (http://david.abcc.ncifcrf.gov/). Gene 
ontology (GO) analysis was carried out using this tool to identify the most 
important enriched biological and cellular processes. The DAVID web-tool 
facilitated also the identification of the canonical signaling pathways 
significantly enriched with the predicted target genes of each miRNAs, which 
were then analyzed using Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) database [59]. To improve the functional meaning of the results, 
KEGG pathway analysis was also performed using DIANA miRPath v2.0 with 
homologous human miRNA and gene union options. DIANA miRPath uses 
predicted miRNA targets (in CDS or 3’-UTR regions) provided by the DIANA-
microT-CDS algorithm, or experimentally validated miRNA interactions 
derived from DIANA-TarBase v6.0 [60]. 
 
3.6. Results 
The distribution of bulls was based on their Day 7 blastocyst rate (graph 4). 
Two main categories were created depending on the blastocyst rate: high (≥ 
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25.1 %) and low (≤15.1 %) groups (figure 1). The high group (H group) 
differed significantly from low group (L group) (32.1 ± 4.5 vs 10.7 ± 4.8, 
P<0.01). The 3 extreme bulls of each category were chosen for small RNA 
sequencing and are indicated in the rest of the thesis as follows: bull 1 (H), 
bull 2 (B), bull 3 (C), as high blastocyst rate and bull 4 (A), bull 5 (E) and bull 6 
(G) as Low. 
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Figure 2. Distribution was carried out using Day 7 blastocyst rate of each bull. Mean 
value and standard error of mean (SEM, error bars) are depicted. 
 
3.6.1. Characterization of miRNA deep sequencing data 
To investigate the involvement of miRNAs in bovine sperm associated with a 
diverse blastocyst rate, 3 miRNA libraries of H and L blastocyst groups, 
respectively, were generated using total RNA from Day 7 IVP blastocysts. 
These were sequenced using the Illumina HiSeq2500 small RNA deep 
sequencing technology with 50 bases long sequence reads, i.e. raw reads, 
generated for bull1, bull2, bull3 (H group) and bull5, bull6 (L group). Bull 4 
sequencing failed and was excluded from data analysis. Accordingly, 24.6 
and 12.9 million reads, i.e. clean reads, were obtained after filtering of low 
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quality reads from libraries of the H and L group, respectively (table 4). Quality 
filtered sequence reads were used to identify known annotated and prediction 
of novel miRNAs. From all reads which passed the quality control criteria, 
18.2M reads in H group and 8.7M in L group were mapped to the bovine 
reference genome, comprising 74.1 % and 66.8 % of the total quality reads 
obtained, respectively. Furthermore, 549,090 reads in H group and 218,537 in 
L group were found to be similar to known bovine and human miRNAs 
reported in miRBase release 21.  
 
Table 4. Summary of sequence reads alignment to bovine reference genome and 
known miRNAs annotated in miRBase. 
 
Mapped reads (n)#
29298950
11992592
13412562
9506437
7850467
2.8
Bull 6 11468277 68.5 168995 2.2
Low blastocyst rate
Bull 5 14440423 65.8 268079
16085421 74.6 352711 2.9
Bull 3 18961284 70.7 381012 2.8
%know miRNA 
mapped reads
High blastocyst rate
Bull 1 38843847 75.4 913546 3.1
Bull 2
Bull group Sample ID* Filtered reads (n) % Mapped reads Known MiRNA mapped reads (n)§
 
*: Bull1, Bull2, Bull3 denote for biological triplicates of high blastocyst rate 
bulls and Bull5, Bull6 denote for biological triplicates of low blastocyst rate 
bulls. 
#: Number of quality filtered reads aligned to bovine reference genome 
(assembly UMD3.1).  
§ Proportion of mapped sequence reads aligned to known annotated miRNAs 
in miRBase release 21 
 
 
3.6.2. MiRNAs expressed in Day 7 embryos of H and L blastocyst rate 
bulls 
MiRNAs with at least 1 read count in at least two of the three biological 
replicates were considered as detected. Among the short RNAs that could be 
mapped to known bovine and human miRNA precursors, the most abundant 
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length was 22 nucleotides (nt) for both the H and L group, which corresponds 
with the expected miRNA size (Figure 3). 
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Figure 3. Length distribution (nucleotide = nt) of miRNA populations in low (a) and 
high (b) blastocyst rate bulls. 
 
 
A total of 692 and 377 known bovine and homologous human miRNAs were 
detected in H and L group, respectively, of which 283 miRNAs were in 
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human hsa-miR-4755-5p and has-miR-548-3p were found to be specific to H 
group. While, 94 miRNAs were unique to L group (Graph 1). 
Many of the detected miRNAs were found in both the H and L groups. Among 
the top 10 abundantly expressed miRNAs in each group, 8 miRNAs (bta-miR-
10b, bta-miR-423, bta-miR-92a, bta-miR-191, bta-miR-378a, bta-miR-148a, 
bta-miR-192, bta-miR-22) were expressed in common in both H and L groups 
(table 5). Among these, bta-miR-10b and bta-miR-423 were the two most 
abundantly expressed miRNAs with a read count of 129,517 and 36,460 in H 
group and 47,775 and 21,813 in L group and accounting for 48.3 and 15.9% 
of the sequence reads aligned to known miRNAs, respectively. Nevertheless, 
the overwhelming majority of the detected miRNAs in both libraries had fewer 
than 50 read counts (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 1. Comparison of known miRNAs, which were expressed in the blastocysts of 
H and L groups and were annotated in MiRBASE for human and cattle (Venn 
diagram; H group = high blastocyst rate bulls, B group = low blastocyst rate bulls). 
The Venn diagram was built using mean average read count of biological replicates. 
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Table 5. List of top 10 highly abundantly expressed miRNAs in high and low 
blastocyst rate bulls. 
High blastocyst rate bulls Low blastocyst rate bulls
miRNA ID Avarage read counts* miRNA ID Avarage read counts*
bta-miR-10b 129517 bta-miR-10b 47775
bta-miR-423-5p 36460 bta-miR-423-5p 21813
bta-miR-92a 51670 bta-miR-92a 25310
bta-miR-191 29438 bta-miR-191 11804
bta-miR-378 47152 bta-miR-378 16875
bta-miR-148a 23568 bta-mR-148a 7253
bta-miR-192 18989 bta-miR-22 5686
bta-miR-22 18735 bta-miR-192 5600
bta-miR-30d 11657 bta-miR-16b 4844
bta-miR-30e 11029 bta-miR-92b 4680  
 
 
 
 
3.6.3. MiRNAs gene expression and functional analysis 
Differential expression analysis revealed that 3 miRNAs were significantly 
differentially expressed between H and L blastocyst rate bulls. The expression 
level of these miRNAs, which were annotated for human in miRBase release 
21, was significantly reduced in the L group with respect to H group, e.g. Log2 
Fold Change (table 3). Moreover, 2 of these miRNAs (hsa-miR-4755-5p and 
hsa-miR-548d-3p) were expressed only in the blastocysts of H group. While, 
hsa-miR-1225-3p was expressed in the blastocysts of both groups. 
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Table 6. List of miRNAs down-regulated in Day 7 blastocysts of L group (miRNA ID, 
Fold change = Log2 Fold Change, P-value and FDR = False Discovery Rate).  
 
miRNA ID Fold Change p-value FDR
Novel:hsa-miR-4755-5p -10,5 <0.0001 0.0045
Novel:hsa-miR-548d-3p -10,1 0.0002 0.0372
Novel:hsa-miR-1225-3p -6,0 0.0002 0.0372
 
 
To understand the functional involvement of these miRNAs in bovine early 
embryo development, target genes of each differentially expressed miRNAs 
were predicted and used to determine the most significantly enriched GO 
biological functions and KEGG signaling pathways using DAVID. In addition, 
KEGG pathway analysis was also performed using miRPath v 2.0. 
First, gene ontology (GO) analysis on predicted target genes revealed that biological 
processes associated with transcription regulation, cellular biosynthetic processes, 
including nucleic acid metabolism, and cell and embryonic morphogenesis, were 
among the highly enriched GO terms (Table S3 – supplementary material). KEGG 
pathway analysis, which was performed using DAVID web-tool, identified 56 enriched 
canonical signaling pathways (Table S4 – supplementary material). These canonical 
pathways were grouped into classes based on functions and biological processes 
using the KEGG pathway database (http://www.genome.jp/kegg/pathway.html). 
Many of the pathways were associated with oncogenesis. The most enriched 
pathway was indeed that of cancer but there were tumor-specific enriched 
pathways including colorectal, melanoma and chronic myeloid leukemia, and 
general cancers including reproductive tissues and prostate cancers. The other 
enriched classes were linked to: 1) cellular processes, where the most 
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enriched pathways were those associated with cell adhesion (Regulation of 
actin cytoskeleton, Tight Junction and cell adhesion molecules (CAMs)) 
cell proliferation (MAPK signaling pathway) and cell survival and growth, 
(TGF-beta, apoptosis and neurotrophin pathways); 2) Cell communication 
(Endocytosis and calcium pathways); 3) cell metabolism (Insulin and 
phosphatidylinositol pathways). Finally, DIANA MirPath analysis was 
carried out using hsa-miR-4755-5p and hsa-miR-548d-3p simultaneously 
(table 7) and hsa-miR-1225-5p alone (table 8). 
 
 
 
Table 7. Kegg pathways from DIANA miRPath v 2.0, which were enriched by 
target genes of hsa-miR-4755-5p and hsa-miR-548d-3p. 
KEGG pathway p-value Target genes MiRNAs
ErbB signaling pathway (hsa04012) 0.0001389508
CAMK2D, ERBB2, 
SHC1, BTC hsa-miR-4755-5p, hsa-miR-548d-3p
Transcriptional misregulation in 
cancer (hsa05202) 0.001395331
HMGA2, CCND2, 
NCOR1, DDX5, 
PPARG, MEIS1
hsa-miR-4755-5p
African trypanosomiasis (hsa05143) 0.002354351 SELE, APOL1 hsa-miR-4755-5p
Ubiquitin mediated proteolysis (hsa04120) 0.005949636
RFWD2, UBA6, 
PARK2, BIRC2 hsa-miR-4755-5p
Apoptosis (hsa04210) 0.009663038
CSF2RB, IRAK1, 
BIRBC2 hsa-miR-4755-5p
Huntington's disease (hsa05016) 0.01833565
CREB5, AP2A2, 
PPARG, CNAQ, 
PPARGC1A, SDHD
hsa-miR-4755-5p
Ubiquinone and other terpenoid-quinone 
biosynthesis (hsa00130) 0.04608754 NQO1 hsa-miR-4755-5p  
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Table 8. Kegg pathways from DIANA miRPath v 2.0, which were enriched by target 
genes of hsa-miR-1225-5p. 
KEGG pathway p-value Target genes MiRNAs
Protein processing in endoplasmic 
reticulum(hsa04141) 0.003416487 SSR1, DERL1, ERO1LB hsa-miR-1225-3p
Proteasome (hsa03050) 0.007827826 PSME4, IFNG hsa-miR-1225-3p
Amphetamine addiction (hsa05031) 0.009343598 CAMK4, GRIA4 hsa-miR-1225-3p
Biosynthesis of unsaturated fatty 
acids (hsa01040) 0.0284081 ELOVL2 hsa-miR-1225-3p
Type I diabetes mellitus (hsa04940) 0.0284081 IFNG hsa-miR-1225-3p
Protein digestion and absorption (hsa04974) 0.0284081 ATP1A4, DPP4 hsa-miR-1225-3p
Lysine degradation (hsa00310) 0.03504665 KMY2C hsa-miR-1225-3p
Graft-versus-host disease (hsa05332) 0.04021567 IFNG hsa-miR-1225-3p
 
 
 
 
 
 
 
 
 
Figure 4. ErbBB signaling pathway and predicted target genes of miR-4755-5p and 
miR-548d-3p. Target genes of miRNAs are indicated in yellow. 
!
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Figure 5. Protein processing in endoplasmatic reticulum pathway and predicted 
target genes of miR-1225-3p. Target genes of miRNAs are indicated in yellow. 
 
 
 
Figure 6. Gene network representation of interaction between the three differentially 
expressed miRNAs and their predicted target genes, which are important in 
blastocyst formation and differentiation processes. Three different hubs can be seen: 
5 genes (VASP, TGFBR1, FN1, LEP, RAD51B) are common target of miR-4755-5p 
and miR-1225-3p, while one gene (HAND1) is a common target between miR-4755-
5p and miR-548d-3p. 
!!
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3.7. Discussion 
In total, the three miRNAs which were the most significantly reduced in the 
group of bulls with low competent sperm associated with a lower in vitro 
blastocyst rate, have not been annotated in cattle and are novel homologous 
human. Moreover, they have not been previously described in regard to early 
embryogenesis. The results presented here suggest their involvement in 
bovine blastocyst development. Using miRPath v2.0 the most significant 
KEGG pathways associated with miR-4755-5p and miR-548d-3p (-10.1 and -
10.1 log2 Fold Change lower expression in low compared with high group), 
which were identified only in the blastocysts of high competent sperm, were 
predicted to regulate, the expression of genes involved in the ErbBB signaling 
pathway. This result is in agreement with findings in mice embryos where 
overxpression of ErBB signaling genes is associated to placental 
abnormalities and embryonic lethality [61]. An important gene involved in this 
molecular mechanism is ErBB1, expression of which is increased when 
placenta hyperplasia occurs [62]. Expression of this gene is strictly correlated 
to ErBB2 (figure 4), which is a predicted target of miR-548d. Furthermore, 
SHC1 activity, which is dependent on ErBB2, is a predicted target of miR-
4755-5p. The expression of this gene is used to assess blastocyst quality in 
cattle [63, 64]. As these miRNAs have higher expression in the high 
blastocyst competent sperm embryos, those of low competent sperm may 
have an higher expression of this gene, which is not what would be expected. 
Blastocysts obtained after fertilization using low competent sperm may have 
compromised expression of ErBB signalling, which may be associated to 
altered fetal developmental programming and overal survival.  
Expression of miR-1225-5p is reduced in blastocysts obtained from low 
competent sperm. This miRNA may reduce the expression of genes involved 
in protein degradation processes in the endoplasmic reticulum (ER, figure 5). 
Protein degradation, which is also reflected by an enrichment of byosinthetic 
processes in GO terms involving genes targeted by this miRNA, may be 
higher in embryos produced using low competent sperm. Alterations in ER 
protein processing have been recently associated with a higher sensitivity of 
early embryo to exogenous factors, which impact on epigenetic modifications, 
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including miRNAs levels and embryo survival [65]. Thus, the lower sperm 
competence may be associated with increased sensitivity of the embry to 
environmental factors. 
To improve the functional interpretation of the results, target prediction 
analysis was performed using miRWalk, which allows the combination of 
several gene prediction tools. This approach identified many other canonical 
pathways, which are known to be important in early embryo development, and 
which may be affected as a result of differences in miRNAs levels in the 
blastocysts. These pathways included: regulation of actin cytoskeleton, tight 
Junction and cell adhesion molecules (CAMs), MAPK, TGF-beta, apoptosis, 
neurotrophin, endocytosis, calcium, GnRH, insulin and phosphatidylinositol 
signaling pathway. All these are intracellular gene networks and are linked to 
cellular processes, which may affect embryonic development and 
differentiation. The Actin cytoskeleton pathway is reported to be essential for 
regulation of actin dynamics, which occur during processes of maturation and 
development in early embryogenesis [66]. Tight junction and cell adhesion 
molecules (CAMs) signaling pathways control cell interactions and are 
involved in blastocyst compaction, which is important for blastocele formation 
and consequent implantation [67, 68]. MAPK signals are involved in embryo 
development and reported to be important in pluripotency [69]. The inhibition 
of MAPK genes during early bovine embryogenesis is associated with 
incresed expression of NANOG, SOX2 and POU5F1 [70]. TGF-beta, 
apoptosis and neurotrophin signaling pathways are also important in 
controlling cell proliferation. Among these, TGF-beta signals have been 
reported to be critical for bovine embryo development. Increased expression 
of these genes is associated with degeneration of embryos [71]. In the results 
presented here blastocyts associated to a lower sperm competence may have 
overexpression of apoptotic signals. Endocytosis signals are reported to be 
important in pre-attachment development of bovine embryos. Indeed, 
induction of autophagic activity during early embryogenesis increases the 
blastocyst developmental rate [72]. Furthermore, autophagy is a negative 
regulator of ER stress in early embryos. This is in agreement with the results 
obtained here, where ER signals, which are associated to protein 
degradation, may be overexpressed in blastocysts obtained from low 
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competent sperm. Hence the embryos may be more sensible to stress fators. 
Calcium signals are important in several reproductive processes e.g. oocyte 
activation during fertilization in mouse [73], and interacts with other canonical 
pathways, including MAPK and apopotosis pathways, which are important as 
indicators of embryo quality. Calcium signalling may have a role during 
embryo development and blastocyst competence. Insulin and 
phosphatidylinositol signaling pathways are both important in cell metabolism. 
Loss of insulin repectors, such as IGFR1, which is a predicted target of miR-
548d, may have affect imprinted genes [74]. Finally, phosphatidylinositol 
signaling pathway, which has diverse effects on cell processes, may have a 
potential role in growth and survival of bovine blastocysts [75, 76]. 
Among all the predicted target genes of the differentially expressed  miRNAs, 
there were 22 genes,  which are known to be involved in blastocyst formation 
and developmental processes. Among these, 5 genes (VASP, TGFBR1, FN1, 
LEP, RAD51B) are predicted targets of miR-1225-3p and miR-4755-5p. While 
HAND1 is targetted by miR-4755-5p and miR-458d-3p (Figure 6). VASP is 
involved in conceptus elongation [77] and trophoblast invasion during 
implantation [78]. TGFBR1 may be important during gastrulation as is 
abundant in human epiblastic cells [79]. Fibronectin 1 (FN1) is also a 
candidate for gastrulation and implantation in bovine embryo [80]. LEP is an 
important autocrine signal for trophoblastic growth [81]. While, RAD51B plays 
a role in cell proliferation and early embryonic development [82]. Finally, 
HAND1 is associated with trophoblastic cell differentation also in cattle [83]. 
All these genes are implicated in embryo development and implantion 
processes, and some play a role in placenta development. Thus, changing the 
timing or levels of their expression may affect tardiver processes including 
implantation and placenta formation in the embryos. 
In conclusion, the results presented here identified miRNAs that are likely to 
be involved in the regulation of bovine embryo development through various 
gene targets and signaling pathways. Three of all the expressed miRNAs 
were differentially expressed between blastocysts produced using high and 
low competent sperms. These results suggest a paternal influence during 
early embryogenesis, which may impact on the developmental potential of the 
early embryos. Further studies will be necessary to confirm these data. A 
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focused study of the expression of miRNAs and together with their predicted 
target genes in early stages up to blastocyst from spermatozoa of different 
developmental potential will reveal the role of these small RNAs at fertilization 
through to zygote and morula. 
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CHAPTER 4 
Identification of microRNAs as biomarkers of 
competent oocytes  
4.1. Introduction 
Cows with a low antral follicle count (AFC) have reduced fertility, a poor 
response to superovulation, low circulating concentrations of progesterone [1] 
and poor pregnancy rate [2]. Indeed, the number of mid-antral follicles of 2-6 
mm in diameter, which is used to assess AFC, is negatively correlated with 
several ovarian traits [3]. Low AFC ovaries are small, have poor 
vascularization [4] and few healthy follicles. However, follicular fluids from low 
AFC ovaries have high levels of ovarian hormones, including Growth 
Hormone (GH) and Progesterone (P4) [5]. These factors result in low ovarian 
function and poor quality oocytes, which have low developmental [6,7].  
Previous studies indicate that reduced oocyte developmental competence 
may be the consequence of vascular defects and reduced nitric oxide (NO) 
availability. NO elicits a wide spectrum of intracellular effects and can be 
stimulatory or inhibitory during oocyte maturation depending on the 
concentration [4]. The poor quality oocytes from low AFC ovaries have a high 
frequency of chormosomal mutations, which have been associated with 
alterations in the localization of Progesterone Receptor Membrane 
Component 1 and Aurora Kinase B [8]. The molecular mechanisms affecting 
the developmental competence oocytes are unknown, however, in humans 
[9], mice [10] and cattle [11], it has been shown that it is the final period of 
oocyte growth where developmental potential is gained [30]. MicroRNAs 
(miRNAs), which are involved in ovarian function, are found in the diverse 
compartments of ovarian follicles, including granulosa cells [12, 13], theca 
cells [14], follicular fluid and oocyte itself [15]. The role of miRNAs during 
follicle development has been studied in humans [16-18], mice [19, 20], cattle 
[21-23], pigs [24, 25] and horses [26]. These studies suggest that the miRNAs 
may regulate cellular differentiation processes, which occur during follicular 
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development in a defined spatio-temporal manner. In cattle, follicular fluid 
miRNAs were found to change during folliculogenesis [27]. Moreover, they 
were found both free and associated with exosomes, the latter may facilitate 
transport of specific miRNAs into follicular cells [21].  
Dynamic changes in miRNA expression have been described during oocyte 
maturation, where a large proportion of maternal genes are directly or 
indirectly under the control of miRNAs [28]. However, in normal condition, 
miRNA activity seems to be reduced in fully grown oocytes, although their 
biogenesis is unaffected and their mRNA targets are present [29]. Therefore, 
reducing miRNA activity may be associated with acquisition of developmental 
competence, and miRNAs may not be required until the zygotic genome 
activation is completed and the pluripotency program, which also controls 
miRNA expression [67], is established. 
The goal of the present study was to unravel some of the molecular pathways 
regulated by miRNAs, which are associated with oocyte developmental 
competence.  
 
4.2. Materials and methods 
4.2.1. Follicular fluid and oocyte collection 
Ovaries were obtained from a local abattoir and were transported to the 
laboratory in warmed (27-30°C) Dulbecco Phospate Buffered Saline (PBS). 
Ovaries with more than 10 follicles of 2-6 mm in diameter and a dominat 
follicles (>8 mm) were assigned to high Antral Follicle Count group (H group), 
while those with less than 10 follicles of 2-6 mm were classified as low AFC 
group (L group). The classification did not take into account corpus luteum as 
suggested in previous studies [3, 6].  
Follicles were aspirated using a 19-gauge needle and both follicular fluids and 
cumulus-oocyte complexes (COC) were pooled according to the classification 
into 50 mL Falcon tubes, which were warmed at 38.8°C. Blood cells and 
debris were removed from the follicular fluids by centrifugation at 10 minutes 
at 1500 g and were then stored at -80° C. 
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Cumulus-oocyte complexes (COCs), which had sedimented to the bottom of 
tube, were identified using a stereomicroscope and COCs that were medium 
brown in color with five or more complete layers of cumulus cells were 
collected [31]. Oocyte denuding was carried out by incubating COCs in 
modified PBS (supplemented with 36 µg/L pyruvate and 50 µg/mL 
gentamycin), and 0.5 mg/mL BSA (Sigma Aldrich, fraction V, A-9647, USA) 
with 100 UI/mL hyaluronidase (Sigma Aldrich, H3757, USA) for 3 minutes and 
then mechanically pipetting. Pools of 10 denuded oocytes were stored at -80° 
C. 
 
4.2.2. Progesterone (P4) quantification 
 
Progesterone (P4) in follicular fluids was determined in undiluted samples 
using a competitive enzyme immunoassay. An in-house produced anti-P4 
monoclonal antibody was used as capture antibody and progesterone-11-HS-
HRP (Fitzgerald Industries International, Concord, MA) as labeled hormone. 
The procedure was carried out as described by Borromeo and colleagues [32] 
and was determined in 5 biological replicates of folicular fluid from good and 
poor AFC sampled on different slaughter days, concomitantly with follicular 
fluid and oocyte collection. Statistical analysis was performed by T-student 
test. P-values less than 0.05 were considered to be statistically significant.  
 
4.2.3. Determination of oocyte mithocondrial activity	  
Mitochondrial activity was determined by staining oocytes with two mitotracker 
probes (Invitrogen by Life Technologies, Carlsbad, CA, USA): MitoTracker FM 
Green (MTG), which allows the analysis of relative mitochondrial activity 
because it stains all mitochondria without distinguishing them according to the 
membrane potential (Δψ), and MitoTracker Orange CMTMRos (MTO), which 
stains only active mitochondria. 
Briefly, denuded oocytes, which were obtained as indicated above (par. 
4.2.1.), were incubated in 0.4 % PBS/BSA (Sigma Aldrich, fraction V, A-9647, 
USA) to which 280 nM MTG, 200 nM MTO and 5 µg/µl Hoechst 33452 were 
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added and they were then incubated for 30 minutes at 38.8°C with 5% CO2 in 
air and maximum humidity. The oocytes were then washed three times in 
PBS/polyvinylpyrrolidone (PVP), mounted on slides and were observed using 
an epifluorence microscope (Axio scope A1, ZEISS) at specific wavelengths 
for MTG (488 nm), MTO (546 nm) and Hoechst (380 nm) dyes.  
Mitochondrial activity was estimated as the MTO/MTG Ratio using digital 
images of both mitotracker probes obtained at the same exposure time. 
Quantification of fluorescence was carried out using ImageJ. All experiments 
were repeated 5 times on different slaughter days. Statistical differences were 
analyzed using a T-student test. P-values less than 0.05 were considered to 
be statistically significant.  
 
4.2.4. Small RNA extraction from follicular fluids 
MiRNAs were extracted from three pools of 300µl of follicular fluid from H and 
L groups using Nucleospin MiRNA plasma (MACHEREY-NAGEL GmbH & 
Co. KG,  Germany), which is specific for biofluid small RNA extraction, 
following the manufacturer’s instructions. The high AFC group samples are 
indicated in the rest of the chapter as: FF1, FF2 and FF3 and the low group 
samples as FF4, FF5 and FF6. 
 
4.2.5. Total RNA extraction from oocytes 
Total RNA extraction was performed from three pools of 30 oocytes from H 
and L groups and processing procedure 2 (see Chapter 2, par. 2.2.3.1.). RNA 
quality and quantity of each sample was assessed using a RNA Pico Chip 
and a 2100 Agilent Bioanalyzer. The samples are indicated as: Ovo1, Ovo2 
and Ovo3 for the H group and Ovo4, Ovo5 and Ovo6 for the L group. 
 
4.2.6. Small RNA sequencing	  
Library preparation and deep sequencing were carried out for both follicular 
fluid and oocyte RNA samples using the procedure described in Chapter 2 
(par 2.2.4.). Libraries from follicular fluids and oocytes were sequenced into 
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two lanes of an Illumina HiSeq2500 using a 50 bases long sequence read 
module.  
 
4.3.7. Bioinformatic and functional analysis	  
Filtering of raw sequences, annotation and discovery of miRNAs were carried 
out according to the pipeline described in Chapter 2 (Chapter 2, par. 2.2.5.). 
Gene expression analysis was perfomed using the R package ‘EdgeR’ 
(http://bioconductor.org/packages/release/bioc/html/edgeR.html) to identify differentially 
expressed miRNAs. MiRNAs with log2 fold change differences ≥ 1, P-value ≤ 
0.05 and False Discovery Rate (FDR) ≤ 0.1 were considered as statistically 
differentially expressed. The interaction between differentially expressed 
miRNAs and their target mRNAs was predicted using two procedures:  
 
1) miRWalk 2.0; a widely used web-based database to predict animal miRNA-
target mRNA interactions [33]. In total 6 prediction programs were combined 
into a pipeline for the analysis as follows: miRanda-rel2010 [34], PicTar2 [35], 
PITA [36], RNA22v2 [37], RNAhybrid2.1 [38] and Targetscan6.2 [39]. The lists 
of predicted target genes of individual miRNAs were imported to DAVID Bioinformatics 
systems; a freely available bioinformatic tool (http://david.abcc.ncifcrf.gov/). Gene 
ontology (GO) analysis was carried out using this tool to identify most 
important enriched biological and cellular processes. The DAVID web-tool 
facilitated the identification of the canonical signaling pathways significantly 
enriched with the predicted target genes of each miRNAs, which were then 
analyzed using Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
database [40].  
 
2) DIANA miRPath v2.0 using homologous human miRNA and gene union 
options. DIANA miRPath predicts miRNA targets (in CDS or 3’-UTR regions) 
provided by the DIANA-microT-CDS algorithm, or experimentally validated 
miRNA interactions derived from DIANA-TarBase v6.0 [41]. This information 
is used by DIANA miRPath for KEGG pathway analysis. Only the canonical 
pathways with P-value <0.01 were chosen and the predicted target genes of 
miRNAs from these pathways were taken into account for GO analysis and 
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gene interactions, which were performed using ClueGo plugin into Cytoscape 
V 3.2.1 [42].	  
	  
	  
	  
	  
	  
	  
	  
4.3. Results 
4.3.1. Mithocondrial activity and P4 quantification 	  
To assess the overall mitochondria activity, 26 Germinal vesicle (GV) oocytes 
of L group and 29 of H group were immunostained and the MTO/MTG Ratio 
was calculated in order to evaluate overall activity of mithocondria (Table 1b 
and figure 2). In particular, all the GV oocytes were similar in their 
developmental stage as they had a GV2-GV3 chromatin configuration of 
nucleus (Figure 2) [43, 44]. But, the GV oocytes of L group seem to have a 
lower activity of mithocondria. Indeed, these oocytes had a lower MTO/MTG 
ratio than those of H group (Table 1(b): 1.0 ± 0.1 versus 1.4 ± 0.1, 
respectively, P<0.05). Furthermore, Follicular fluids, which were collected 
from L group, had higher P4 concentration (ng/mL) than those of H group 
(Table 1(a): 85.1 ± 28.5 versus 51.7 ± 21.9, respectively, P<0.05).  
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Table 1. (a) P4 quantification of follicular fluids from L and H Antral Follicle Count 
ovaries. Data are represented as mean value ± Standard Error of Mean (SEM); (b) 
MTO/MTG ratio between H and L group oocytes. Data are represented as mean 
value ± Standard Error of Mean (SEM). 
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Figure 2. Images of an L (a) and H (b) group oocyte after MTO, MTG and 
HOECHST 33452 staining. 1) real image of the oocyte 2) mitotracker Orange image 
which, was acquired at 546 nm length ; 3) mitotracker green image, which was 
acquired at 488 nm length; 4) Hoechst 33452 image, which was acquired at 380 nm.  
MTO and MTG probes bind to the mitochondria and allow the evaluation of 
mitochondria activity. Hoechst 33452 binds DNA and allows the determination of 
developmental stage of the oocyte associated with the nuclear chromatin 
configuration [43, 44]. 
	  
	  
4.3.2. Characterization of miRNA deep sequencing data	  
To investigate the miRNAs associated with oocyte developmental 
competence, 3 miRNA libraries of L and H groups were generated using RNA 
from follicular fluids and oocytes. After filtering of low quality reads 13.7M 
(95.8 %) and 15.2M (95.7 %) reads were mapped to the bovine reference 
genome from follicular fluid libraries of the L and H groups, respectively (Table 
2a) and 71.3M (94.8 %) and 47.1M (91.9 %) reads from oocyte libraries of L 
and H group, respectively (Table 2b). Quality filtered sequence reads were 
used to identify annotated human and bovine miRNAs present in miRBase 
release 21. For all reads which passed the quality control criteria from the 
follicular fluid libraries, 6.0M and 3.9M from L and H groups, respectively, 
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were found to be similar to known bovine or human miRNAs, comprising 
45.8% and 25.5% of the total quality reads obtained. For oocyte libraries 2.3M 
(3.2%) and 1.1M (2.4%) of L and H groups, respectively, were mapped to 
known bovine or human miRNAs. 
 
 
Table 2. Summary of sequence reads aligned to bovine reference genome and 
known miRNAs annotated in miRBase for follicular fluid (a) and oocyte (b) samples. 
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*: FF1, FF2, FF3, OVO1, OVO2 and OVO3 denote for biological triplicates of 
Follicular fluid and oocyte from high group and FF4, FF5, FF6, OVO4, OVO5, OVO6 
denote for biological triplicates of follicular fluid and oocyte from low group. 
#: Number of quality filtered reads aligned to bovine reference genome (assembly 
UMD3.1).  
§ Proportion of mapped sequence reads aligned to known annotated miRNAs in 
miRBase release 21 
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4.3.3. MiRNAs expressed in follicular fluids and oocytes 	  
MiRNAs with as least 1 read in at least two of the three biological replicates 
were considered as detected. Among the short RNAs that could be mapped to 
known bovine and human miRNA precursors, the most abundant length was 
23 nucleotides (nt) for both follicular fluid (a) and oocyte miRNAs (b) of L and 
H group, which corresponds with mature miRNA size (Figure 3). 
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Figure 3. Length distribution (nucleotide = nt) of miRNA populations in follicular fluid 
(a) and oocyte (b) miRNAs from L and H groups, respectively. 
 
 
Annotation of miRNA sequences with miRDeep identified 1236 known 
miRNAs, across follicular fluid and oocyte samples (Graph 3). The mean 
number of follicular fluid miRNAs was similar between L and H groups, which 
were on average 497 ± 85 in L and 520 ± 22 in H (P>0.05), of which 203 were 
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in common. The mean number of miRNA expressed in oocytes was higher in 
the L group with respect to the H group: 373 ± 12 vs 285 ± 36 (P<0.05), 
respectively, of these 301 were in common between the groups. Moreover, 
follicular fluids and oocytes of H group (P<0.0001) had a different mean 
number of expressed miRNAs, which was not different between follicular 
fluids and oocytes of L group (P>0.05).  
The miRNAs bta-miR-10b, bta-miR-27b, bta-miR-143 and bta-miR-22 were 
the abundantly expressed in follicular fluids of both L and H groups; of these 
miRNA bta-miR-10b had the highest level of expression with a read count of 
3.0M in L and 1.5M in H groups; accounting for 50.1% and 39.2% of the 
sequence reads aligned to known miRNAs, respectively. The miRNAs bta-
miR-10b, bta-miR-92a and a miRNA with the human homologue hsa-miR-
6509-3p had the highest level of expression in the oocytes of L and H groups. 
Bta-miR-10b was the most abundant with a read count of 1.7 M in L and 
758,461 in H group, which represented the 32.3% and 66.4% of the mapped 
reads to known miRNAs, respectively. Moreover, hsa-miR-6509-3p and hsa-
miR-513c-5p, which were only annotated for human, were abundantly 
expressed in the oocytes of both H and L groups. In particular, the reads of 
hsa-miR-6509-3p accounted the 8.5% and 9.7% in L and H groups, 
respectively, while those of hsa-miR-513c-5p were represented by 1.0 % in L 
and 1.2 % in H group. 
Apart from these highly expressed miRNAs, tthe majority of annotated 
miRNAs had fewer than 50 reads (data not shown). Among the top 10 
abundantly expressed miRNAs in each group, 4 miRNAs (bta-miR-10b, bta-
miR-423, bta-miR-22 and bta-miR-148) were expressed in both follicular fluids 
and oocytes of L and H groups (Table 3 and 4). 
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Graph 3. Venn diagram. Comparison of common known and homologous human 
miRNAs between High (H) group and Low (L) group of both follicular fluid and oocyte 
samples. 
 
 
 
Table 3. List of Top 10 highly abundantly expressed miRNAs in follicular fluids of L 
and H groups. 
Follicular fluid miRNAs in L group Follicular fluid miRNAs in H group
miRNA ID Avarage read counts* miRNA ID Avarage read counts*
bta-miR-10b 3007349 bta-miR-10b 1519637
bta-miR-27b 519897 bta-miR-27b 399262
bta-miR-143 389404 bta-miR-22 248940
bta-miR-22 324146 bta-miR-143 223850
bta-miR-423 124454 bta-miR-30a 101416
bta-miR-148a 118611 bta-miR-25 96767
bta-miR-21 97675 bta-miR-30e 83203
bta-miR-30a 79320 bta-miR-186 70867
bta-miR-25 71122 bta-miR-148a 66214
bta-miR-378 62790 bta-miR-423 53478  
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Table 4. List of Top 10 highly abundantly expressed miRNAs in oocytes of L and H 
groups. 
Oocyte miRNAs in L group Oocyte miRNAs in H group
miRNA ID Avarage read counts* miRNA ID Avarage read counts*
bta-miR-92a 1693243 bta-miR-10b 758461
bta-miR-10b 1497538 Novel:hsa-miR-6509-3p 110264
Novel:hsa-miR-6509-3p 195705 bta-miR-92a 44550
bta-miR-26a 106697 bta-miR-423 20994
bta-miR-22 57394 bta-miR-148a 17476
bta-miR-423 49303 bta-miR-22 17175
bta-miR-148a 45677 Novel:hsa-miR-513c-5p 14042
bta-miR-27b 23421 bta-miR-16b 10557
Novel:hsa-miR-513c-5p 23310 bta-miR-92b 9352
bta-miR-30d 14527 Novel:hsa-miR-4446-5p 9315  
 
 
 
4.3.4. Differential expression of follicular fluid miRNAs in L and H group	  
Comparison of the expression level of miRNAs between L and H groups in the 
follicular fluids identified 66 differentially expressed miRNAs. The majority of 
the annotated miRNAs were expressed in follicular fluids of both L and H 
groups (data not shown; P≤0.05 and FDR≤ 0.1). Among the differentially 
expressed miRNAs, there were 50 with a reduced and 16 with increased level 
of expression in the group of low antral follicle count ovaries with respect to 
those with an high antral follicle count (Table S5 – supplementary material). 
Some of these miRNAs were clusters located in the same chomosomal region 
and may be co-regulated; these included: miR-450a and miR-450b, miR-99a 
and let-7c, miR-24-3p and miR-195, miR30c and miR-30a, miR-18a and miR-
92a. The Log2 fold change values in L group ranged from -2.71 (bta-miR-885) 
up to -4.11 (bta-miR-150).  
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4.3.5. Differential expression of oocyte miRNAs in L and H group	  
Analysis of H and L group oocytes identified 6 miRNAs which were 
differentially expressed (P ≤0.05 and FDR ≤ 0.1). Among these miRNAs, five 
had higher expression in the L group (bta-mir-145, bta-mir-150, bta-mir-342, 
bta-mir-450b and bta-mir-380) and one (bta-miR-10a) had lower expression 
with respect to H group. Interestingly, three of differentially expressed 
miRNAs (bta-miR-10a, bta-miR-150 and bta-miR-450b) in the oocytes were 
also differentially expressed between follicular fluids of H and L groups, but 
with inverse expression, i.e. the miRNA, with increased expression in the 
oocyte of L group, was reduced in the L group follicular fluid and viceversa. 
The Log2 fold change values in L group ranged from -1.62 (bta-miR-10a) up to 
9.51 (bta-miR-145). 
 
4.3.6. Prediction of novel bovine miRNAs in follicular fluids and oocytes	  
The small RNA sequences were used to identify known annotated miRNAs 
present in the oocytes and follicular fluids and also to identify novel miRNA 
sequences. Potential novel miRNAs were identified using miRDeep2 software 
and, only when the sequences were identified into two of the three biological 
replicates of L and H groups of both follicular fluids and oocytes with at least 1 
read count, they were considered to be a putative novel miRNAs. There were 
708 putative novel miRNAs identified. These sequences were searched 
against miRBase release 21 to identify homologous known annotated 
matured miRNAs, and BLASTN tool (www.ensembl.org) was used to identify 
the genomic location. Only one sequence (novel_2_53382) had some 
similarity to the bta-miR-2285 family, even though this sequence was not 
annotated in miRBase release 21 (Figure 4), in addition it aligned with a 
different chromosomal region from mir-2285 family (Table 5). Thus, indicating 
that it may be a novel miRNA which may belong to that miRNA family. 
Genomic context analysis of these predicted novel miRNAs revealed that 5 
novel miRNAs were transcribed from intergenic region, 3 from intronic region 
of transcripts (BCAT2, COPG2 and GART) and one other from exonic region 
of the ZNF358 gene (Table 5). Of the novel miRNAs identified, 7 were 
differentially expressed in follicular fluids and 2 in oocytes. 
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Table 5. Putative novel miRNAs expressed in follicular fluids and oocytes of L and H antral follicle count ovaries.  
 
Sample type
Provisional 
Matured miRNA 
miRNA ID 
Sequence 
Mature miRNA sequence genomic coordinates and strand of miRNA precursors 
Average 
read count 
in L group
Average 
read 
count in H 
group
Genomic region of 
novel miRNAs and 
overlapping 
transcript 
Novel:19_46128 UUCCCGCCGGCGUAUGCUGCUGU 19:43830014-43830039[Forward] 3.7 28 intergenic
Novel:18_44358 UUCUCAGCCCCAGGGGUUCCU 18: 55872705-55872727[Reverse] 1.3 15.8 intronic, BCAT2
Novel:4_87488 ACUUUUGCCCCUAGUAACGGACU 4:95112096-95112121[Forward] 46.7 132 intronic, COPG2
Novel:X_110269 UGAGCACACCUGCCUGAGCAGA X:30280443-30280467[Forward] 2.7 24.3 intergenic
Novel:2_53382 AAAACCUCAACGAACUCUUUGG 2:115554887-115554911[Reverse] 21.7 4.3 intergenic
Novel:7_99116 AUGAAGAUCUGGAGCCUGUCUCC 7:17610270-17610295[Forward] 5 13 exonic, ZNF358
Novel:1_108989 UCCUAAAGGAGAUCAGUCCUGGGUG 1:1268082-1291083[Forward] 194 87.3 intronic, GART
Novel:20_55299 UCCUUUCUGAGCCACCAGGGA 20:19697855-19697877[Reverse] 123.3 691.3 intergenic
Novel:1_3066 UUCCUGCAAACUUAUCCUAUG 1:89855043-89855065[Reverse] 3154 540 intergenic
Follicular fluid
Oocyte
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Figure 4. Alignment of the novel_2_53382 sequence using miRBase release 21. 
 
 
4.3.7. Target gene prediction, Gene ontology and pathways enriched by 
differentially expressed miRNAs in follicular fluids	  
Analysis of miRNA expression in follicular fluids identified 66 miRNAs that 
were differentially expressed between L and H groups with significance of 
P<0.005, increasing the stringency, using a threshold of P<0.001, 25 
remained significant and these differentially expressed miRNAs were used in 
the functional analysis (Table S5 – supplementary material). DIANA miRPath 
identified 53 KEGG pathways which were enriched by these miRNAs (Table 
S6 – supplementary material). Among the most enriched KEGG pathways, 
there were several canonical pathways which were associated with cellular 
processes, in particular: cell adhesion (Focal adhesion signaling pathway), 
cell proliferation (Cell cycle, MAPK, RNA transport, Wnt, mTOR, PI3K-Akt 
and ErbB signaling pathways), cell surival and growth (Neurotrophin 
signaling pathway, Oocyte meiosis, TGF-beta signaling pathway) and cell 
metabolism (Insulin signaling pathway). 
Among the 10 most significant KEGG pathways, there were 161 predicted 
target genes of miRNAs. Of these, only five (BCL2, FOXO3, KIT, TP53, 
VEGFA) are known to be involved in ovarian follicle development. GO 
analysis showed that these genes are predominantly involved in biological 
processes including cell cycle regulation, cell proliferation, apoptosis, post-
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traslational modifications, macromolecule biosynthesis and cell migration 
(Table S7 – supplementary material).  
 
 
 
4.3.8. Target gene prediction, Gene ontology and pathways enriched by 
differentially expressed miRNAs in oocytes	  
Functional analysis of predicted target genes of miRNAs identified the 
biological functions that were putatively differentially regulated between the L 
and H group oocytes. The target genes for the abundant expressed miRNAs 
and, thus, were likely to have lower expression in L group, influenced GO 
terms such us cell proliferation, RNA transport and localization, catabolic 
modification of macromolecules and response to hormone stimulus (Table 
S8 – supplementary material). While, GO terms enriched with genes targeted 
by miRNAs with lower expression in the L vs H groups were mainly 
associated with mechanisms involving RNA transcription (Table S9 – 
supplementary material). KEGG pathway analysis indicated that 36 canonical 
pathways were enriched with target genes of miRNAs with higher expression 
in the L vs H group oocytes and 18 were associated with target genes of 
reduced miRNAs. Moreover, 10 of the KEGG pathways were found to be 
commonly enriched by both abundant and reduced miRNAs in the L vs H 
group oocytes (Graph 4). The miRNAs highly expressed in the L group 
oocytes targeted genes involved in signaling pathways that are relevant for 
oocyte quality including PI3K-Akt, Jak-STAT, mTOR and ErbB. Other 
signaling pathways identified are important in controlling oocyte maturation, 
including meiosis, progesterone-mediated oocyte maturation and apopotosis; 
these had higher expression of miRNAs in L group with respect to H group. 
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Wnt signaling pathway 
Pathways in cancer 
Endocytosis 
GnRH signaling pathway 
MAPK signaling pathway 
Calcium signaling pathway 
Pathways enriched by both up and 
down regulated miRNAs Pathways enriched only by down 
regulated miRNA 
Pathways enriched only by up regulated 
miRNAs 
Apoptosis 
Neurotrophin signaling pathway 
Hedgehog signaling pathway 
Progesterone-mediated oocyte maturation 
Insulin signaling pathway 
Cytokine-cytokine receptor interaction 
Oocyte meiosis 
PI3K-Akt signaling pathway 
Focal adhesion 
Ubiquitin mediated proteolysis 
RNA transport 
Axon guidance 
Jak-STAT signaling pathway 
ErbB signaling pathway 
mRNA surveillance pathway 
mTOR signaling pathway 	  
Graph 4. Venn diagram comparing the up- and down-regulated canonical signaling 
pathways. 	  	  	  	  
	  	  	  	  	  	  	  	  	  
Figure 5. Representation of gene interactions between FOXO3, TP53, BCL2, 
VEGFA and KIT and their miRNA regulation. 	  
!
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Figure 6. Representation of gene interactions between BCL2, VEGFA, EGF and 
PABPC1L and their miRNA regulation. 	  
4.4. Discussion 
This study used a model based on low and high antral follicle count ovaries, 
which is known to be associated with oocyte developmental potential [6]. 
Follicular fluids and immature oocytes from mid-antral follicles of 2-6 mm in 
diameter were collected and studied. The number of these follicles is 
representative of the ovarian reserve and is a practical way to measure 
ovarian function, which has been used in several species including humans 
[45] and cattle [5].  
The results identified several biological processes, which are critical for 
oocyte developmental potential and may be compromised in the follicles and 
oocytes of low quality ovaries because of a miRNA mis-regulation. Several 
miRNAs identified have been described in previous studies of normal ovarian 
physiology focusing on follicular fluid and cells which form the ovarian 
follicles, i.e. oocytes, theca and granulosa cells during correct follicle 
development of cattle [21-23, 27, 46-48] and human [16-18, 49, 50]. Among 
these, miR-769, miR-1343, miR-450a, miR-204, miR-100, miR-99a, miR-
1271 and miR-451 were abundantly expressed in granulosa cells during 
development of follicles from subordinate to dominant preovulatory [48]. In 
the present study, these miRNAs had lower levels of expression in low 
quality ovaries. Similarly, miR-190b, which has been found to increase in 
theca cells of dominant with respect to subordinate follicles [27], was reduced 
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in follicular fluids of the poor quality ovaries. The small RNAs let-7c and miR-
451 have been shown to be present at a higher level in exomes in the 
follicular fluid of follicles from growing oocytes compared with fully-grown 
oocytes [21]. In the present study exomes were not separated from 
circulating miRNAs, however, these miRNAs were reduced in follicular fluids 
of mid-antral follicles in low quality ovaries.  
All these miRNAs in follicular fluid are likely to affect granulosa and theca 
cells, however, there are miRNAs such as miR-320, which was reduced in 
follicular fluids of low quality ovaries, and which may have an effect directly 
on the oocyte. Indeed, this miRNA is reduced in follicular fluids of women 
with polycystic ovarian syndrome and the reduction of this miRNA impacts on 
oocyte quality in mouse during early embryogenesis affecting embryo 
developmental potential [49].  
The present study identified 1236 miRNAs, some of which were differentially 
expressed in follicular fluids and oocytes from high and low AFC ovaries. To 
assess the gene networks, which may be involved in the alteration of 
biological processes during follicle development in low quality ovaries, KEGG 
pathway analysis was performed. Many canonical signaling pathways in the 
follicles of low quality ovaries were targeted by miRNAs with reduced levels 
of expression. As miRNAs usually repress gene expression, target pathways 
of these miRNAs may have an increased expression. Among the canonical 
pathways, the most enriched for differentially expressed miRNA gene targets 
was the PI3K-Akt signaling pathway. This pathway is known to control follicle 
growth, differentiation and survival [51, 52], and includes the genes BCL2, 
FOXO3, TP53, VEGFA and KIT, which were predicted targets of miR-204-
5p, miR-197-3p, miR-146b-5p, miR-30d-5p and miR-383. The reduction of 
these miRNAs in follicular fluids of low quality ovaries may be associated 
with abnormal expression of cell proliferation signals, which may in turn affect 
the development of follicles. It has been reported that inhibition of VEGFA 
increases apoptosis in granulosa cells through an imbalance among the 
BCL2 family members in mouse [53]. This study showed that FOXO3 
expression may be reduced via miR-197 resulting in the repression of 
VEFGA and consequent misregulation of BCL2 (figure 5). These molecular 
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processes may increase apoptosis and lead to premature atresia of follicles 
and corresponding oocytes in the low AFC ovaries. 
Among the predicted target genes of the differentaly expressed miRNAs, four 
genes PABPC1L [64], VEGFA [65], BCL2 [66] and EGF [68], are known to 
be important in oocyte biological processes and interact with each other 
(Figure 6). Among these genes, BCL2, as discussed above, has been shown 
to have an aberrant level of expression in poor quality porcine oocytes, and 
is correlated with a low mitochondrial activity [66]. These results indicate that 
the overall lower mitochondrial activity of the low quality oocytes may result 
from inhibition of BCL2 expression mediated by miR-342 and miR-150.  
The negative impact of miRNAs in the follicles of low quality ovaries may also 
be exercised through other signaling pathways such as Neurotrophin, Oocyte 
meiosis and TGF-beta signaling. Neurotrophins are known to regulate follicle 
formation and development [54]. TGF-Beta ︎  signaling plays an important role 
in controlling the production of peptide hormones by the ovary, including 
Antimüllerian hormone (AMH) [55], and is associated with the differential 
expression of TGF-β/BMP genes in human ovary from the primordial to the 
late secondary stage follicles [56]. Several of the differentially expressed 
miRNAs predicted to target genes involved in this pathway such as SMAD4, 
SMAD7, TGFBR1 and TGFBR2. These genes, if not correctly regulated, may 
induce an earlier atresia of follicles. Pertubation of TGF-beta signals may 
explain the higher concentration of Progesterone found in follicular fluids of 
low quality ovaries. Previous studies have reported that the lower 
concentration of AMH is associated to the higher concentration of 
progesterone [3]. It is known that high concentration of Progesterone impact 
negatively on the oocyte quality in cattle [57] and humans [58]. 
The poor follicular environment is likely to impact on the oocyte maturation 
and quality. The immature oocytes collected from follicles of high and low 
quality ovaries, had 8 miRNAs, which were differentially expressed. KEGG 
pathway and Gene Ontology analysis indicated that several molecular 
mechanisms and biological processes may have been affected in these 
oocytes. Among the differentially expressed miRNAs, miR-150 is described 
to be abundant in immature bovine oocytes and diminishes at the time of 
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embryo genomic activation [59]. In the present study miR-150 was more 
abundant in low than high quality oocytes, although this miRNA was among 
the most expressed miRNA in oocyte of both groups. The level of expression 
of miR-150 is likely to be important and hence the elevated expression in low 
quality oocyte may have an adverse effect on the target pathways.  
Among the other differentially expressed miRNAs between high an low AFC 
ovaries, miR-145 affects the TGF-beta signaling pathway and is important in 
the development of primordial follicle in mouse: inhibition decreases the 
proportion of primordial follicle and increases that of growing follicles [60]. 
MiR-150 is abundant in low quality oocytes demonstrating that the oocyte 
maturation may be affected by TGF-beta signalling. In particular, initiation of 
primordial follicle development and primordial follicle quiescence may be 
seriously compromised in low quality ovaries. 
Functional analysis of differentially expressed miRNAs in the oocytes 
identified that the principal biological processes, which are targetted in 
oocytes from low AFC ovaries, are RNA synthesis and translation. These 
molecular processes are required for the accumulation of maternal RNAs 
and to build proteins in the oocyte, which is associated with acquiring 
developmental competence [30]. The expression of oocyte miRNAs may 
follow maternal RNA accumulation [59, 61, 62] and, thus, oocyte miRNAs 
may be silent during oocyte maturation. It is likely that there are miRNAs, 
which are actively involved in coordinating maternal RNA accumulation 
during oocyte maturation. Indeed, KEGG pathway analysis showed that the 
target genes of the abundant miRNAs expressed in the oocyte include RNA 
transport, ubiquitin mediated proteolysis and mRNA surveillance signaling 
pathways. These results indicate that there are gene networks in the low 
quality oocytes which may regulate the accumulation of maternal RNA that 
are misregulated through variations in miRNA levels. Other canonical 
pathways may be compromised. Canonical pathways in which target genes 
of the miRNAs with increased expression in the L group include: Focal 
Adhesion, Jack-stat, ERBB and mTOR signaling patways. Among these, 
focal adhesion pathway regulates the communication between oocyte and its 
cumulus cell [63] and may be down-regulated. The canonical pathways, 
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which may have an increased expression, are: apoptosis, progesterone-
mediated oocyte maturation and oocyte meiosis. Increased expression of 
apoptosis signals is likely to be harmful for oocyte quality. Oocyte meiosis 
signals are mediated in part by progesterone, which is important in 
stimulating the resumption of the two meiotic division cycles required in the 
maturation of the oocyte, and if excessive may be associated with low quality 
oocytes leading to earlier atresia.  
Interestingly, miR-450b, miR-150 and miR-10a were found to be differentially 
expressed in both follicular fluids and oocytes. MiR-450b and miR-150 were 
abundant in low quality oocytes but were reduced in the follicular fluid, while 
miR-10a, which was reduced in the oocytes, was abundant in the follicular 
fluid. These differences may be due to the secretion of these miRNAs by the 
cells of the follicle, such us theca or granulosa cells, and stored in follicular 
fluid, then contribute to the development of the different cell types during the 
follicle maturation process. Indeed, among these miRNAs, miR450b was 
found to be abundant in granulosa cells of dominant follicles in cows [48].  
In conclusion, the results of the present study indicate that miRNAs may be 
important for oocyte maturation and the acquisition of developmental 
competence, which may be influenced by several biological processes 
regulated by miRNAs and important for follicle health. Moreover, the oocyte 
quality may be associated with the pattern of miRNAs present in both 
follicular fluids and oocytes. Thus, follicular fluid derived miRNAs may be 
real-time markers of oocyte quality, which could be used to improve 
Reproductive Biotechnologies. Further studies will be necessary to determine 
if the miRNAs shown to be differentially expressed between high and low 
AFC ovaries in this study regulate the predicted target genes. The study 
should then be extended to explore the regulation of gene expression as the 
oocyte matures and gains competence to be ready for the fertilization. This 
knowledge of the biological processes and gene networks involved during 
folliculogenesis and oogenesis is important for improving fertility in livestock 
and humans. 	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CONCLUSIONS 
 
The PhD program created new knowledge on the paternal and maternal 
contribution on early embryo development to help decipher early 
reproductive physiology. All the experiments were focused on profiling 
miRNA expression, which was carried out using high-throughput sequencing. 
These methodologies potentially identify all the miRNAs present in a sample 
and can provide a global vision of the gene networks and molecular 
mechanisms relevant, in this case, to blastocysts, oocytes and follicular 
fluids. The data produced has improved knowledge of miRNAs in bovine 
oocytes and embryos. Both known and novel bovine miRNAs, were used for 
prediction, including the identification of bovine miRNAs which were 
homologous to human ones. The data confirmed the evolutionary 
conservation of miRNAs among species. 
 
The study of paternal influences on early embryogenesis identified the sperm 
contribution of a small set of miRNAs to blastocyst developmental 
competence. These results indicate that miRNAs are actively involved in 
regulating embryogenesis through the control of important gene networks 
relevant for embryo development. Further study will be necessary to confirm 
these data and, in particular, it may be useful to look at the expression of 
both differentially expressed miRNAs and predicted target genes in 
spermatozoa and early embryo stages, from zygote, through 2-16 cell stage 
embryos to morula. This will enable the assessment of the role of parental 
mRNA during the process from fertilization to the pre-implantation embryo. 
These extended studies may identify miRNAs that can be used as 
biomarkers of blastocyst quality.  
 
The miRNA data for follicular fluids and oocytes from ovaries of different 
functionality identified a miRNA expression blueprints associated with the 
high and low quality of oocytes, which may alter the expression of a number 
of genes relevant for both folliculogenesis and oogenesis. These results 
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contribute to our understanding of molecular mechanisms involved in oocyte 
maturation and acquisition of competence.  
Further experiments should be performed to confirm these findings both  in 
vitro and in vivo. Gene expression analysis of both miRNAs and relevant 
target genes associated to oocyte competence should be further investigated 
to confirm the regulatory targets for the miRNAs. In addition, miRNA and 
mRNA expression should be examined in immature and in vitro matured 
oocytes. RNA interference experiments could also be carried out to examine 
the effects of miRNAs on other cells which constitute to the ovarian follicle, 
specifically theca and granulosa cells. Moreover, in vivo studies will be 
necessary to determine whether follicular fluid miRNAs can act outside the 
ovary and if their level in the bloodstream can be detected thereby providing 
non-invasive, real-time markers to determine oocyte quality in living animals. 
 
In conclusion, knowledge derived from this 3-year PhD study has provided 
background information for new tools to improve in vitro embryo production 
(IVP) for advanced reproductive biotechnologies. 
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SUPPLEMENTARY MATERIAL 
 
CHAPTER 2 
PROFILING OF microRNAs IN BOVINE BLASTOCYSTS USING DEEP SEQUENCING 
 
Table S1. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways obtained using DIANA miRPath v2.0 are reported up to P-value 
<0.0001. The target genes and homologous human miRNAs are reported for each KEGG pathways. 
 
KEGG pathways P-value TARGET GENES miRNAs 
Cell cycle (hsa04110) 7.59e-11 
ESPL1, CDC6, GSK3B, RBL2, 
E2F1, SMC1A, E2F2, CDC14A, CDC25,MC
M6, CCND2, ORC1, CDKN1B, STAG2, CD
KN2A, CDK6, TP53, ANAPC10, SMAD, 
CCNE2, E2F5, SKP2, MYC, TTK, RB1, CD
C7, CDC20, BUB1B, MAD2L1, TGFB2, CC
NE1, CDKN1A, CDKN2D, RAD21, MCM3, 
CDC25A 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-92a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
Prion 
diseases (hsa05020) 2.98e
-08 EGR1, PRKACA, PRNP, IL1A hsa-miR-22-3p, hsa-miR-148a-3p, hsa-miR-191-5p, hsa-miR-423-5p, hsa-miR-192-5p 
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Pathways in 
cancer (hsa05200) 2.01e
-06 
FZD7, FOS, GSK3B, STAT3, E2F1, 
TGFBR1, ERBB2, E2F2, BID, TCF4, APC, 
CRK, WNT1, RAD51, WNT5A, BCL2, 
CDKN1B, PLD1, WNT3, BRCA2, IGF1R 
,EGFR, CDKN2A, APPL1, RET, CDK6, 
PML, TP53, PTK2, ITGAV, FZD4, MMP2, 
MAPK9, SMAD4, MSH6, CCNE2, SKP2, 
MYC, MMP9, MSH2, PIK3R1, RB1, SOS1, 
HSP90B1, FGF2, FZD1, FAS, TGFB2, 
PPARG, NKX3-1, CCNE1, CDKN1A, 
CYCS, SUFU, TCF7, VEGFA, PTEN, TGFB
R2, TFG 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-92a-3p, hsa-miR-371a-3p, hsa-miR-26a-5p, 
hsa-miR-21-5p, hsa-miR-30d-5p, hsa-miR-423-5p, 
hsa-miR-192-5p 
Prostate 
cancer (hsa05215) 5.86e
-05 
GSK3B, E2F1, ERBB2, E2F2, TCF4, BCL2,
 CDKN1B, INSRR, IGF1R, EGFR, TP53, C
CNE2, PIK3R1, RB1, SOS1, HSP90B1, NK
X3-
1, CREB3L2, CCNE1, PDGFD, CDKN1A, T
CF7, PTEN 
hsa-miR-22-3p, hsa-miR-148a-3p, hsa-miR-371a-3p, 
hsa-miR-26a-5p,hsa-miR-21-5p hsa-miR-30d-5p, hsa-
miR-423-5p, hsa-miR-192-5p 
Colorectal 
cancer (hsa05210) 1.19e
-04 
FOS, GSK3B, TGFBR1, TCF4, APC, BCL2,
 APPL1, TP53, MAPK9, SMAD4, MSH6, M
YC, MSH2, PIK3R1, TGFB2, CYCS, TCF7, 
TGFBR2 
hsa-miR-378a-3p, hsa-miR-148a-3p, hsa-miR-92a-3p, 
hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
Bladder 
cancer (hsa05219) 1.47e
-04 
E2F1, ERBB2, E2F2, THBS1, EGFR, CDK
N2A, RPS6KA5, TP53, MMP2, MYC, MMP9
, RB1, CDKN1A, VEGFA 
hsa-miR-378a-3p,  hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-92a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
HTLV-I 
infection (hsa05166) 1.47e
-04 
FZD7, EGR1, FOS, GSK3B, E2F1, TGFBR
1, MYB, RANBP1, IL1R1, E2F2, APC, WNT
1, WNT5A, CCND2, ZFP36, HLA-
C, WNT3, MRAS, MAP3K1, XBP1, HLA-
DOA, CDKN2A, TP53, NFATC4, RANBP3, I
L15, CRTC2, FZD4, NFAT5, MAPK9, 
ANAPC10, SMAD4, MYC, HLA-
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-92a-3p, hsa-miR-371a-3p, hsa-miR-26a-5p, 
hsa-miR-21-5p, hsa-miR-30d-5p, hsa-miR-423-5p,hsa-
miR-192-5p 
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DPA1, PRKACA, PIK3R1, RB1, ATF1, CDC
20, BUB1B, MAD2L1, FZD1, HLA-
G, KAT2B, TGFB2, CDKN1A, XPO1, TGFB
R2 
Hepatitis B (hsa05161) 7.61e-04 
FOS, STAT3, E2F1, TGFBR1, E2F2, IFNB1
, BCL2, CDKN1B, MAP3K1, TLR4, CDK6,D
DX3X, TP53, NFATC4, APAF1, LAMTOR5, 
NFAT5, MAPK9, SMAD4, CCNE2, MYC, M
MP9, PIK3R1, RB1, FAS, TGFB2, CREB3L
2, CCNE1, CDKN1A, CYCS, PTEN 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-92a-3p,hsa-miR-26a-5p, hsa-miR-21-5p, hsa-
miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
Wnt signaling 
pathway (hsa04310) 1.75e
-03 
FZD7, CTNNBIP1, GSK3B, TBL1X, TCF4, 
APC, VANGL1, WNT1, WNT5A, CCND2, R
OCK2, WNT3, TP53, NFATC4, FRAT2, PRI
CKLE1, NLK, 
PLCB1, FZD4, NFAT5, MAPK9, GPC4, SM
AD4, CSNK1A1, MYC, PRKACA, FZD1, PR
ICKLE2,TCF7, DAAM1, TBL1XR1 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-92a-3p, 
hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
p53 signaling 
pathway (hsa04115) 2.75e
-03 
CCNG1, ZMAT3, BID, THBS1, CCND2, PE
RP, CDKN2A, CDK6, TP53, APAF1, CCNE
2 , 
SESN1, MDM4, FAS, SERPINB5, CCNE1, 
CDKN1A, CYCS, PTEN 
hsa-miR-22-3p, hsa-miR-148a-3p, hsa-miR-92a-3p, 
hsa-miR-26a-5p, hsa-miR-21-5p, hsa-miR-30d-5p, 
hsa-miR-423-5p, hsa-miR-192-5p 
Transcriptional 
misregulation in 
cancer (hsa05202) 
4.79e-02 
CCNT2, NFKBIZ, ID2, HMGA2, CCND2, H
OXA9, PBX1, CDKN1B, IGF1R, RUNX2, P
ML, SUPT3H, TP53, SS18, PTK2, HIST1H3
I, MYC, NR4A3, MMP9, BMP2K, CDK14, T
F1, SP1, PPARG, WHSC1, H3F3B, CDKN1
A, SSX2B, SIX4, PLAU, SMAD1, TGFBR2, 
NGFR, MEIS1 
hsa-miR-10b-5p, hsa-miR-378a-3p, hsa-miR-22-3p, 
hsa-miR-92a-3p, hsa-miR-371a-3p, hsa-miR-26a-5p, 
hsa-miR-21-5p, hsa-miR-30d-5p, hsa-miR-423-5p, 
hsa-miR-192-5p 
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Chronic myeloid 
leukemia (hsa05220) 6.39e
-02 
E2F1, TGFBR1, E2F2, CRK, CDKN1B, CD
KN2A, CDK6, TP53, SMAD4, MYC, PIK3R1
, 
RB1, SOS1, TGFB2, GAB2, CDKN1A, TGF
BR2 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-92a-3p, 
hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-423-5p, hsa-miR-192-5p 
TGF-beta signaling 
pathway (hsa04350) 1.35e
-01 
TGFBR1, ID2, THBS1, ROCK2, ID4, ACVR
2B, ZFYVE16, SMAD4, E2F5, MYC, ID1, C
VR2A, SP1, TGFB2, BMP7, SMAD1, TGFB
R2, BMPR2, RPS6KB1 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-92a-3p, 
hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-192-5p 
Pancreatic 
cancer (hsa05212) 1.71e
-01 
STAT3, E2F1, TGFBR1, ERBB2, E2F2, RA
D51, PLD1, BRCA2, EGFR, CDKN2A, CDK
6, TP53, MAPK9, SMAD4, PIK3R1, RB1, T
GFB2, VEGFA, TGFBR2 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-92a-3p, 
hsa-miR-371a-3p, hsa-miR-26a-5p, hsa-miR-21-5p, 
hsa-miR-30d-5p, hsa-miR-192-5p 
Fanconi anemia 
pathway (hsa03460) 7.26e
+00 
BLM, RMI1, RAD51, USP1, REV1, EME1, B
RCA2, BRCA1, FANCM, ERCC4, REV3L, P
OLQ, FANCI 
hsa-miR-21-5p, hsa-miR-192-5p 
Small cell lung 
cancer (hsa05222) 4.48e
+01 
E2F1, E2F2, BCL2, CDKN1B, CDK6, TP53,
 APAF1, PTK2, ITGAV, CCNE2, SKP2, MY
C, PIK3R1, RB1, CCNE1, CYCS, PTEN 
hsa-miR-378a-3p, hsa-miR-22-3p, hsa-miR-148a-3p, 
hsa-miR-26a-5p, hsa-miR-21-5p, hsa-miR-30d-5p, 
hsa-miR-192-5p 
ErbB signaling 
pathway (hsa04012) 6.15e
+01 
GSK3B, HBEGF, ERBB2, NRG4, CRK, CD
KN1B, EGFR, PTK2, MAPK9,MYC, PIK3R1
, SOS1, PAK6, BTC, CDKN1A, RPS6KB 
hsa-miR-378a-3p, hsa-miR-371a-3p, hsa-miR-26a-5p, 
hsa-miR-21-5p, hsa-miR-423-5p, hsa-miR-192-5p 
Endometrial 
cancer (hsa05213) 6.15e
+01 GSK3B, ERBB2, TCF4, APC, EGFR, TP53, MYC, PIK3R1, SOS1, TCF7 
hsa-miR-378a-3p, hsa-miR-192-5p, hsa-miR-371a-3p, 
hsa-miR-26a-5p, hsa-miR-21-5p, hsa-miR-30d-5p, 
hsa-miR-423-5p 
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Table S2. Annotation cluster analysis carried out using DAVID web-tool is reported for the first 10 gene clusters identified. Each cluster is 
described by enrichment score, which is based on an EASE scores (an alternative name of Fisher Exact Statistics in DAVID system, 
referring to one-tail Fisher Exact Probability Value used for gene-enrichment analysis) of each term members; the higher value represents 
the more enriched cluster. Moreover, GO category and term, genes associated in the cluster according to their function are reported. P-
value and False Discovery Rate (FDR) were less than 0.0001 (data not shown).  
 
Annotation 
Cluster 
Enrichment 
Score GO Term Genes 
1 
 
 
15.76 
 
GO:0042325~regulati
on of phosphorylation 
CCNT2, BLM, ERBB2, BMPR2, TTK, TLR4, CCNG1, PTEN, TGFB2, CCNE2, 
CDKN2A, CDKN2D, MAP3K1, BCL2, ILK, PRKACA, PDGFD, THBS1, FGF2, APC, 
EGFR, CDC6, RBL2, TGFBR1, TGFBR2, SMAD4, RB1, CDC25A, CDC25B, 
ACVR2A, ACVR2B, CDKN1A, CDKN1B, CCND2, BMP7 
GO:0051174~regulati
on of phosphorus 
metabolic process 
CCNT2, BLM, ERBB2, BMPR2, TTK, TLR4, CCNG1, PTEN, TGFB2, CCNE2, 
CDKN2A, CDKN2D, MAP3K1, BCL2, ILK, PRKACA, PDGFD, THBS1, FGF2, APC, 
EGFR, CDC6, RBL2, TGFBR1, TGFBR2, SMAD4, RB1, CDC25A, CDC25B, 
ACVR2A, ACVR2B, CDKN1A, CDKN1B, CCND2, BMP7 
GO:0019220~regulati
on of phosphate 
metabolic process 
CCNT2, BLM, ERBB2, BMPR2, TTK, TLR4, CCNG1, PTEN, TGFB2, CCNE2, 
CDKN2A, CDKN2D, MAP3K1, BCL2, ILK, PRKACA, PDGFD, THBS1, FGF2, APC, 
EGFR, CDC6, RBL2, TGFBR1, TGFBR2, SMAD4, RB1, CDC25A, CDC25B, 
ACVR2A, ACVR2B, CDKN1A, CDKN1B, CCND2, BMP7 
2 
 
 
14.31 
 
GO:0043067~regulati
on of programmed cell 
death 
BID, MMP9, ZMAT3, ERBB2, BTC, PML, TLR4, PTEN, TGFB2, IGF1R, CDKN2A, 
CDKN2D, SOS1, MAP3K1, BCL2, ILK, FAS, THBS1, MYC, FGF2, IL1A, APC, EGFR, 
MSH6, MSH2, TGFBR1, CYCS, SKP2, TP53, BRCA2, BRCA1, HSP90B1, CDKN1A, 
CDKN1B, IFNB1, GSK3B, VEGFA, MAPK9, APAF1, NGFR, PRNP, PERP, BMP7 
GO:0010941~regulati
on of cell death 
BID, MMP9, ZMAT3, ERBB2, BTC, PML, TLR4, PTEN, TGFB2, IGF1R, CDKN2A, 
CDKN2D, SOS1, MAP3K1, BCL2, ILK, FAS, THBS1, MYC, FGF2, IL1A, APC, EGFR, 
MSH6, MSH2, TGFBR1, CYCS, SKP2, TP53, BRCA2, BRCA1, HSP90B1, CDKN1A, 
CDKN1B, IFNB1, GSK3B, VEGFA, MAPK9, APAF1, NGFR, PRNP, PERP, BMP7 
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GO:0042981~regulati
on of apoptosis 
BID, MMP9, ZMAT3, ERBB2, BTC, PML, TLR4, PTEN, TGFB2, IGF1R, CDKN2A, 
CDKN2D, SOS1, MAP3K1, BCL2, ILK, FAS, THBS1, MYC, IL1A, APC, EGFR, MSH6, 
MSH2, TGFBR1, CYCS, SKP2, TP53, BRCA2, BRCA1, HSP90B1, CDKN1A, 
CDKN1B, IFNB1, GSK3B, VEGFA, MAPK9, APAF1, NGFR, PRNP, PERP, BMP7 
3 
 
 
 
 
14.08 
GO:0005654~nucleop
lasm 
CCNT2, E2F1, E2F2, SUPT3H, XPO1, BLM, E2F5, PML, ANAPC10, ATF1, CCNE2, 
CCNE1, FOS, CDKN2A, DDX3X, FANCI, HOXA9, TCF4, POLQ, RUNX2, MYC, 
ERCC4, CDC7, TBL1XR1, CDC6, KAT2B, RBL2, USP1, TP53, SMAD4, BRCA2, 
CDC20, RB1, SMAD1, APPL1, MCM3, BRCA1, CDC25A, CDC25B, RAD51, MCM6, 
RPS6KA5, CDKN1A, PBX1, NGFR, TBL1X 
GO:0031981~nuclear 
lumen 
E2F1, CCNT2, E2F2, XPO1, E2F5, ZMAT3, CCNE2, FOS, CCNE1, CDKN2A, FANCI, 
MYB, MYC, CDC7, CDC6, TBL1XR1, RBL2, USP1, TP53, RB1, MCM3, RAD51, 
MCM6, NGFR, SUPT3H, BLM, PML, ANAPC10, SUFU, ATF1, DDX3X, HOXA9, 
POLQ, TCF4, RUNX2, ERCC4, KAT2B, NLK, EME1, SMAD4, BRCA2, CDC20, 
SMAD1, APPL1, BRCA1, CDC25A, STAT3, CDC25B, RPS6KA5, CDKN1A, SP1, 
PBX1, TBL1X 
GO:0043233~organell
e lumen 
E2F1, CCNT2, E2F2, XPO1, E2F5, ZMAT3, TGFB2, CCNE2, FOS, CCNE1, 
CDKN2A, FANCI, MYB, MYC, CDC7, CDC6, TBL1XR1, RBL2, USP1, CYCS, TP53, 
RB1, MCM3, RAD51, MCM6, VEGFA, NGFR, SUPT3H, BLM, PML, ANAPC10, 
SUFU, ATF1, DDX3X, HOXA9, POLQ, TCF4, THBS1, RUNX2, ERCC4, KAT2B, NLK, 
EME1, SMAD4, BRCA2, CDC20, SMAD1, APPL1, STAT3, CDC25A, BRCA1, 
CDC25B, RPS6KA5, HSP90B1, CDKN1A, SP1, PBX1, TBL1X 
GO:0031974~membr
ane-enclosed lumen 
E2F1, CCNT2, E2F2, XPO1, E2F5, ZMAT3, TGFB2, CCNE2, FOS, CCNE1, 
CDKN2A, FANCI, MYB, MYC, CDC7, CDC6, TBL1XR1, RBL2, USP1, CYCS, TP53, 
RB1, MCM3, RAD51, MCM6, VEGFA, NGFR, SUPT3H, BLM, PML, ANAPC10, 
SUFU, ATF1, DDX3X, HOXA9, POLQ, TCF4, THBS1, RUNX2, ERCC4, KAT2B, NLK, 
EME1, SMAD4, BRCA2, CDC20, SMAD1, APPL1, STAT3, CDC25A, BRCA1, 
CDC25B, RPS6KA5, HSP90B1, CDKN1A, SP1, PBX1, TBL1X 
GO:0070013~intracell
ular organelle lumen 
E2F1, CCNT2, E2F2, XPO1, E2F5, ZMAT3, CCNE2, FOS, CCNE1, CDKN2A, FANCI, 
MYB, MYC, CDC7, CDC6, TBL1XR1, RBL2, USP1, CYCS, TP53, RB1, MCM3, 
RAD51, MCM6, NGFR, SUPT3H, BLM, PML, ANAPC10, SUFU, ATF1, DDX3X, 
HOXA9, POLQ, TCF4, RUNX2, ERCC4, KAT2B, NLK, EME1, SMAD4, BRCA2, 
CDC20, SMAD1, APPL1, STAT3, BRCA1, CDC25A, CDC25B, RPS6KA5, HSP90B1, 
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CDKN1A, SP1, PBX1, TBL1X 
4 
 
 
12.40 
 
GO:0002520~immune 
system development 
BLM, MMP9, PPARG, PML, IL15, TGFB2, BCL2, HOXA9, FAS, PIK3R1, APC, EGR1, 
MSH6, MSH2, TGFBR1, TGFBR2, TP53, BRCA2, CDK6, RB1, SIX4, ID2, SP1, 
VEGFA, PBX1 
GO:0048534~hemopo
ietic or lymphoid 
organ development 
EGR1, BLM, MSH2, MMP9, TGFBR1, PPARG, TGFBR2, TP53, PML, BRCA2, CDK6, 
RB1, IL15, SIX4, TGFB2, SP1, ID2, BCL2, VEGFA, HOXA9, PBX1, FAS, PIK3R1, 
APC 
GO:0030097~hemopo
iesis 
EGR1, BLM, MSH2, MMP9, PPARG, TGFBR2, TP53, PML, BRCA2, CDK6, RB1, 
IL15, TGFB2, ID2, SP1, BCL2, VEGFA, HOXA9, PBX1, FAS, PIK3R1, APC 
5 
 
 
12.21 
 
GO:0051338~regulati
on of transferase 
activity 
CCNT2, BLM, ERBB2, PPARG, CCNG1, PTEN, TGFB2, CCNE2, CDKN2A, MAP3K1, 
CDKN2D, ILK, PRKACA, THBS1, FGF2, APC, EGFR, CDC6, RBL2, TGFBR1, 
TGFBR2, RB1, CDC25A, CDC25B, ACVR2B, CDKN1A, CDKN1B, CCND2 
GO:0043549~regulati
on of kinase activity 
CCNT2, BLM, ERBB2, CCNG1, PTEN, TGFB2, CCNE2, CDKN2A, MAP3K1, 
CDKN2D, ILK, PRKACA, THBS1, FGF2, APC, EGFR, CDC6, RBL2, TGFBR1, 
TGFBR2, RB1, CDC25A, CDC25B, ACVR2B, CDKN1A, CDKN1B, CCND2 
GO:0045859~regulati
on of protein kinase 
activity 
CCNT2, BLM, ERBB2, CCNG1, PTEN, TGFB2, CCNE2, CDKN2A, MAP3K1, 
CDKN2D, ILK, PRKACA, THBS1, FGF2, APC, EGFR, CDC6, TGFBR1, TGFBR2, 
RB1, CDC25A, CDC25B, ACVR2B, CDKN1A, CDKN1B, CCND2 
6 
 
 
 
 
 
 
 
11.19 
 
kinase 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, CDKN2A, 
MAP3K1, ILK, PRKACA, CDK14, CDC7, EGFR, CSNK1A1, RET, ROCK2, NLK, 
TGFBR1, TGFBR2, CDK6, RPS6KA5, ACVR2A, ACVR2B, CDKN1A, CDKN1B, 
GSK3B, BMP2K, BUB1B, MAPK9, PLAU 
binding site:ATP 
ERBB2, BMPR2, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, TGFBR2, 
CDK6, RPS6KA5, ACVR2A, ACVR2B, HSP90B1, GSK3B, BMP2K, BUB1B, MAPK9 
domain:Protein kinase 
ERBB2, BMPR2, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, TGFBR2, 
CDK6, ACVR2A, ACVR2B, GSK3B, BMP2K, BUB1B, MAPK9 
IPR017441:Protein 
kinase, ATP binding 
site 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, CDK6, 
RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, BUB1B, MAPK9 
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IPR000719:Protein 
kinase, core 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, TGFBR2, 
CDK6, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, MAPK9 
GO:0004672~protein 
kinase activity 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, TGFB2, INSRR, PAK6, IGF1R, PTK2, 
MAP3K1, ILK, PRKACA, CDK14, CDC7, EGFR, CSNK1A1, RET, ROCK2, TGFBR1, 
NLK, TGFBR2, CDK6, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, BUB1B, 
MAPK9 
active site:Proton 
acceptor 
ERBB2, BMPR2, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, PRKACA, 
CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, TGFBR2, CDK6, 
RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, BUB1B, MAPK9 
transferase 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, CDC7, EGFR, CSNK1A1, RET, KAT2B, REV1, ROCK2, NLK, 
TGFBR1, TGFBR2, CDK6, WHSC1, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, 
BUB1B, MAPK9, REV3L 
7 
 
 
 
 
 
10.47 
IPR000719:Protein 
kinase, core 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, INSRR, PAK6, IGF1R, PTK2, MAP3K1, ILK, 
PRKACA, CDK14, EGFR, CSNK1A1, CDC7, RET, ROCK2, TGFBR1, NLK, TGFBR2, 
CDK6, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, MAPK9 
GO:0006468~protein 
amino acid 
phosphorylation 
ERBB2, BMPR2, PML, TFG, TTK, RPS6KB1, INSRR, TGFB2, PAK6, IGF1R, PTK2, 
MAP3K1, BCL2, ILK, PRKACA, THBS1, FGF2, CDK14, CDC7, CSNK1A1, EGFR, 
RET, ROCK2, NLK, TGFBR1, TGFBR2, CDK6, RPS6KA5, ACVR2A, ACVR2B, 
GSK3B, BMP2K, MAPK9, BMP7 
GO:0006796~phosph
ate metabolic process 
CDC14A, ERBB2, PML, BMPR2, TTK, TFG, RPS6KB1, PTEN, INSRR, TGFB2, 
PAK6, IGF1R, PTK2, MAP3K1, BCL2, ILK, PRKACA, THBS1, FGF2, CDK14, 
PIK3R1, CDC7, CSNK1A1, EGFR, RET, ROCK2, MSH2, NLK, TGFBR1, TGFBR2, 
CDK6, CDC25A, CDC25B, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, MAPK9, 
BMP7 
GO:0006793~phosph
orus metabolic 
process 
CDC14A, ERBB2, PML, BMPR2, TTK, TFG, RPS6KB1, PTEN, INSRR, TGFB2, 
PAK6, IGF1R, PTK2, MAP3K1, BCL2, ILK, PRKACA, THBS1, FGF2, CDK14, 
PIK3R1, CDC7, CSNK1A1, EGFR, RET, ROCK2, MSH2, NLK, TGFBR1, TGFBR2, 
CDK6, CDC25A, CDC25B, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, MAPK9, 
BMP7 
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GO:0016310~phosph
orylation 
ERBB2, BMPR2, PML, TTK, TFG, RPS6KB1, INSRR, TGFB2, PAK6, IGF1R, PTK2, 
MAP3K1, BCL2, ILK, PRKACA, THBS1, FGF2, CDK14, PIK3R1, CDC7, CSNK1A1, 
EGFR, RET, MSH2, ROCK2, NLK, TGFBR1, TGFBR2, CDK6, RPS6KA5, ACVR2A, 
ACVR2B, GSK3B, BMP2K, MAPK9, BMP7 
GO:0004672~protein 
kinase activity 
ERBB2, BMPR2, TFG, TTK, RPS6KB1, TGFB2, INSRR, PAK6, IGF1R, PTK2, 
MAP3K1, ILK, PRKACA, CDK14, CDC7, EGFR, CSNK1A1, RET, ROCK2, TGFBR1, 
NLK, TGFBR2, CDK6, RPS6KA5, ACVR2A, ACVR2B, GSK3B, BMP2K, BUB1B, 
MAPK9 
8 
 
 
10.35 
 
GO:0043065~positive 
regulation of 
apoptosis 
BID, MMP9, ZMAT3, PML, TLR4, PTEN, TGFB2, CDKN2A, MAP3K1, BCL2, SOS1, 
FAS, MYC, APC, MSH6, TGFBR1, TP53, SKP2, BRCA2, BRCA1, CDKN1A, 
CDKN1B, IFNB1, MAPK9, NGFR, BMP7, PERP 
GO:0043068~positive 
regulation of 
programmed cell 
death 
BID, MMP9, ZMAT3, PML, TLR4, PTEN, TGFB2, CDKN2A, MAP3K1, BCL2, SOS1, 
FAS, MYC, APC, MSH6, TGFBR1, TP53, SKP2, BRCA2, BRCA1, CDKN1A, 
CDKN1B, IFNB1, MAPK9, NGFR, BMP7, PERP 
GO:0010942~positive 
regulation of cell 
death 
BID, MMP9, ZMAT3, PML, TLR4, PTEN, TGFB2, CDKN2A, MAP3K1, BCL2, SOS1, 
FAS, MYC, APC, MSH6, TGFBR1, TP53, SKP2, BRCA2, BRCA1, CDKN1A, 
CDKN1B, IFNB1, MAPK9, NGFR, BMP7, PERP 
9 
 
 
 
 
 
9.40 
GO:0051272~positive 
regulation of cell 
motion 
EGFR, PLD1, MMP9, TGFBR1, RPS6KB1, TGFB2, IGF1R, BCL2, ILK, VEGFA, 
HBEGF, THBS1, FGF2, PIK3R1, APC 
GO:0030335~positive 
regulation of cell 
migration 
EGFR, PLD1, MMP9, RPS6KB1, TGFB2, IGF1R, BCL2, VEGFA, ILK, HBEGF, 
THBS1, FGF2, PIK3R1, APC 
GO:0040017~positive 
regulation of 
locomotion 
EGFR, PLD1, MMP9, RPS6KB1, TGFB2, IGF1R, BCL2, VEGFA, ILK, HBEGF, 
THBS1, FGF2, PIK3R1, APC 
GO:0051270~regulati
on of cell motion 
EGFR, PLD1, MMP9, TGFBR1, RPS6KB1, PTEN, TGFB2, IGF1R, CDKN1B, BCL2, 
MAP3K1, ILK, VEGFA, HBEGF, THBS1, FGF2, PIK3R1, APC 
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GO:0040012~regulati
on of locomotion 
EGFR, PLD1, MMP9, RPS6KB1, PTEN, TGFB2, IGF1R, IFNB1, BCL2, MAP3K1, ILK, 
VEGFA, HBEGF, THBS1, FGF2, PIK3R1, APC 
GO:0030334~regulati
on of cell migration 
EGFR, PLD1, MMP9, RPS6KB1, PTEN, TGFB2, IGF1R, BCL2, MAP3K1, ILK, 
VEGFA, HBEGF, THBS1, FGF2, PIK3R1, APC 
10 
 
 
 
 
 
 
 
 
 
9.13 
 
GO:0010557~positive 
regulation of 
macromolecule 
biosynthetic process 
E2F1, BLM, PPARG, TLR4, TGFB2, CCNE1, FOS, WNT1, IGF1R, MAP3K1, NFAT5, 
TCF4, THBS1, FGF2, MYC, RUNX2, IL1A, EGR1, TBL1XR1, TGFBR1, SMAD4, 
TP53, RB1, SMAD1, NR4A3, SIX4, BRCA1, STAT3, SP1, VEGFA, PBX1, BMP7, 
TBL1X 
GO:0009891~positive 
regulation of 
biosynthetic process 
E2F1, BLM, PPARG, TLR4, TGFB2, CCNE1, FOS, WNT1, IGF1R, MAP3K1, NFAT5, 
TCF4, THBS1, FGF2, MYC, RUNX2, IL1A, EGR1, EGFR, TBL1XR1, TGFBR1, 
SMAD4, TP53, RB1, SMAD1, NR4A3, SIX4, BRCA1, STAT3, SP1, VEGFA, PBX1, 
BMP7, TBL1X 
GO:0031328~positive 
regulation of cellular 
biosynthetic process 
E2F1, BLM, PPARG, TLR4, CCNE1, FOS, WNT1, IGF1R, MAP3K1, NFAT5, TCF4, 
THBS1, FGF2, MYC, RUNX2, IL1A, EGFR, EGR1, TBL1XR1, TGFBR1, SMAD4, 
TP53, RB1, SMAD1, NR4A3, SIX4, BRCA1, STAT3, SP1, VEGFA, PBX1, BMP7, 
TBL1X 
GO:0051173~positive 
regulation of nitrogen 
compound metabolic 
process 
E2F1, BLM, PPARG, CCNE1, FOS, WNT1, IGF1R, MAP3K1, NFAT5, TCF4, FGF2, 
MYC, RUNX2, EGFR, EGR1, TBL1XR1, TGFBR1, SMAD4, TP53, RB1, SMAD1, 
NR4A3, SIX4, BRCA1, STAT3, RAD51, SP1, VEGFA, PBX1, BMP7, TBL1X 
GO:0010628~positive 
regulation of gene 
expression 
E2F1, BLM, PPARG, CCNE1, FOS, WNT1, MAP3K1, NFAT5, TCF4, FGF2, MYC, 
RUNX2, EGR1, TBL1XR1, TGFBR1, SMAD4, TP53, RB1, SMAD1, NR4A3, SIX4, 
STAT3, BRCA1, SP1, VEGFA, MAPK9, PBX1, BMP7, TBL1X 
GO:0045935~positive 
regulation of 
nucleobase, 
nucleoside, nucleotide 
and nucleic acid 
metabolic process 
E2F1, BLM, PPARG, CCNE1, FOS, WNT1, IGF1R, MAP3K1, NFAT5, TCF4, FGF2, 
MYC, RUNX2, EGR1, TBL1XR1, TGFBR1, SMAD4, TP53, RB1, SMAD1, NR4A3, 
SIX4, BRCA1, STAT3, RAD51, SP1, VEGFA, PBX1, BMP7, TBL1X 
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GO:0045893~positive 
regulation of 
transcription, DNA-
dependent 
E2F1, PPARG, FOS, WNT1, CCNE1, MAP3K1, NFAT5, TCF4, FGF2, MYC, RUNX2, 
EGR1, TBL1XR1, SMAD4, TP53, RB1, SMAD1, NR4A3, SIX4, STAT3, BRCA1, SP1, 
VEGFA, PBX1, BMP7, TBL1X 
GO:0051254~positive 
regulation of RNA 
metabolic process 
E2F1, PPARG, FOS, WNT1, CCNE1, MAP3K1, NFAT5, TCF4, FGF2, MYC, RUNX2, 
EGR1, TBL1XR1, SMAD4, TP53, RB1, SMAD1, NR4A3, SIX4, STAT3, BRCA1, SP1, 
VEGFA, PBX1, BMP7, TBL1X 
GO:0045941~positive 
regulation of 
transcription 
E2F1, BLM, PPARG, FOS, WNT1, CCNE1, MAP3K1, NFAT5, TCF4, FGF2, MYC, 
RUNX2, EGR1, TBL1XR1, TGFBR1, SMAD4, TP53, RB1, SMAD1, NR4A3, SIX4, 
STAT3, BRCA1, SP1, VEGFA, PBX1, BMP7, TBL1X 
GO:0045944~positive 
regulation of 
transcription from 
RNA polymerase II 
promoter 
E2F1, EGR1, TBL1XR1, PPARG, TP53, SMAD4, RB1, NR4A3, SMAD1, SIX4, 
STAT3, FOS, SP1, MAP3K1, VEGFA, NFAT5, PBX1, BMP7, TBL1X, FGF2, RUNX2, 
MYC 
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CHAPTER 3 
 
Differences in miRNAs after in vitro fertilization using sperm with high and low blastocyst developmental potential 
 
Table S3. Gene Ontology (GO) analysis was performed using the list of predicted target genes of differentially expressed miRNAs. GO 
terms for biological function, gene count, which indicates how much the GO term is enriched of predicted genes, P-value and False 
Discovery Rate (FDR) are reported.  
GO Term Gene count P-Value FDR 
GO:0006350~transcription 623 9.41e+13 1.79e+06 
GO:0045449~regulation of transcription 750 1.02e+13 1.94e+06 
GO:0006357~regulation of transcription from RNA polymerase II 
promoter 251 1.37e+14 2.61e+07 
GO:0010557~positive regulation of macromolecule biosynthetic process 227 1.02e+14 1.93e+07 
GO:0009891~positive regulation of biosynthetic process 238 1.43e+14 2.72e+07 
GO:0031328~positive regulation of cellular biosynthetic process 235 1.58e+14 3.00e+07 
GO:0010604~positive regulation of macromolecule metabolic process 282 2.42e+13 4.61e+07 
GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 217 2.49e+14 4.74e+08 
GO:0051173~positive regulation of nitrogen compound metabolic 
process 222 3.73e+14 7.10e+07 
GO:0010628~positive regulation of gene expression 203 7.40e+14 1.41e+08 
GO:0045941~positive regulation of transcription 198 8.10e+13 1.54e+09 
GO:0031175~neuron projection development 105 2.91e+14 5.54e+08 
GO:0045893~positive regulation of transcription, DNA-dependent 171 2.92e+14 5.56e+08 
GO:0051254~positive regulation of RNA metabolic process 172 3.22e+14 6.13e+08 
	  135	  
GO:0007167~enzyme linked receptor protein signaling pathway 131 3.64e+13 6.94e+08 
GO:0048666~neuron development 130 3.92e+14 7.47e+08 
GO:0051252~regulation of RNA metabolic process 526 6.40e+14 1.22e+09 
GO:0007242~intracellular signaling cascade 380 1.42e+14 2.71e+10 
GO:0006355~regulation of transcription, DNA-dependent 512 2.42e+14 4.61e+09 
GO:0030030~cell projection organization 136 2.53e+14 4.82e+10 
GO:0007169~transmembrane receptor protein tyrosine kinase signaling 
pathway 92 3.74e+14 7.13e+09 
GO:0006468~protein amino acid phosphorylation 220 3.92e+14 7.46e+09 
GO:0045944~positive regulation of transcription from RNA polymerase 
II promoter 136 4.60e+14 8.76e+09 
GO:0048812~neuron projection morphogenesis 87 1.41e+14 2.68e+11 
GO:0030182~neuron differentiation 153 2.01e+14 3.84e+11 
GO:0006793~phosphorus metabolic process 297 4.62e+13 8.81e+09 
GO:0006796~phosphate metabolic process 297 4.62e+13 8.81e+09 
GO:0048858~cell projection morphogenesis 95 5.92e+14 1.13e+12 
GO:0048667~cell morphogenesis involved in neuron differentiation 84 6.02e+14 1.15e+12 
GO:0007409~axonogenesis 79 6.24e+14 1.19e+12 
GO:0007267~cell-cell signaling 196 6.79e+14 1.29e+11 
GO:0032990~cell part morphogenesis 98 7.45e+14 1.42e+12 
GO:0000902~cell morphogenesis 126 1.76e+14 3.35e+11 
GO:0016192~vesicle-mediated transport 186 3.71e+13 7.07e+10 
GO:0048598~embryonic morphogenesis 110 5.75e+13 0.001 
GO:0032989~cellular component morphogenesis 135 8.21e+14 0.002 
GO:0000904~cell morphogenesis involved in differentiation 91 8.62e+14 0.002 
GO:0033674~positive regulation of kinase activity 86 1.93e+14 0.004 
GO:0045184~establishment of protein localization 233 2.87e+14 0.005 
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GO:0045860~positive regulation of protein kinase activity 83 3.00e+14 0.006 
GO:0015031~protein transport 231 3.03e+14 0.006 
GO:0016310~phosphorylation 238 9.43e+14 0.018 
GO:0008104~protein localization 259 1.06e+14 0.020 
GO:0051347~positive regulation of transferase activity 86 1.09e+14 0.021 
GO:0019220~regulation of phosphate metabolic process 153 1.80e+14 0.034 
GO:0051174~regulation of phosphorus metabolic process 153 1.80e+14 0.034 
GO:0010629~negative regulation of gene expression 158 1.90e+14 0.036 
GO:0000122~negative regulation of transcription from RNA polymerase 
II promoter 92 2.58e+14 0.049 
GO:0016481~negative regulation of transcription 145 2.81e+14 0.053 
GO:0048729~tissue morphogenesis 67 2.96e+14 0.056 
GO:0044057~regulation of system process 103 4.59e+14 0.087 
GO:0046578~regulation of Ras protein signal transduction 75 4.77e+14 0.091 
GO:0046907~intracellular transport 196 5.25e+14 0.100 
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Table S4. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis. which was performed using DAVID web-tool and 
predicted target genes of differentially expressed miRNAs. KEGG pathways, gene count, which indicates how much the KEGG pathway is 
enriched of predicted genes, and P-value are reported.  
 
KEGG pathway Gene count P-Value 
hsa04310:Wnt signaling pathway 69 1.57e+07 
hsa04010:MAPK signaling pathway 92 2.11e+11 
hsa04020:Calcium signaling pathway 65 4.11e+11 
hsa04012:ErbB signaling pathway 37 1.08e+12 
hsa04920:Adipocytokine signaling pathway 30 1.96e+12 
hsa04370:VEGF signaling pathway 30 0.002 
hsa04720:Long-term potentiation 27 0.004 
hsa04514:Cell adhesion molecules (CAMs) 45 0.005 
hsa04340:Hedgehog signaling pathway 23 0.005 
hsa04960:Aldosterone-regulated sodium reabsorption 17 0.017 
hsa04350:TGF-beta signaling pathway 30 0.019 
hsa04540:Gap junction 30 0.026 
hsa04730:Long-term depression 24 0.035 
hsa04630:Jak-STAT signaling pathway 47 0.035 
hsa05210:Colorectal cancer 45 4.57e+05 
hsa05200:Pathways in cancer 113 2.02e+10 
hsa05214:Glioma 32 5.08e+09 
hsa05213:Endometrial cancer 28 5.70e+09 
hsa05215:Prostate cancer 39 3.04e+11 
hsa05223:Non-small cell lung cancer 27 4.74e+10 
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hsa05220:Chronic myeloid leukemia 34 4.86e+11 
hsa05217:Basal cell carcinoma 26 2.12e+11 
hsa05212:Pancreatic cancer 31 3.44e+11 
hsa04912:GnRH signaling pathway 39 3.49e+11 
hsa04270:Vascular smooth muscle contraction 43 4.05e+12 
hsa04150:mTOR signaling pathway 24 6.10e+11 
hsa05218:Melanoma 30 6.39e+11 
hsa05211:Renal cell carcinoma 27 0.006 
hsa05014:Amyotrophic lateral sclerosis (ALS) 21 0.011 
hsa05221:Acute myeloid leukemia 22 0.017 
hsa05222:Small cell lung cancer 29 0.021 
hsa05216:Thyroid cancer 13 0.022 
hsa04520:Adherens junction 39 3.98e+08 
hsa04144:Endocytosis 65 1.87e+11 
hsa04510:Focal adhesion 68 5.33e+11 
hsa04210:Apoptosis 35 5.96e+11 
hsa04914:Progesterone-mediated oocyte maturation 33 0.002 
hsa04810:Regulation of actin cytoskeleton 69 0.002 
hsa04530:Tight junction 46 0.004 
hsa04114:Oocyte meiosis 38 0.008 
hsa04910:Insulin signaling pathway 58 5.11e+08 
hsa04916:Melanogenesis 43 1.42e+11 
hsa04722:Neurotrophin signaling pathway 50 2.85e+11 
hsa04360:Axon guidance 50 9.44e+10 
hsa04660:T cell receptor signaling pathway 41 7.37e+11 
hsa04062:Chemokine signaling pathway 62 0.002 
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hsa04666:Fc gamma R-mediated phagocytosis 36 0.002 
hsa04664:Fc epsilon RI signaling pathway 30 0.004 
hsa04670:Leukocyte transendothelial migration 41 0.005 
hsa04662:B cell receptor signaling pathway 26 0.028 
hsa00310:Lysine degradation 20 0.003 
hsa04070:Phosphatidylinositol signaling system 27 0.013 
hsa05414:Dilated cardiomyopathy 32 0.013 
hsa04930:Type II diabetes mellitus 19 0.014 
hsa04130:SNARE interactions in vesicular transport 16 0.018 
hsa04120:Ubiquitin mediated proteolysis 42 0.039 
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CHAPTER 4 
 
Differences in miRNAs after in vitro fertilization using sperm with high and low blastocyst developmental potential 
 
Table S5. List of differentially expressed miRNAs between follicular fluids of high and low antral follicle count ovaries. MiRNA ID, Log Fold 
Change (LogFC), P-value and False Discovery Rate (FDR) are reported.  
 
MiRNA ID LogFC P-Value FDR 
bta-miR-769 -2.524 7.92E-09 4.22E-06 
bta-miR-1343 -2.924 2.24E-08 5.96E-06 
bta-miR-450a -2.915 6.06E-08 8.79E-06 
bta-miR-30d -2.170 9.62E-08 1.03E-05 
bta-miR-204 -4.025 1.34E-07 1.19E-05 
bta-miR-100 1.897 3.94E-07 3.00E-05 
bta-miR-99a 1.748 2.70E-06 0.000 
Novel:hsa-miR-320a 2.071 2.53E-05 0.001 
bta-miR-197 -2.884 3.38E-05 0.002 
bta-miR-151 -1.551 3.69E-05 0.002 
bta-miR-146b -1.660 3.70E-05 0.002 
bta-miR-24-3p 1.434 5.45E-05 0.002 
bta-miR-374b -2.647 0.000 0.004 
bta-miR-1271 -2.656 0.000 0.004 
bta-miR-98 -2.087 0.000 0.005 
Novel:hsa-miR-4640-5p -2.857 0.000 0.006 
bta-miR-10a 1.522 0.000 0.006 
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bta-miR-190b -1.901 0.000 0.006 
bta-let-7c -1.748 0.000 0.006 
bta-miR-451 -2.578 0.000 0.006 
bta-miR-31 -1.927 0.000 0.007 
bta-miR-4286 -2.308 0.001 0.011 
bta-miR-3613 -3.772 0.001 0.013 
bta-miR-30c -1.500 0.001 0.013 
Novel:hsa-miR-4707-5p -3.653 0.001 0.013 
bta-miR-450b -1.308 0.001 0.017 
Novel:hsa-miR-6878-5p -2.058 0.001 0.017 
bta-miR-449a -1.723 0.001 0.020 
bta-miR-301a -1.524 0.001 0.020 
bta-miR-150 -4.112 0.002 0.022 
bta-miR-383 -1.957 0.002 0.024 
bta-miR-18a -2.447 0.002 0.027 
bta-miR-149 -1.422 0.002 0.027 
bta-miR-16b -1.276 0.002 0.028 
bta-miR-92a -1.084 0.002 0.028 
bta-miR-362 1.351 0.002 0.030 
bta-miR-30f -1.474 0.003 0.033 
bta-miR-324 -1.856 0.004 0.042 
bta-miR-93 -1.143 0.004 0.046 
bta-miR-148b -1.359 0.004 0.046 
bta-miR-885 2.715 0.004 0.046 
bta-miR-16a -1.472 0.005 0.054 
bta-miR-628 -1.798 0.006 0.058 
	  142	  
bta-miR-33b -1.674 0.006 0.059 
bta-miR-874 1.043 0.006 0.059 
bta-miR-504 1.526 0.006 0.061 
bta-miR-320a 1.051 0.006 0.061 
bta-miR-127 0.968 0.007 0.063 
bta-miR-2399 2.549 0.007 0.064 
bta-let-7b -1.053 0.007 0.064 
bta-miR-374a -1.609 0.008 0.071 
bta-miR-29d 1.441 0.009 0.073 
Novel:hsa-miR-4722-5p 2.073 0.010 0.077 
bta-miR-27a 0.919 0.010 0.081 
bta-miR-195 -1.419 0.010 0.081 
bta-miR-1247 1.475 0.011 0.083 
Novel:hsa-miR-665 1.380 0.012 0.087 
bta-miR-223 -2.890 0.012 0.087 
bta-miR-328 -1.240 0.012 0.090 
bta-miR-30e -1.033 0.012 0.090 
bta-miR-30a -0.841 0.013 0.093 
Novel:hsa-miR-3960 -1.286 0.013 0.093 
bta-miR-2313 -1.581 0.013 0.093 
bta-miR-194 -1.229 0.014 0.093 
bta-miR-3431 -0.945 0.014 0.095 
bta-miR-365-3p -1.470 0.015 0.099 
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Table S6. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, P-value, count of predicted target genes (#genes) and 
differentially expressed miRNAs (#miRNAs), which were obtained using DIANA miRPath v2.0, are reported. 
 
KEGG pathway  P-value #genes #miRNAs 
Pathways in cancer 1.054e-11 62 17 
Chronic myeloid leukemia 6.655e-11 21 10 
Focal adhesion 8.588e-11 43 13 
Viral carcinogenesis 1.576e-10 45 14 
Bladder cancer 3.949e-10 15 10 
PI3K-Akt signaling pathway 1.907e-08 59 18 
ErbB signaling pathway 3.958e-08 21 8 
Neurotrophin signaling pathway 4.724e-08 27 13 
TGF-beta signaling pathway 1.588e-07 21 11 
Prostate cancer 2.544e-07 20 13 
Hepatitis B 1.185e-06 29 14 
Colorectal cancer 2.149e-06 15 11 
HIF-1 signaling pathway 1.855e-05 23 8 
MAPK signaling pathway 5.036e-05 43 14 
Non-small cell lung cancer 0.000 13 8 
Small cell lung cancer 0.000 17 8 
Pancreatic cancer 0.000 17 12 
NF-kappa B signaling pathway 0.000 18 8 
Endometrial cancer 0.000 12 9 
Insulin signaling pathway 0.001 24 10 
Transcriptional misregulation in cancer 0.001 31 10 
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Fc gamma R-mediated phagocytosis 0.001 18 7 
HTLV-I infection 0.001 40 14 
Amoebiasis 0.001 19 6 
mTOR signaling pathway 0.001 13 8 
Acute myeloid leukemia 0.001 12 7 
Melanoma 0.001 13 8 
Glioma 0.001 15 9 
NOD-like receptor signaling pathway 0.002 13 4 
Endocytosis 0.002 32 12 
Long-term depression 0.003 15 5 
African trypanosomiasis 0.003 8 4 
GnRH signaling pathway 0.003 16 6 
Alcoholism 0.003 30 8 
Vascular smooth muscle contraction 0.004 20 7 
Wnt signaling pathway 0.005 25 11 
Osteoclast differentiation 0.005 22 8 
Long-term potentiation 0.005 13 6 
Cell cycle 0.006 24 11 
Chemokine signaling pathway 0.010 28 10 
Epstein-Barr virus infection 0.011 31 10 
Thyroid cancer 0.014 7 7 
Melanogenesis 0.019 16 8 
Basal cell carcinoma 0.024 10 7 
Lysine degradation 0.028 10 7 
Regulation of actin cytoskeleton 0.029 32 11 
Measles 0.030 22 10 
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Chagas disease (American trypanosomiasis) 0.036 16 6 
Shigellosis 0.044 11 7 
p53 signaling pathway 0.044 12 7 
Oocyte meiosis 0.048 19 9 
RNA transport 0.048 22 6 
Cytokine-cytokine receptor interaction 0.049 34 9 
 
 
Table S7. Gene Ontology (GO) analysis was performed using the list of predicted target genes of differentially expressed miRNAs 
between folliclular fluids of high and low antral follicle count ovaries. GO terms for biological function, predicted targe genes of 
differentially expressed miRNAs, P-value and False Discovery Rate (FDR) are reported. Data are reported only for FDR less than 0.01. 
 
GO Term Genes P-Value FDR 
GO:0006468~protein amino acid 
phosphorylation 
FGFR3, ERBB3, STK11, ERBB2, STK36, RPS6KB2, RPS6KB1, KIT, IGF1R, 
PTK2, BCL2, MAP3K1, CAMK2D, PRKAA2, THBS1, FRS2, PDK1, IRAK1, 
CTBP1, RET, FLT1, ROCK1, SMAD7, MYLK3, TGFBR1, TGFBR2, MYLK4, 
RAF1, MYLK2, CDK6, CDK4, PRKCB, DAPK1, NTRK3, MAPK1, ACVR2A, 
RPS6KA3, CCND1, CAMK4, GSK3B, RIPK2, RELN, MAPK8, MTOR, ABL2, 
MYLK, ACVR1, F2R 
4.70e-11 8.13e-07 
GO:0042127~regulation of cell proliferation FGFR3, OSMR, ERBB3, STK11, ERBB2, MITF, EGLN3, FOXO1, FGF10, 
RPS6KB1, KIT, GLI2, IGF1R, CUL2, CDKN2B, BCL2, CAMK2D, THBS1, MYC, 
CCNA2, APC, CEBPA, CTBP1, IL6, IL2RA, FLT1, TGFBR1, NODAL, TGFBR2, 
6.90e-09 1.19e-03 
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TP53, SMAD4, CDK6, IL6R, CDK4, BRCA1, MAPK1, NRAS, CDKN1A, CCND1, 
CDKN1B, HDAC1, ID2, ETS1, VEGFA, HBEGF, RIPK2, MTOR, LAMC1, F2R 
GO:0043067~regulation of programmed 
cell death 
TRAF1, MCL1, ERBB3, BCAR1, ERBB2, MITF, FOXO1, NFKB1, PMAIP1, 
FOXO3, KIT, CUL2, IGF1R, COMP, MAP3K1, BCL2, RHOA, FAS, THBS1, 
TRAF6, MYC, ARHGDIA, APC, IRAK1, IL6, IL2RA, VAV3, ROCK1, TGFBR1, 
TP53, BIRC5, IL6R, BIRC3, YWHAE, BRCA1, TP73, DAPK1, MAPK1, NRAS, 
CDKN1A, CDKN1B, HDAC1, ETS1, GSK3B, VEGFA, RIPK2, MAPK8, ACVR1, 
F2R 
2.63e-06 4.55e-04 
GO:0010941~regulation of cell death TRAF1, MCL1, ERBB3, BCAR1, ERBB2, MITF, FOXO1, NFKB1, PMAIP1, 
FOXO3, KIT, CUL2, IGF1R, COMP, MAP3K1, BCL2, RHOA, FAS, THBS1, 
TRAF6, MYC, ARHGDIA, APC, IRAK1, IL6, IL2RA, VAV3, ROCK1, TGFBR1, 
TP53, BIRC5, IL6R, BIRC3, YWHAE, BRCA1, TP73, DAPK1, MAPK1, NRAS, 
CDKN1A, CDKN1B, HDAC1, ETS1, GSK3B, VEGFA, RIPK2, MAPK8, ACVR1, 
F2R 
3.08e-08 5.33e-04 
GO:0043069~negative regulation of 
programmed cell death 
MCL1, ERBB3, ERBB2, MITF, FOXO1, NFKB1, KIT, IGF1R, BCL2, COMP, 
RHOA, FAS, THBS1, TRAF6, MYC, ARHGDIA, APC, IRAK1, IL6, ROCK1, 
TGFBR1, TP53, BIRC5, BIRC3, TP73, DAPK1, NRAS, CDKN1A, HDAC1, GSK3B, 
VEGFA, RIPK2, MAPK8, ACVR1, F2R 
4.43e-07 7.67e-04 
GO:0060548~negative regulation of cell 
death 
MCL1, ERBB3, ERBB2, MITF, FOXO1, NFKB1, KIT, IGF1R, BCL2, COMP, 
RHOA, FAS, THBS1, TRAF6, MYC, ARHGDIA, APC, IRAK1, IL6, ROCK1, 
TGFBR1, TP53, BIRC5, BIRC3, TP73, DAPK1, NRAS, CDKN1A, HDAC1, GSK3B, 
4.85e-07 8.39e-04 
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VEGFA, RIPK2, MAPK8, ACVR1, F2R 
GO:0016310~phosphorylation FGFR3, ERBB3, STK11, ERBB2, STK36, RPS6KB2, RPS6KB1, KIT, IGF1R, 
PTK2, BCL2, MAP3K1, CAMK2D, PRKAA2, THBS1, FRS2, PDK1, IRAK1, 
CTBP1, RET, FLT1, ROCK1, SMAD7, MYLK3, TGFBR1, TGFBR2, MYLK4, 
RAF1, MYLK2, CDK6, CDK4, PRKCB, DAPK1, NTRK3, MAPK1, ACVR2A, 
RPS6KA3, CCND1, CAMK4, GSK3B, RIPK2, RELN, MAPK8, MTOR, ABL2, 
MYLK, ACVR1, F2R 
1.05e-06 1.81e-02 
GO:0042981~regulation of apoptosis TRAF1, MCL1, ERBB3, ERBB2, BCAR1, MITF, FOXO1, NFKB1, PMAIP1, 
FOXO3, IGF1R, CUL2, BCL2, MAP3K1, COMP, RHOA, FAS, TRAF6, THBS1, 
MYC, ARHGDIA, APC, IRAK1, IL6, IL2RA, VAV3, ROCK1, TGFBR1, TP53, BIRC5, 
IL6R, BIRC3, YWHAE, BRCA1, TP73, DAPK1, MAPK1, NRAS, CDKN1A, 
CDKN1B, HDAC1, ETS1, GSK3B, VEGFA, RIPK2, MAPK8, ACVR1, F2R 
1.29e-06 2.23e-02 
GO:0043066~negative regulation of 
apoptosis 
MCL1, ERBB3, ERBB2, MITF, FOXO1, NFKB1, IGF1R, BCL2, COMP, RHOA, 
FAS, THBS1, TRAF6, MYC, ARHGDIA, APC, IRAK1, IL6, ROCK1, TGFBR1, 
TP53, BIRC5, BIRC3, TP73, DAPK1, NRAS, CDKN1A, HDAC1, GSK3B, VEGFA, 
RIPK2, MAPK8, ACVR1, F2R 
3.21e-05 5.56e-04 
GO:0006796~phosphate metabolic process FGFR3, STK11, ERBB3, ERBB2, STK36, RPS6KB2, RPS6KB1, KIT, IGF1R, 
PTK2, MAP3K1, BCL2, CAMK2D, PRKAA2, THBS1, FRS2, PDK1, IRAK1, RET, 
CTBP1, FLT1, ROCK1, SMAD7, MYLK3, TGFBR1, MYLK4, TGFBR2, RAF1, 
MYLK2, CDK6, CDK4, DAPK1, PRKCB, NTRK3, MAPK1, ACVR2A, RPS6KA3, 
CCND1, PPP1CA, CAMK4, GSK3B, RIPK2, MAPK8, RELN, MTOR, ABL2, MYLK, 
8.16e-05 1.41e-01 
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PPP2R2A, ACVR1, F2R 
GO:0006793~phosphorus metabolic 
process 
FGFR3, STK11, ERBB3, ERBB2, STK36, RPS6KB2, RPS6KB1, KIT, IGF1R, 
PTK2, MAP3K1, BCL2, CAMK2D, PRKAA2, THBS1, FRS2, PDK1, IRAK1, RET, 
CTBP1, FLT1, ROCK1, SMAD7, MYLK3, TGFBR1, MYLK4, TGFBR2, RAF1, 
MYLK2, CDK6, CDK4, DAPK1, PRKCB, NTRK3, MAPK1, ACVR2A, RPS6KA3, 
CCND1, PPP1CA, CAMK4, GSK3B, RIPK2, MAPK8, RELN, MTOR, ABL2, MYLK, 
PPP2R2A, ACVR1, F2R 
8.16e-05 1.41e-01 
GO:0008284~positive regulation of cell 
proliferation 
FGFR3, OSMR, ERBB2, FGF10, RPS6KB1, KIT, GLI2, IGF1R, BCL2, CAMK2D, 
MYC, CCNA2, IL6, IL2RA, FLT1, TGFBR1, NODAL, TGFBR2, CDK6, IL6R, CDK4, 
MAPK1, NRAS, CDKN1A, CCND1, CDKN1B, ID2, HDAC1, VEGFA, RIPK2, 
HBEGF, MTOR, LAMC1, F2R 
4.07e-03 7.04e-01 
GO:0010604~positive regulation of 
macromolecule metabolic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, KIT, GLI2, SRF, IGF1R, REL, MAP3K1, 
BCL2, TCF4, THBS1, TRAF6, MYC, CCNA2, APC, CEBPA, IRAK1, IL6, AR, 
EGR2, SMAD7, TGFBR1, NODAL, TP53, SMAD4, CREB5, IL6R, CDK4, BRCA1, 
TP73, RAD51, MAPK1, ACVR2A, CCND1, HDAC1, ETS1, VEGFA, MTOR, 
ACVR1, F2R 
1.82e-01 3.89e+02 
GO:0051272~positive regulation of cell 
motion 
PLD1, IL6, FLT1, BCAR1, TGFBR1, MYLK2, RPS6KB1, IL6R, KIT, MAPK1, IGF1R, 
ETS1, BCL2, VEGFA, HBEGF, THBS1, F2R, APC 
7.31e-01 1.34e+04 
GO:0012501~programmed cell death TRAF1, PHLPP1, E2F1, E2F2, MCL1, ERBB3, EGLN3, NFKB1, PMAIP1, FOXO3, 
KIT, GSN, MAP3K1, BCL2, FAS, THBS1, TRAF6, MYC, IL6, IL2RA, LTBR, VAV3, 
ROCK1, TP53, RAF1, BIRC5, BIRC3, YWHAE, BRCA1, TP73, DAPK1, NRAS, 
1.05e+01 1.73e+04 
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CDKN1B, RIPK2, MAPK8, F2R 
GO:0051270~regulation of cell motion PLD1, IL6, FLT1, SMAD7, BCAR1, TGFBR1, MYLK2, RPS6KB1, IL6R, KIT, 
MAPK1, IGF1R, CDKN1B, ETS1, BCL2, MAP3K1, VEGFA, HBEGF, THBS1, 
CHRD, F2R, APC 
4.53e+00 7.87e+02 
GO:0007167~enzyme linked receptor 
protein signaling pathway 
IRAK1, RET, FGFR3, FLT1, ERBB3, SMAD7, TGFBR1, BCAR1, ERBB2, 
TGFBR2, SMAD4, RAF1, FOXO1, FGF10, KIT, FLNA, NTRK3, IGF1R, ACVR2A, 
PTK2, ID1, MAP3K1, VEGFA, HBEGF, CHRD, FRS2, ACVR1 
1.23e+02 2.13e+05 
GO:0007242~intracellular signaling 
cascade 
FGFR3, ERBB3, ERBB2, RPS6KB2, RPS6KB1, KIT, HIST2H4A, HIST2H4B, 
IGF1R, GSN, MAP3K1, RHOA, TRAF6, THBS1, GNG5, FRS2, CCNA2, 
ARHGDIA, SHC4, HIST1H4H, PDK1, IRAK1, AR, RET, PLD1, FLT1, VAV3, 
ROCK1, SMAD7, TGFBR1, TP53, RAF1, YWHAE, BRCA1, FLNA, TP73, PRKCB, 
IFNAR1, DAPK1, MAPK1, NRAS, IFNAR2, CCND1, RPS6KA3, CRKL, GSK3B, 
MAPK8, RAP1B, MTOR, CRK, F2R 
1.56e+01 2.71e+04 
GO:0008219~cell death TRAF1, PHLPP1, E2F1, E2F2, MCL1, ERBB3, EGLN3, NFKB1, PMAIP1, FOXO3, 
KIT, GSN, MAP3K1, BCL2, FAS, THBS1, TRAF6, MYC, IL6, AR, IL2RA, LTBR, 
VAV3, ROCK1, TP53, RAF1, BIRC5, BIRC3, YWHAE, BRCA1, TP73, DAPK1, 
NRAS, CDKN1B, RIPK2, MAPK8, F2R 
2.55e+02 4.42e+04 
GO:0010033~response to organic 
substance 
MCL1, OSMR, ERBB3, ERBB2, BCAR1, FOXO1, RPS6KB1, PMAIP1, SRF, 
IGF1R, CDKN2B, GSN, BCL2, ATF6B, FAS, THBS1, MYC, CCNA2, GNG5, 
IRAK1, IL6, AR, PLD1, EGR2, TGFBR1, TGFBR2, IL6R, BRCA1, MAPK1, 
CDKN1A, CCND1, ID2, ID1, RIPK2, MTOR, PPP2R2A, F2R 
2.78e+02 4.80e+04 
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GO:0006915~apoptosis TRAF1, PHLPP1, E2F1, E2F2, MCL1, ERBB3, EGLN3, NFKB1, PMAIP1, FOXO3, 
GSN, MAP3K1, BCL2, FAS, THBS1, TRAF6, MYC, IL6, IL2RA, LTBR, VAV3, 
ROCK1, TP53, RAF1, BIRC5, BIRC3, YWHAE, BRCA1, TP73, DAPK1, NRAS, 
RIPK2, MAPK8, F2R 
2.94e+02 5.09e+04 
GO:0016265~death TRAF1, PHLPP1, E2F1, E2F2, MCL1, ERBB3, EGLN3, NFKB1, PMAIP1, FOXO3, 
KIT, GSN, MAP3K1, BCL2, FAS, THBS1, TRAF6, MYC, IL6, AR, IL2RA, LTBR, 
VAV3, ROCK1, TP53, RAF1, BIRC5, BIRC3, YWHAE, BRCA1, TP73, DAPK1, 
NRAS, CDKN1B, RIPK2, MAPK8, F2R 
3.15e+02 5.46e+04 
GO:0010557~positive regulation of 
macromolecule biosynthetic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, IGF1R, REL, MAP3K1, TCF4, 
THBS1, TRAF6, CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, TGFBR1, 
NODAL, SMAD4, TP53, CREB5, CDK4, BRCA1, TP73, MAPK1, HDAC1, ETS1, 
VEGFA, MTOR, ACVR1, F2R 
5.22e+01 9.03e+04 
GO:0031328~positive regulation of cellular 
biosynthetic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, IGF1R, REL, MAP3K1, TCF4, 
THBS1, TRAF6, CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, TGFBR1, 
NODAL, SMAD4, TP53, CREB5, CDK4, BRCA1, TP73, MAPK1, HDAC1, ETS1, 
VEGFA, MTOR, ACVR1, F2R 
1.98e+03 3.43e+06 
GO:0009967~positive regulation of signal 
transduction 
IL6, LTBR, FLT1, ERBB3, ERBB2, TGFBR1, SMAD4, FGF10, IL6R, KIT, FLNA, 
NRAS, ACVR2A, CDKN2B, REL, ITGA8, VEGFA, RHOA, RIPK2, RELN, MTOR, 
TRAF6, THBS1, F2R 
2.83e+03 4.89e+05 
GO:0040017~positive regulation of 
locomotion 
IL6, PLD1, FLT1, BCAR1, FGF10, RPS6KB1, IL6R, KIT, IGF1R, MAPK1, BCL2, 
VEGFA, HBEGF, THBS1, F2R, APC 
2.84e+03 4.92e+05 
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GO:0009891~positive regulation of 
biosynthetic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, IGF1R, REL, MAP3K1, TCF4, 
THBS1, TRAF6, CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, TGFBR1, 
NODAL, SMAD4, TP53, CREB5, CDK4, BRCA1, TP73, MAPK1, HDAC1, ETS1, 
VEGFA, MTOR, ACVR1, F2R 
3.00e+02 5.18e+05 
GO:0010647~positive regulation of cell 
communication 
COL4A4, IL6, LTBR, FLT1, ERBB3, TGFBR1, ERBB2, SMAD4, FGF10, IL6R, KIT, 
FLNA, NRAS, ACVR2A, CDKN2B, REL, ITGA8, VEGFA, RHOA, RIPK2, RELN, 
MTOR, TRAF6, THBS1, F2R 
3.51e+02 6.07e+05 
GO:0006928~cell motion ERBB2, BCAR1, RPS6KB1, KIT, GLI2, SRF, PTK2, THBS1, ARHGDIA, APC, 
RET, IL6, FLT1, VAV3, EGR2, ROCK1, NODAL, TGFBR1, IL6R, YWHAE, 
COL5A1, ID1, ITGA5, ETS1, HBEGF, RELN, MAPK8, LAMC1, ACVR1 
6.05e+02 1.05e+07 
GO:0016477~cell migration RET, IL6, VAV3, FLT1, ROCK1, NODAL, BCAR1, TGFBR1, RPS6KB1, IL6R, KIT, 
SRF, YWHAE, COL5A1, PTK2, ID1, ITGA5, HBEGF, RELN, LAMC1, THBS1, 
ACVR1, APC 
6.23e+02 1.08e+07 
GO:0051674~localization of cell RET, IL6, VAV3, FLT1, ROCK1, NODAL, BCAR1, TGFBR1, RPS6KB1, IL6R, KIT, 
SRF, YWHAE, COL5A1, PTK2, ID1, ITGA5, ETS1, HBEGF, RELN, LAMC1, 
THBS1, ACVR1, APC 
6.54e+00 1.13e+07 
GO:0048870~cell motility RET, IL6, VAV3, FLT1, ROCK1, NODAL, BCAR1, TGFBR1, RPS6KB1, IL6R, KIT, 
SRF, YWHAE, COL5A1, PTK2, ID1, ITGA5, ETS1, HBEGF, RELN, LAMC1, 
THBS1, ACVR1, APC 
6.54e+00 1.13e+07 
GO:0051094~positive regulation of 
developmental process 
IL6, IL2RA, TGFBR2, SMAD4, RPS6KB1, NFKB1, IL6R, KIT, FOXO3, GLI2, SRF, 
NTRK3, ACVR2A, CDKN2B, ID2, ETS1, IL4R, BCL2, RHOA, THBS1, ARHGDIA, 
7.21e+02 1.25e+07 
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ACVR1, APC 
GO:0030335~positive regulation of cell 
migration 
IL6, PLD1, FLT1, BCAR1, RPS6KB1, IL6R, KIT, IGF1R, MAPK1, BCL2, VEGFA, 
HBEGF, THBS1, F2R, APC 
1.24e+04 2.14e+06 
GO:0045597~positive regulation of cell 
differentiation 
IL6, IL2RA, TGFBR2, SMAD4, NFKB1, IL6R, KIT, FOXO3, GLI2, SRF, NTRK3, 
ACVR2A, CDKN2B, ID2, ETS1, IL4R, BCL2, RHOA, ARHGDIA, APC, ACVR1 
1.40e+03 2.42e+07 
GO:0006916~anti-apoptosis IRAK1, MCL1, TGFBR1, FOXO1, BIRC5, NFKB1, BIRC3, DAPK1, IGF1R, 
HDAC1, GSK3B, COMP, BCL2, VEGFA, RIPK2, FAS, TRAF6, THBS1, MYC, 
ARHGDIA 
2.00e+04 3.46e+07 
GO:0010628~positive regulation of gene 
expression 
E2F1, MITF, FOXO1, NFKB1, FOXO3, KIT, GLI2, SRF, REL, MAP3K1, TCF4, 
CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, NODAL, TGFBR1, SMAD4, TP53, 
CREB5, BRCA1, TP73, MAPK1, HDAC1, ETS1, VEGFA, ACVR1, F2R 
2.43e+04 4.21e+06 
GO:0045935~positive regulation of 
nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, IGF1R, REL, MAP3K1, TCF4, 
CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, TGFBR1, NODAL, SMAD4, TP53, 
CREB5, BRCA1, TP73, RAD51, MAPK1, HDAC1, ETS1, VEGFA, ACVR1, F2R 
2.70e+04 4.68e+06 
GO:0040012~regulation of locomotion PLD1, IL6, FLT1, SMAD7, BCAR1, FGF10, RPS6KB1, IL6R, KIT, MAPK1, IGF1R, 
BCL2, MAP3K1, VEGFA, HBEGF, THBS1, CHRD, F2R, APC 
6.01e+03 1.04e+08 
GO:0051173~positive regulation of nitrogen 
compound metabolic process 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, IGF1R, REL, MAP3K1, TCF4, 
CCNA2, MYC, CEBPA, IRAK1, AR, IL6, EGR2, TGFBR1, NODAL, SMAD4, TP53, 
CREB5, BRCA1, TP73, RAD51, MAPK1, HDAC1, ETS1, VEGFA, ACVR1, F2R 
6.13e+03 1.06e+08 
GO:0045941~positive regulation of 
transcription 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, REL, MAP3K1, TCF4, CCNA2, 
MYC, CEBPA, IRAK1, AR, IL6, EGR2, NODAL, TGFBR1, SMAD4, TP53, CREB5, 
6.63e+04 1.15e+08 
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BRCA1, TP73, MAPK1, HDAC1, ETS1, VEGFA, F2R, ACVR1 
GO:0030334~regulation of cell migration PLD1, IL6, FLT1, SMAD7, BCAR1, RPS6KB1, IL6R, KIT, MAPK1, IGF1R, BCL2, 
MAP3K1, VEGFA, HBEGF, THBS1, CHRD, F2R, APC 
7.72e+03 1.34e+08 
GO:0009725~response to hormone 
stimulus 
PLD1, AR, IL6, EGR2, ERBB3, BCAR1, ERBB2, TGFBR1, TGFBR2, FOXO1, 
RPS6KB1, IL6R, SRF, BRCA1, MAPK1, IGF1R, CCND1, CDKN1A, BCL2, MTOR, 
FAS, THBS1, CCNA2, GNG5 
2.59e+04 4.47e+07 
GO:0051174~regulation of phosphorus 
metabolic process 
IRAK1, IL6, VAV3, FLT1, SMAD7, TGFBR1, ERBB2, TGFBR2, SMAD4, IL6R, KIT, 
YWHAE, TP73, ACVR2A, CCND1, CDKN1A, CDKN1B, CDKN2B, BCL2, 
MAP3K1, RELN, MTOR, TRAF6, THBS1, FRS2, APC, F2R 
3.78e+04 6.53e+07 
GO:0019220~regulation of phosphate 
metabolic process 
IRAK1, IL6, VAV3, FLT1, SMAD7, TGFBR1, ERBB2, TGFBR2, SMAD4, IL6R, KIT, 
YWHAE, TP73, ACVR2A, CCND1, CDKN1A, CDKN1B, CDKN2B, BCL2, 
MAP3K1, RELN, MTOR, TRAF6, THBS1, FRS2, APC, F2R 
3.78e+04 6.53e+07 
GO:0042325~regulation of phosphorylation IRAK1, IL6, VAV3, FLT1, SMAD7, TGFBR1, ERBB2, TGFBR2, SMAD4, IL6R, KIT, 
TP73, ACVR2A, CCND1, CDKN1A, CDKN1B, CDKN2B, BCL2, MAP3K1, RELN, 
MTOR, TRAF6, THBS1, FRS2, APC, F2R 
9.26e+04 1.60e+09 
GO:0009719~response to endogenous 
stimulus 
PLD1, AR, IL6, EGR2, ERBB3, BCAR1, ERBB2, TGFBR1, TGFBR2, FOXO1, 
RPS6KB1, IL6R, SRF, BRCA1, MAPK1, IGF1R, CCND1, CDKN1A, BCL2, MTOR, 
FAS, THBS1, CCNA2, GNG5 
1.86e+05 3.21e+09 
GO:0007243~protein kinase cascade IRAK1, RET, FGFR3, FLT1, ERBB3, ERBB2, TGFBR1, RPS6KB2, RPS6KB1, KIT, 
DAPK1, IFNAR1, MAPK1, IFNAR2, IGF1R, RPS6KA3, CRKL, MAP3K1, MAPK8, 
TRAF6, THBS1, FRS2, F2R 
2.01e+05 3.47e+08 
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GO:0045596~negative regulation of cell 
differentiation 
SMAD7, NODAL, TGFBR1, TP53, FGF10, CDK6, KIT, GLI2, HIST2H4A, 
HIST2H4B, MAPK1, PTK2, CCND1, HDAC1, IL4R, RHOA, CHRD, ARHGDIA, 
HIST1H4H, APC 
3.82e+05 6.61e+08 
GO:0045893~positive regulation of 
transcription, DNA-dependent 
E2F1, CEBPA, AR, IL6, EGR2, NODAL, MITF, TP53, SMAD4, FOXO1, CREB5, 
NFKB1, FOXO3, GLI2, SRF, BRCA1, TP73, REL, HDAC1, ETS1, MAP3K1, 
VEGFA, TCF4, MYC, F2R 
8.42e+05 1.46e+10 
GO:0051254~positive regulation of RNA 
metabolic process 
E2F1, CEBPA, AR, IL6, EGR2, NODAL, MITF, TP53, SMAD4, FOXO1, CREB5, 
NFKB1, FOXO3, GLI2, SRF, BRCA1, TP73, REL, HDAC1, ETS1, MAP3K1, 
VEGFA, TCF4, MYC, F2R 
9.95e+05 1.72e+10 
GO:0051726~regulation of cell cycle E2F1, E2F2, TP53, MYLK2, CDK6, BIRC5, CDK4, BRCA1, CCND1, CDKN1A, 
CDKN1B, CDKN2B, HDAC1, PRDM4, ID2, ETS1, BCL2, CAMK2D, CCNA2, 
MYC, APC 
1.09e+07 1.88e+10 
GO:0007166~cell surface receptor linked 
signal transduction 
OSMR, BCAR1, MITF, FOXO1, FGF10, GLI2, HHIP, FRS2, GNG5, IRAK1, 
WNT10B, RET, FLNA, IFNAR1, MAPK1, IFNAR2, ACVR2A, CCND1, VEGFA, 
RIPK2, ACVR1, FGFR3, ERBB3, C3, ERBB2, ITGA10, KIT, IGF1R, PTK2, 
MAP3K1, TRAF6, APC, FZD8, FLT1, VAV3, IL2RA, SMAD7, TGFBR1, TGFBR2, 
SMAD4, RAF1, BIRC3, NTRK3, FZD10, ITGA5, ID1, GSK3B, ITGA8, HBEGF, 
CHRD, F2R 
1.78e+07 3.08e+09 
GO:0006357~regulation of transcription 
from RNA polymerase II promoter 
E2F1, MITF, FOXO1, NFKB1, FOXO3, GLI2, SRF, MAP3K1, RHOA, TCF4, MYC, 
CHD4, CEBPA, IL6, CTBP1, AR, EGR2, SMAD7, NODAL, SMAD4, TP53, BRCA1, 
IFNAR2, ID2, HDAC1, ID1, ETS1, VEGFA, CRK, HDAC8 
2.69e+07 4.66e+10 
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GO:0043065~positive regulation of 
apoptosis 
IL2RA, VAV3, TGFBR1, TP53, PMAIP1, FOXO3, YWHAE, BRCA1, TP73, DAPK1, 
MAPK1, CUL2, CDKN1A, CDKN1B, ETS1, MAP3K1, BCL2, RIPK2, MAPK8, FAS, 
TRAF6, MYC, APC 
3.37e+06 5.84e+09 
GO:0043068~positive regulation of 
programmed cell death 
IL2RA, VAV3, TGFBR1, TP53, PMAIP1, FOXO3, YWHAE, BRCA1, TP73, DAPK1, 
MAPK1, CUL2, CDKN1A, CDKN1B, ETS1, MAP3K1, BCL2, RIPK2, MAPK8, FAS, 
TRAF6, MYC, APC 
3.84e+06 6.64e+09 
GO:0010942~positive regulation of cell 
death 
IL2RA, VAV3, TGFBR1, TP53, PMAIP1, FOXO3, YWHAE, BRCA1, TP73, DAPK1, 
MAPK1, CUL2, CDKN1A, CDKN1B, ETS1, MAP3K1, BCL2, RIPK2, MAPK8, FAS, 
TRAF6, MYC, APC 
4.17e+06 7.22e+10 
GO:0007169~transmembrane receptor 
protein tyrosine kinase signaling pathway 
RET, FGFR3, FLT1, ERBB3, BCAR1, ERBB2, FGF10, FOXO1, RAF1, KIT, FLNA, 
NTRK3, IGF1R, PTK2, VEGFA, HBEGF, FRS2 
5.29e+06 9.16e+08 
GO:0007389~pattern specification process EGR2, FLT1, NODAL, TGFBR1, TGFBR2, SMAD4, FGF10, GLI2, ACVR2A, 
CRKL, VEGFA, RELN, HHIP, FRS2, CHRD, PITX2, ACVR1, APC 
9.71e+06 1.68e+10 
GO:0035239~tube morphogenesis RET, FLT1, NODAL, TGFBR2, SMAD4, FGF10, GLI2, SRF, PPP1CA, BCL2, 
VEGFA, TRAF6, ACVR1 
2.15e+07 3.72e+10 
GO:0043549~regulation of kinase activity IRAK1, VAV3, FLT1, ERBB2, TGFBR1, TGFBR2, KIT, TP73, CCND1, CDKN1A, 
CDKN1B, CDKN2B, MAP3K1, RELN, MTOR, TRAF6, THBS1, FRS2, F2R, APC 
2.32e+07 4.01e+10 
GO:0051329~interphase of mitotic cell 
cycle 
E2F1, CUL2, CDKN1A, CCND1, CDKN1B, CDKN2B, BCL2, CAMK2D, CDK6, 
BIRC5, CDK4, ACVR1 
2.36e+08 4.08e+10 
GO:0010627~regulation of protein kinase 
cascade 
IL6, LTBR, ERBB3, ERBB2, TGFBR1, MYLK2, IL6R, TP73, FLNA, REL, MAP3K1, 
RHOA, RIPK2, MTOR, TRAF6, F2R, APC 
2.39e+08 4.13e+11 
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GO:0008285~negative regulation of cell 
proliferation 
CEBPA, IL6, CTBP1, IL2RA, STK11, ERBB2, TGFBR2, TP53, SMAD4, FGF10, 
CDK6, CUL2, CDKN1A, CDKN1B, CDKN2B, ETS1, BCL2, THBS1, F2R, APC 
2.77e+08 4.80e+10 
GO:0035295~tube development CEBPA, RET, FLT1, NODAL, TGFBR1, TGFBR2, SMAD4, FGF10, GLI2, SRF, 
PPP1CA, BCL2, VEGFA, HHIP, TRAF6, ACVR1 
3.05e+07 5.28e+11 
GO:0051325~interphase E2F1, CUL2, CDKN1A, CCND1, CDKN1B, CDKN2B, BCL2, CAMK2D, CDK6, 
BIRC5, CDK4, ACVR1 
3.19e+08 5.52e+10 
GO:0051338~regulation of transferase 
activity 
IRAK1, VAV3, FLT1, ERBB2, TGFBR1, TGFBR2, KIT, TP73, CCND1, CDKN1A, 
CDKN1B, CDKN2B, MAP3K1, RELN, MTOR, TRAF6, THBS1, FRS2, F2R, APC 
4.47e+06 7.74e+10 
GO:0044087~regulation of cellular 
component biogenesis 
COL4A4, TGFBR1, KIT, SRF, PTK2, CDKN1B, GSN, MAP3K1, GSK3B, RHOA, 
MTOR, THBS1, APC 
7.51e+07 1.30e+12 
GO:0045859~regulation of protein kinase 
activity 
IRAK1, FLT1, ERBB2, TGFBR1, TGFBR2, KIT, TP73, CCND1, CDKN1A, 
CDKN1B, CDKN2B, MAP3K1, RELN, MTOR, TRAF6, THBS1, FRS2, F2R, APC 
7.55e+07 1.31e+11 
GO:0032535~regulation of cellular 
component size 
HPN, AR, FGFR3, TGFBR1, TP53, SMAD4, CDK4, TP73, NTRK3, CDKN1A, 
CDKN1B, PRDM4, GSN, BCL2, MAP3K1, HBEGF, MTOR 
7.78e+06 1.35e+11 
GO:0008361~regulation of cell size HPN, AR, FGFR3, TGFBR1, TP53, SMAD4, CDK4, TP73, NTRK3, CDKN1A, 
CDKN1B, PRDM4, BCL2, HBEGF, MTOR 
9.38e+07 1.62e+11 
GO:0008283~cell proliferation E2F1, AR, IL2RA, OSMR, BCAR1, ERBB2, TP53, RAF1, FGF10, KIT, GLI2, 
IFNAR2, ACVR2A, PRDM4, BCL2, VEGFA, RIPK2, RAP1B, HHIP, FRS2, MYC 
1.13e+09 1.95e+12 
GO:0065003~macromolecular complex 
assembly 
TRAF1, E2F2, HIST2H4A, HIST2H4B, HIST1H2BO, IGF1R, PTK2, HIST1H2BN, 
HIST1H2BK, HIST1H2BL, GSN, MAP3K1, HIST1H2BI, FAS, PRKAA2, MYC, 
APC, HIST1H4H, IRAK1, HIST1H2BC, HIST1H2BD, HIST1H2BF, HIST1H2BG, 
1.24e+09 2.14e+12 
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HIST1H2BH, SMAD4, TP53, BIRC3, FLNA, RAD51, HIST2H2BF, LAMC1 
GO:0006917~induction of apoptosis VAV3, TGFBR1, TP53, FOXO3, PMAIP1, YWHAE, BRCA1, TP73, DAPK1, 
MAPK1, CUL2, CDKN1A, CDKN1B, ETS1, MAPK8, FAS, TRAF6, MYC 
1.38e+09 2.38e+12 
GO:0012502~induction of programmed cell 
death 
VAV3, TGFBR1, TP53, FOXO3, PMAIP1, YWHAE, BRCA1, TP73, DAPK1, 
MAPK1, CUL2, CDKN1A, CDKN1B, ETS1, MAPK8, FAS, TRAF6, MYC 
1.44e+08 2.49e+12 
GO:0051130~positive regulation of cellular 
component organization 
C3, TGFBR1, SMAD4, FGF10, KIT, SRF, NTRK3, CDKN1B, MAP3K1, GSK3B, 
RHOA, MTOR, ARHGDIA, APC 
1.45e+09 2.50e+12 
GO:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter 
E2F1, CEBPA, AR, IL6, EGR2, NODAL, MITF, TP53, SMAD4, FOXO1, NFKB1, 
FOXO3, GLI2, SRF, HDAC1, ETS1, MAP3K1, VEGFA, MYC 2.24e+09 3.88e+11 
GO:0048545~response to steroid hormone 
stimulus 
IL6, ERBB2, TGFBR1, TGFBR2, RPS6KB1, IL6R, BRCA1, MAPK1, CCND1, 
CDKN1A, BCL2, FAS, THBS1, CCNA2 
2.88e+08 4.98e+11 
GO:0043933~macromolecular complex 
subunit organization 
TRAF1, E2F2, HIST2H4A, HIST2H4B, HIST1H2BO, IGF1R, PTK2, HIST1H2BN, 
HIST1H2BK, HIST1H2BL, GSN, MAP3K1, HIST1H2BI, FAS, PRKAA2, MYC, 
APC, HIST1H4H, IRAK1, HIST1H2BC, HIST1H2BD, HIST1H2BF, HIST1H2BG, 
HIST1H2BH, SMAD4, TP53, BIRC3, FLNA, RAD51, HIST2H2BF, LAMC1 
4.26e+08 7.36e+11 
GO:0010740~positive regulation of protein 
kinase cascade 
IL6, LTBR, ERBB3, TGFBR1, ERBB2, IL6R, FLNA, REL, RHOA, RIPK2, MTOR, 
TRAF6, F2R 
4.43e+08 7.66e+11 
GO:0046777~protein amino acid 
autophosphorylation 
NTRK3, IGF1R, IRAK1, PTK2, MAP3K1, ERBB2, TGFBR1, CAMK2D, MTOR, KIT 
5.00e+08 8.66e+10 
GO:0009611~response to wounding IL6, IL2RA, ERBB3, C3, ERBB2, TGFBR2, FGF10, RPS6KB1, NFKB1, IL6R, SRF, 6.06e+08 0.001 
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COL5A1, TP73, ITGA5, GSN, BCL2, MAP3K1, RIPK2, HBEGF, THBS1, F2R, 
ACVR1 
GO:0048754~branching morphogenesis of 
a tube 
PPP1CA, FLT1, BCL2, VEGFA, TGFBR2, SMAD4, FGF10, GLI2, ACVR1 
6.85e+08 0.001 
GO:0001944~vasculature development FLT1, SMAD7, NODAL, TGFBR1, TGFBR2, FOXO1, FGF10, SRF, COL5A1, 
PTK2, CRKL, ID1, VEGFA, THBS1, ACVR1 
1.04e+10 0.002 
GO:0007507~heart development CRKL, ID2, ID1, ERBB3, SMAD7, ERBB2, NODAL, TGFBR1, TGFBR2, MYLK2, 
GLI2, SRF, COL5A1, ACVR1 
1.05e+10 0.002 
GO:0048661~positive regulation of smooth 
muscle cell proliferation 
IL6, FLT1, VEGFA, TGFBR2, HBEGF, RPS6KB1, IL6R 
1.15e+10 0.002 
GO:0045637~regulation of myeloid cell 
differentiation 
ACVR2A, ID2, ETS1, MITF, CDK6, FAS, FOXO3, HIST2H4A, APC, HIST1H4H, 
HIST2H4B 
1.22e+09 0.002 
GO:0043434~response to peptide hormone 
stimulus 
IGF1R, PLD1, AR, EGR2, ERBB3, BCL2, BCAR1, FOXO1, RPS6KB1, IL6R, 
MTOR, CCNA2 
1.45e+10 0.003 
GO:0048534~hemopoietic or lymphoid 
organ development 
CEBPA, CRKL, ID2, TGFBR1, BCL2, VEGFA, TGFBR2, TP53, FGF10, CDK6, 
KIT, FAS, NFKB2, TRAF6, APC 
1.59e+09 0.003 
GO:0022402~cell cycle process E2F1, STK11, TP53, CDK6, BIRC5, CDK4, BRCA1, TP73, RAD51, CUL2, CCND1, 
CDKN1A, CDKN1B, CDKN2B, GSK3B, BCL2, CAMK2D, THBS1, CCNA2, MYC, 
APC, ACVR1 
1.70e+09 0.003 
GO:0006333~chromatin assembly or 
disassembly 
HIST1H2BC, HIST1H2BD, HIST1H2BF, HIST1H2BG, HIST1H2BH, HIST2H4A, 
HIST2H4B, HIST1H2BO, HIST1H2BN, HIST1H2BK, HIST1H2BL, HIST1H2BI, 
1.82e+10 0.003 
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HIST2H2BF, HDAC8, CHD4, HIST1H4H 
GO:0001763~morphogenesis of a 
branching structure 
PPP1CA, FLT1, BCL2, VEGFA, TGFBR2, SMAD4, FGF10, GLI2, ACVR1 
1.88e+10 0.003 
GO:0032101~regulation of response to 
external stimulus 
NTRK3, IL6, IL2RA, C3, OSMR, VEGFA, TGFBR2, FGF10, IL6R, MTOR, THBS1, 
F2R 
1.98e+10 0.003 
GO:0007423~sensory organ development ERBB3, ERBB2, MITF, FGF10, COL5A2, COL5A1, CDKN1B, BCL2, ITGA8, 
MAP3K1, VEGFA, FRS2, MYC, APC 
2.12e+10 0.004 
GO:0033674~positive regulation of kinase 
activity 
IRAK1, VAV3, FLT1, ERBB2, TGFBR1, TGFBR2, KIT, CCND1, MAP3K1, RELN, 
TRAF6, THBS1, FRS2, F2R 
2.34e+09 0.004 
GO:0007178~transmembrane receptor 
protein serine/threonine kinase signaling 
pathway 
ACVR2A, IRAK1, ID1, SMAD7, MAP3K1, TGFBR1, TGFBR2, SMAD4, CHRD, 
ACVR1 2.56e+10 0.004 
GO:0007050~cell cycle arrest CUL2, CDKN1A, CDKN1B, CDKN2B, STK11, TP53, THBS1, MYC, TP73, APC 2.56e+10 0.004 
GO:0030278~regulation of ossification ACVR2A, IL6, EGR2, BCL2, CDK6, IL6R, CHRD, ACVR1, APC 2.81e+09 0.005 
GO:0048584~positive regulation of 
response to stimulus 
IRAK1, IL6, C3, OSMR, BCAR1, FGF10, IL6R, BRCA1, NTRK3, MAPK1, VEGFA, 
RIPK2, TRAF6, THBS1 
2.96e+10 0.005 
GO:0000082~G1/S transition of mitotic cell 
cycle 
CUL2, CDKN1A, CCND1, CDKN1B, BCL2, CAMK2D, CDK4, ACVR1 
3.14e+10 0.005 
GO:0001702~gastrulation with mouth 
forming second 
ACVR2A, NODAL, SMAD4, FRS2, CHRD, ACVR1 
3.15e+08 0.005 
GO:0002520~immune system development CEBPA, CRKL, ID2, TGFBR1, BCL2, VEGFA, TGFBR2, TP53, FGF10, CDK6, 3.20e+10 0.006 
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KIT, FAS, NFKB2, TRAF6, APC 
GO:0002684~positive regulation of immune 
system process 
IRAK1, IL6, IL2RA, C3, BCAR1, TGFBR2, IL6R, MAPK1, CDKN1A, IL4R, VEGFA, 
RIPK2, TRAF6, THBS1 
3.25e+10 0.006 
GO:0051347~positive regulation of 
transferase activity 
IRAK1, VAV3, FLT1, ERBB2, TGFBR1, TGFBR2, KIT, CCND1, MAP3K1, RELN, 
TRAF6, THBS1, FRS2, F2R 
3.56e+09 0.006 
GO:0030155~regulation of cell adhesion VAV3, ERBB3, GSN, SMAD7, BCL2, ERBB2, CDK6, THBS1, CHRD, ARHGDIA, 
APC 
3.63e+10 0.006 
GO:0045786~negative regulation of cell 
cycle 
CDKN1A, CDKN1B, PRDM4, HDAC1, ETS1, BCL2, TP53, CDK6, APC 
3.74e+09 0.006 
GO:0051247~positive regulation of protein 
metabolic process 
IL6, SMAD7, TGFBR1, SMAD4, IL6R, CDK4, BRCA1, ACVR2A, MAPK1, CCND1, 
BCL2, MTOR, THBS1, APC 
4.08e+09 0.007 
GO:0001568~blood vessel development FLT1, SMAD7, TGFBR1, TGFBR2, FOXO1, FGF10, SRF, COL5A1, PTK2, CRKL, 
ID1, VEGFA, THBS1, ACVR1 
4.47e+09 0.008 
GO:0006334~nucleosome assembly HIST1H2BC, HIST1H2BD, HIST1H2BF, HIST1H2BG, HIST1H2BH, HIST2H4A, 
HIST2H4B, HIST1H2BO, HIST1H2BN, HIST1H2BK, HIST1H2BL, HIST1H2BI, 
HIST2H2BF, HIST1H4H 
4.93e+09 0.009 
GO:0032844~regulation of homeostatic 
process 
ACVR2A, IL2RA, ETS1, SMAD7, BCL2, VEGFA, CDK6, FOXO3, MYC, F2R 
5.95e+09 0.010 
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Table S8. Gene Ontology (GO) analysis was performed using the list of predicted target genes of differentially miRNAs, which were 
significantly abundant in the immature oocytes of low antral follicle count ovaries. GO terms for biological function and count of the genes. 
which indicates how much the GO term is enriched of predicted genes, P-value and False Discovery Rate (FDR) are reported. Data are 
reported only for FDR less than 0.1. 
 
GO Term Gene count P-Value FDR 
GO:0042127~regulation of cell proliferation 32 2.77e+06 4.63e+08 
GO:0008284~positive regulation of cell proliferation 23 6.76e+05 1.13e+10 
GO:0051236~establishment of RNA localization 11 9.47e+07 1.58e+11 
GO:0050658~RNA transport 11 9.47e+07 1.58e+11 
GO:0050657~nucleic acid transport 11 9.47e+07 1.58e+11 
GO:0006403~RNA localization 11 1.27e+08 2.12e+11 
GO:0006913~nucleocytoplasmic transport 13 1.27e+09 2.12e+12 
GO:0051169~nuclear transport 13 1.45e+09 2.43e+12 
GO:0043632~modification-dependent macromolecule catabolic process 23 2.45e+09 4.10e+12 
GO:0019941~modification-dependent protein catabolic process 23 2.45e+09 4.10e+12 
GO:0044265~cellular macromolecule catabolic process 26 2.52e+09 4.22e+11 
GO:0009719~response to endogenous stimulus 19 4.03e+08 6.74e+11 
GO:0015931~nucleobase, nucleoside, nucleotide and nucleic acid transport 11 4.03e+08 6.75e+11 
GO:0051028~mRNA transport 10 4.12e+08 6.90e+11 
GO:0009725~response to hormone stimulus 18 4.88e+08 8.16e+11 
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GO:0051603~proteolysis involved in cellular protein catabolic process 23 5.21e+08 8.71e+11 
GO:0044257~cellular protein catabolic process 23 5.66e+08 9.48e+11 
GO:0030163~protein catabolic process 23 9.53e+08 0.002 
GO:0009057~macromolecule catabolic process 26 1.00e+10 0.002 
GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
23 1.01e+09 0.002 
GO:0043066~negative regulation of apoptosis 17 1.49e+09 0.002 
GO:0010604~positive regulation of macromolecule metabolic process 27 1.62e+09 0.003 
GO:0051173~positive regulation of nitrogen compound metabolic process 23 1.70e+10 0.003 
GO:0051329~interphase of mitotic cell cycle 10 1.74e+10 0.003 
GO:0043069~negative regulation of programmed cell death 17 1.79e+10 0.003 
GO:0060548~negative regulation of cell death 17 1.86e+10 0.003 
GO:0010557~positive regulation of macromolecule biosynthetic process 23 2.18e+10 0.004 
GO:0051325~interphase 10 2.22e+09 0.004 
GO:0010033~response to organic substance 24 3.06e+10 0.005 
GO:0007049~cell cycle 25 3.11e+09 0.005 
GO:0051726~regulation of cell cycle 16 3.14e+10 0.005 
GO:0051168~nuclear export 8 3.70e+09 0.006 
GO:0031328~positive regulation of cellular biosynthetic process 23 4.63e+09 0.008 
GO:0009891~positive regulation of biosynthetic process 23 5.83e+09 0.010 
GO:0051272~positive regulation of cell motion 9 1.11e+11 0.020 
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GO:0042325~regulation of phosphorylation 18 1.23e+11 0.021 
GO:0006916~anti-apoptosis 12 1.52e+11 0.025 
GO:0045893~positive regulation of transcription, DNA-dependent 18 1.66e+11 0.028 
GO:0010628~positive regulation of gene expression 20 1.72e+10 0.029 
GO:0042981~regulation of apoptosis 24 1.82e+10 0.030 
GO:0051254~positive regulation of RNA metabolic process 18 1.84e+11 0.031 
GO:0019220~regulation of phosphate metabolic process 18 2.05e+10 0.034 
GO:0051174~regulation of phosphorus metabolic process 18 2.05e+10 0.034 
GO:0043067~regulation of programmed cell death 24 2.13e+10 0.036 
GO:0010941~regulation of cell death 24 2.26e+11 0.038 
GO:0045859~regulation of protein kinase activity 15 2.36e+11 0.039 
GO:0000082~G1/S transition of mitotic cell cycle 7 3.08e+11 0.051 
GO:0043549~regulation of kinase activity 15 3.43e+10 0.057 
GO:0045941~positive regulation of transcription 19 4.01e+11 0.067 
GO:0001501~skeletal system development 14 4.47e+10 0.075 
GO:0051338~regulation of transferase activity 15 5.37e+10 0.090 
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Table S9. Gene Ontology (GO) analysis was performed using the list of predicted target genes of bta-miR-10a, which was significantly 
reduced in the immature oocytes of low antral follicle count ovaries. GO terms for biological function and count of the genes. which 
indicates how much the GO term is enriched of predicted genes, P-value and false discovery rate are reported. Data are reported only for 
FDR less than 0.1. 
 
GO Term Gene count P- Value FDR 
GO:0045449~regulation of transcription 217 1.04e+09 1.88e+11 
GO:0006357~regulation of transcription from RNA polymerase II promoter 80 1.82e+09 3.29e+11 
GO:0006350~transcription 181 2.22e+09 4.01e+11 
GO:0051252~regulation of RNA metabolic process 157 1.39e+10 0.003 
GO:0006355~regulation of transcription, DNA-dependent 152 4.02e+09 0.007 
GO:0030182~neuron differentiation 50 2.00e+09 0.036 
GO:0010557~positive regulation of macromolecule biosynthetic process 66 4.24e+10 0.077 
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